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ABSTRACT  
 
Human embryonic stem cells (hESC) display pluripotency and unlimited self-renewal while 
retaining a normal karyotype, suggesting they possess mechanisms to minimize the 
consequences of DNA damage. The molecular mechanisms controlling DNA-damage induced 
apoptosis of hESC are poorly understood. This study investigates the role of p53 in DNA 
damaged-induced apoptosis and cell differentiation. hESC are extremely sensitive to 
spontaneous apoptosis, as well as gamma irradiation-, hydrogen peroxide- and etoposide-
induced apoptosis. Indeed, early passage hESC appear to be far more sensitive to etoposide-
induced apoptosis than adapted hESC and cancer cell lines. The data further show that 
undifferentiated hESC that express Oct4 are much more sensitive to etoposide-induced apoptosis 
than their more differentiated progeny. It is shown that p53 is constitutively expressed at high 
levels in the cytoplasm of hESC. Etoposide treatment results in rapid and extensive induction of 
apoptosis and leads to a further increase in p53 and PUMA expression as well as Bax processing. 
p53 both translocates to the nucleus and associates with the mitochondria, accompanied by co-
localisation of Bax with Mcl1. hESC stably transduced with p53 shRNA, display 80 % reduction of 
endogenous p53 and exhibit an 80 % reduction in etoposide-induced apoptosis accompanied by 
constitutive downregulation of Bax and an attenuated upregulation of PUMA. Furthermore, gene 
profile analysis of untreated GFP and p53 shRNA transduced hESC shows that p53 controls a 
set of genes under normal conditions. Around 70 % of these genes contain p53 responsive 
elements. No significant differences were observed between cell cycle entry of GFP and p53 
shRNA transduced cell lines or distribution of phases of cell cycle and the karyotypes of both cell 
lines were found to be normal. p53 had a small but reproducible effect in inhibiting spontaneous 
differentiation. Preliminary studies to address the role of p53 in differentiation of hESC revealed a 
slight resistance of p53 shRNA transduced cell lines to BMP4-induced differentiation and the 
opposite was observed in relation to Activin A treatment. Furthermore, these cells formed 
teratomas (with representative tissues of all three germ layers) when implanted beneath the testis 
capsule of SCID mice that exhibited a higher proportion of immature neural tissue compared to 
control cells, suggesting that these cells are more prone to undergo differentiation to the neural 
lineage, or mature more slowly. This study demonstrates that p53 plays a role in differentiation, is 
required for etoposide-induced apoptosis of hESC and reveals, at least in part, the molecular 
mechanism of DNA damage-induced apoptosis in hESC.  
 
 
 
 
 
 
 
 
 
 - xvi - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 - xvii - 
RESUMO 
 
As células estaminais embrionárias humanas (hESC) possuem características de pluripotência e 
capacidade ilimitada de auto-renovação, mantendo ao mesmo tempo um cariótipo normal, o que 
sugere que estas possuem mecanismos que minimizam as consequências de danos no ADN. Os 
mecanismos moleculares que controlam a apoptose das hESC induzida por danos no ADN são 
pouco compreendidos. Este estudo investiga o papel do p53 na apoptose induzida por agentes 
que causam danos no ADN e na diferenciação celular. As hESC são extremamente sensíveis à 
apoptose espontânea, como também à induzida por radiação gama, peróxido de hidrogénio e 
etopósido. De facto, as hESC com poucas passagens são muito mais sensíveis à apoptose 
induzida por etopósido do que hESC adaptadas e linhas celulares cancerígenas. Os dados deste 
estudo também demostram que as hESC indiferenciadas que expressam Oct4 são mais 
sensíveis à apoptose induzida pelo etopósido do que a sua progenia diferenciada. O p53 é 
constitutivamente expresso em níveis elevados no citoplasma das hESC. O tratamento com 
etopósido leva a uma rápida indução da apoptose e aumento da expressão do p53 e do PUMA, 
bem como ao processamento do Bax. O p53 transloca para o núcleo e associa-se com a 
mitocôndria e isto é acompanhado com a co-localização do Bax com o Mcl1. As hESC 
estavelmente expressam shRNA desenhado para diminuir a expressão do p53, possuem uma 
reducção em 80 % do p53 endógeno e exibem também uma reducção na apoptose induzida pelo 
etoposide, acompanhada por uma diminuição nos níveis do Bax e por uma atenuação no 
aumento dos níveis do PUMA. A análise do perfil da expressão de genes de hESC que 
expressam shRNA para reduzir a expressão do p53 e GFP mostra que o p53 controla um 
conjunto de genes em condições normais. Cerca de 70 % destes genes contêm nos seus 
promotores locais de ligação para o p53. Não foram observadas diferenças significativas na 
distribuição das fases do ciclo celular das hESC que expressam shRNA para reduzir a expressão 
do p53 e GFP e os cariótipos destas células são normais. O p53 tem um pequeno, mas 
reprodutivél efeito na inibição da differenciação espontânea. Estudos preliminares para investigar 
o papel do p53 na diferenciação das hESC revelaram uma pequena resistência das células que 
expressam shRNA para diminuir os níveis do p53 à diferenciação induzida pelo BMP4, sendo o 
oposto observado em relação ao tratamento com Activina A. Estas células formam teratomas 
(com tecidos representativos das três camadas germinativas) quando implantadas na cápsula de 
murganhos immunodeprimidos SCID que exibem uma maior proporção de tecido neural imaturo 
quando comparadas com teratomas formados pelas células controlo, o que sugere que elas 
preferencialmente se diferenciam numa linhagem neural ou que o seu processo de maturação é 
mais lento. Este estudo demonstra que nas hESC, o p53 desempenha um papel na 
diferenciação celular, é necessário para a apoptose induzida pelo etopósido e revela em parte o 
mecanismo molecular que controla a apoptose induzida por danos no ADN das hESC.  
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CHAPTER 1: Introduction 
1.1- HUMAN EMBRYONIC STEM CELLS 
The excitement and controversy surrounding the potential role of human embryonic  
stem cells in transplantation therapy have often overshadowed their potentially  
more important use as a basic research tool for understanding the  
development and function of human tissue (Xu et al, 2002). 
 
Human embryonic stem cell lines (hESC) are established from the inner cell mass (ICM) of the 
blastocyst and differentiate into all cell lineages of the body (Figure 1.1). They were first derived 
in 1998 by James Thomson’s group in the University of Wisconsin-Madison, USA (Thomson et 
al., 1998) and have enormous potential as a source of cells for cell replacement therapies and as 
a model for early human development (Hoffman and Carpenter, 2005). In fact, hESC represent a 
useful experimental system that provides access to stages of the human life cycle that were 
previously inaccessible to experimentation (Pera and Trounson, 2004). Conversely, better 
understanding of stem cell basic biology will help to improve maintenance and differentiation 
protocols for manipulating hESC, thus enabling the dissection of some developmental diseases 
and advancement of more effective treatments. Moreover, because hESC and their derivatives 
are diploid, they are more attractive than the transformed cell lines for drug screening and 
disease modeling. 
Two important features of embryonic stem cells (ESC) are their self-renewal capacity (they can 
be maintained and expanded in culture) and pluripotency (they can differentiate to give rise to 
mesoderm, endoderm and ectoderm as well as germ cells). Unlike human embryonic carcinoma 
cell lines (hECC, the transformed counterpart of hESC), hESC can conserve a normal karyotype 
if cultured under appropriate conditions. 
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Blastocyst stage
ICM
Trophoectoderm
Inactivated layer 
of feeders
Ectoderm Endoderm Mesoderm
 
FIGURE 1.1- Schematic derivation of hESC from ICM of a human blastocyst.  
hESC are derived from pre-implantation stage embryos. In most cases, these are donated to 
research after being deemed surplus to clinical requirements. After being removed from 
blastocyst, the ICM is placed upon an inactivate layer of feeder cells. A hESC line is formed by 
serial passaging of these cells. These cells can be maintained in the undifferentiated state (self-
renewing) for long periods of time or can be differentiated into representatives of three germ 
layers (ectoderm, endoderm and mesoderm).  
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The mouse embryonic stem cells (mESC) were the first mammalian ESC derived and this was 
achieved by Evans, Kaufman and Martin in 1981 (Evans and Kaufman, 1981; Martin, 1981). 
Therefore, most of our understanding of the molecular mechanisms governing self-renewal of 
ESC, and requirements for growth and lineage commitment in the early mammalian embryo, are 
based on the mouse model. However, extensive studies on both mouse and human ESC have 
shown substantial differences, such as the dependence of mESC on leukemia inhibitory factor 
(LIF) to maintain their undifferentiated state (described latter in this chapter), and this may be 
explained by significant divergence between mouse and human development and/or to the fact 
that these cells are isolated/derived at different time points of development (Pera and Trounson, 
2004).  
 
1.1.1- Criteria to define an embryonic stem cell  
According to Pera et al (Pera et al., 2000) and considering mESC as standard, there are several 
criteria that can be used to define an ESC: 1) it originates from a pluripotent cell population, 2) it 
is stably diploid and karyotypically normal in vitro, 3) it can be cultured indefinitely in its primitive 
state, 4) it can differentiate into tissues of the three embryonic germ layers: endoderm, mesoderm 
and ectoderm in vitro or teratomas and 5) it can give rise to any cell in the body when injected 
into a host blastocyst. All these criteria have been confirmed by experimentation for mESC and 
mouse embryonic germ cells. Due to ethical reasons, it is not possible to validate the last criterion 
in hESC (Pera et al., 2000). 
 
1.1.2- Stem cell markers  
Pluripotent cells are characterized by distinctive cellular markers and properties that relate to their 
uncommitted state. These markers were first identified in hECC and in the early embryo and are 
particularly useful to follow stem cell populations and for isolation purposes. 
In order to characterize hESC a number of cell surface markers are currently used, including 
glycolipids and glycoproteins, such as SSEA3, SSEA4, Tra-1-60, Tra-1-81, GCTM2 and CD9. 
Despite their identification, the function of most of these markers is not completely understood. 
CD9 is a tetraspanin transmembrane protein and has probably a role in the organization of 
integrins and other receptors at the cell surface and has been implicated in mESC maintenance 
(Oka et al., 2002) and its expression is induced by STAT3 activation.  
Some common ESC surface markers and their presence in both human and mouse cells are 
shown in table 1.1. 
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TABLE 1.1- Cell-surface markers for pluripotent stem cells (Laslett et al., 2003) 
 mECC and mESC hECC hESC Human ICM 
SSEA1 + - - - 
SSEA2  -  + + + 
SSEA3 - + + + 
TRA-1-60 - + + + 
TRA-1-81 - + + + 
GCTM-2 - + + ? 
TG343 ? + + ? 
CD9 + + + ? 
 
Not only is it important to verify the presence of these markers but also to quantify their 
expression, because it is becoming more evident, especially in the case of hESC, that even an 
apparently undifferentiated population of stem cells is constituted of different subpopulations 
when assessed by a combination of immunological and transcriptional analysis (Laslett et al., 
2007). Downregulation of genes associated with undifferentiated state occurs in a coordinated 
fashion and during the early stages of stem cell differentiation these genes are co-expressed with 
lineage specific transcription factors in a continuum. The study by Laslett and colleagues (2007) 
has important practical implications for culture (for example by identifying new stem cell markers 
and growth factors that can be used to optimize culture conditions) and directed differentiation 
hESC (for example by defining the stages at which cells obtain lineage commitment). It can also 
help in the interpretation of studies of hESC self-renewal and commitment because if the 
population is heterogeneous when a given growth factor is added most likely a subset of cells will 
respond differently.  
Also, certain transcription factors are well known to play a role in stem cell maintenance. Oct3/4 
or Oct4, which belongs to POU family of transcription factors, is expressed by pluripotent stem 
cells in vitro as well as in the ICM of embryo, and is downregulated upon differentiation (Nichols 
et al., 1998; Niwa et al., 2000). Other important transcription factors are Nanog (Chambers et al., 
2003; Mitsui et al., 2003; Hart et al., 2004) and Sox2 (Avilion et al., 2003). These transcription 
factors play crucial role in early development and self-renewal of embryonic stem cells and 
collaborate to form regulatory circuitry consisting of autoregulatory and feedforward loops (Boyer 
et al., 2005). Oct4 and Sox2 can form a protein complex and suppress the expression of Cdx2, 
which is involved in the differentiation to trophectoderm, while Nanog can suppress GATA6, 
involved in the differentiation to primitive endoderm (reviewed by Boyer et al., 2006; Niwa, 2007). 
Perhaps undifferentiated growth is a function of repression of lineage specific differentiation.  
Three independent studies have reported reprogramming of mouse fibroblasts to a pluripotent 
state by ectopic expression of the transcription factors Oct4, Sox2, Klf4 and c-myc (Maherali et al., 
2007; Okita et al., 2007; Wernig et al., 2007) which were selected for Nanog expression. These 
cells were called induced pluripotent stem (iPS) cells and are very similar to mESC regarding 
morphology, deoxyribonucleic acid (DNA) methylation, gene expression and chromatin state. iPs 
cells were shown to contribute to the germline when introduced in mouse blastocysts since they 
were able to produce viable chimaeras. Unfortunately, Okita and colleagues have reported that 
about 20% of mice have developed tumours due to reactivation of c-myc transgene (Okita et al., 
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2007). Recently, iPs cells were generated from human adult dermal fibroblasts with the same 4 
factors mentioned above and from human fetal fibroblasts with Oct4, Sox2, Nanog, and LIN28 , 
opening the possibility of generating patient and disease-specific pluripotent stem cells 
(Takahashi et al., 2007; Yu et al., 2007). 
 
1.1.3- Culture methods for hESC propagation: advantages and limitations 
Two culture methods are widely used to propagate hESC (Figure 1.2): the original technique 
used to culture the cells, referred to herein as the standard method and the serum-free method. 
The standard method of culturing hESC involves weekly mechanical passaging of 
morphologically undifferentiated parts of a hESC colony onto full density (6x10
4
 cell/cm
2
) mouse 
or human fibroblast feeder (MEF and HEF, respectively) layers mitotically inactivated in Dulbeco’s 
modified Eagle’s medium (DMEM) containing 20 % fetal calf serum (FCS) or human serum 
(Reubinoff et al., 2000; Richards et al., 2002; Thomson et al., 1998). This protocol is demanding 
in terms of time, money and effort, but has proven to be a safe and reliable method for the long 
term propagation of hESC. This is highlighted by the fact that hESC thus cultured have rarely 
been reported to develop genetic abnormalities during culture. However, the major drawback of 
this method is the low number of hESC available for experimentation. Some laboratories 
therefore opt to maintain hESC stock cultures using this standard method and regularly establish 
fresh bulk cultures from these stocks for experimentation (Amit et al., 2000). The serum-free 
method of culturing hESC is performed according to a protocol developed by Amit and colleagues 
which involves passaging of enzymatically (for example collagenase and trypsin) or non-
enzymatically (cell dissociation solution, EDTA, etc) dissociated clumps of hESC on 1/3 density 
feeders (2x10
4
 cell/cm
2
) in DMEM/F12 supplemented with 20% Knockout serum replacement 
(KSR) from Invitrogen, and supplemented with fibroblast growth factor 2 (FGF-2). Despite the fact 
that KSR contains fewer components than FCS, its composition is still undefined and it contains a 
large amount of Albumax, a lipid-rich preparation of bovine serum albumin (BSA). This method 
allows for dramatic expansion of hESC. However, a number of reports have indicated that this is 
accompanied by an increase in genetic instability, methylation changes and mitochondrial 
mutations, abnormalities also seen in cancer and hECC (Draper et al., 2004; Mitalipova et al., 
2005; Brimble et al., 2004; Allegrucci et al., 2007). Allegrucci and colleagues examined the DNA 
methylation profiles of more than 2000 genomic loci by restriction landmark genome scanning 
and showed that the culture conditions can induce DNA methylation instability in the hESC 
epigenome (Allegrucci et al., 2007). The unstable loci have been previously associated with a 
tumour phenotype. They also showed that the adaptation of the cell lines to serum-free conditions 
result in additional epigenetic instability (Allegrucci et al., 2007). This study highlights the 
importance of using appropriate techniques to analyze epigenetic changes and evaluate their 
consequences on hESC experimental utility and biosafety, as well the need for optimization of 
derivation and culture protocols of hESC in order to minimize culture-induced instability.  
In addition to optimized culture methods that prevent the occurrence of genetic instability, novel 
technologies to purge abnormal hESC from large scale hESC cultures will have to be developed. 
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Xu et al (Xu et al., 2001) introduced a feeder free culture system for the first time for hESC culture. 
This consists of plating the cells on Matrigel, with MEF conditioned KSR medium supplemented 
with FGF-2 (Amit et al., 2004) (Figure 1.2). Matrigel
TM 
Basement Membrane Matrix (BD 
Biosciences) is a solubilized basement membrane preparation extracted from Engelbreth-Holm-
Swarm (EHS) mouse sarcoma, a tumour rich in extracellular matrix proteins. It contains collagen 
IV, laminin, heparin sulphate proteolycan and entactin, as well as several growth factors such as 
FGF-2, insulin-like growth factor-1, nerve growth factor (NGF), transformed growth factor β1 
(TGFβ1), epidermal growth factor and platelet-derived growth factor (PDGF). Similarly, hESC can 
be cultured on Laminin (purified from EHS mouse tumours or from human placenta) (Xu et al., 
2001) or Fibronectin (extracted from mouse, bovine or human plasma and human foreskin 
fibroblasts) (Amit et al., 2004).  
One of the biggest goals of hESC research is to culture the cells in the absence of animal 
products in order to minimize the risk of contamination with animal pathogens. Another goal is the 
development of a chemically defined media that could be used to test factors that modulate self-
renewal and differentiation, because serum can contain antagonist of those factors. Ludwig and 
colleagues have reported the development of a feeder-independent hESC culture composed of 
protein components uniquely derived from recombinant sources or purified from human material 
which they called TeSR1 (Ludwig et al., 2006b). This is a DMEM/F12 based medium 
supplemented with human serum albumin, FGF-2, LiCl, g-aminobutyric acid (GABA), pipecolic 
acid and TGFβ. They also derived two new cell lines in this defined media, but they developed 
chromosomal abnormalities. Because this media was highly costly, the same group have 
developed a modified version, the mTeSR1, which includes animal sources of protein (bovine 
serum albumin and Matrigel) and cloned zebrafish FGF-2 (Ludwig et al., 2006a). 
There are also studies currently being conducted that aim to identify components that support 
hESC self-renewal, especially the ones secreted by MEF, which will be described later. 
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•6x104 cells/cm2 Feeders
•Serum containing medium
•Mechanical passaging
•2x104 cells/cm2 Feeders
•Serum replacement  medium plus 
FGF-2
•Non-mechanical passaging
(enzymatic or non-enzymatic)
•Matrices and no Feeders
•MEF conditioned medium plus FGF-2
•Passaging (enzymatic or non-enzymatic)
Overview of
plate (day 7)
Colony detail
(at passaging)
Overview
of plate (day 1
after passaging)
Standard method Serum-free method on 
feeder layer
Serum-free method on 
Matrigel
 
FIGURE 1.2- Different methods of culturing of hESC (adapted from Grandela and Wolvetang, 2007). 
 
1.1.4- Maintenance factors of self-renewal and pluripotency 
In order to have a continuous source of hESC for research and therapeutic purposes, it is 
essential to maintain them for extended periods in their undifferentiated state. ESC self-renewal 
can be maintained in vitro by culturing cells in the presence of specific factors. 
 
1.1.4.1- LIF 
LIF, a cytokine that belongs to the IL-6 family, is sufficient to maintain mESC without the 
presence of feeders or serum containing medium. LIF acts via heterodimerization of two 
members of class I cytokines, the low affinity LIF receptor (LIFR) and the signal transducer gp130 
(Davis et al., 1993; Gearing et al., 1992) and ultimately activates the Jak/STAT pathway that is 
sufficient for self-renewal in these cells (Boeuf et al., 1997; Matsuda et al., 1999; Nakamura et al., 
1998; Niwa et al., 1998). Although the LIFR and gp130 are present in hESC, and there is 
activation of STAT members in response to recombinant human LIF or mouse LIF (Daheron et al., 
2004; Humphrey et al., 2004), this is not sufficient to maintain hESC in an undifferentiated state.  
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1.1.4.2- FGF-2 
FGF-2, also known as basic fibroblast growth factor (bFGF), is a member of a family of over 20 
polypeptide growth factors (Ornitz and Itoh, 2001) FGFs are found in different species ranging 
from nematodes to humans. The recombinant FGF-2 is a 16.5-kDa peptide with 144 amino acids 
(Okada-Ban et al., 2000). The biologic activity of FGF-2 is mediated by four related 
transmembrane tyrosine kinase receptors: FGFR-1, -2, -3, and -4, and possibly other 
transmembrane receptors (Powers et al., 2000; Khurana and Simons, 2003). Ligand binding 
results in homodimerization of these receptors, trans-phosphorylation and signal transduction. 
Numerous splice variants of multiple genes generate a wide diversity of FGFRs. FGF-2 has a 
pleiotropic effect on different types of cells and its cellular response can be affected by type of 
receptor binding, rate of intracellular growth factor uptake and interacting molecules inside the 
cell (Goldfarb, 2001). FGF-2 can act as a survival factor by blocking apoptosis (Fisher, 1997; 
Stachowiak et al., 1997), it also stimulates angiogenesis (Slavin, 1995; Bikfalvi, 1995) and cell 
proliferation via activation of the Ras/Raf-MAPK pathway by enabling adaptor proteins Grb2, Shc, 
and Nck to participate in signal transduction cascades (Klein and Schneider, 1997). It can also 
promote tumor progression (Bikfalvi, 1995; Vacca et al., 2001). FGF-2 was been used in hESC 
culture (Xu et al., 2001; Amit et al., 2004) in serum- and feeder-free culture methods because it 
inhibits hESC differentiation. Two studies were published that show that higher doses of FGF-2 
(100 and 40 ng/ml) override the requirement for MEF feeders or its conditioned medium on 
maintenance of hESC and this effect is mediated by the inhibition of BMP signaling (Xu et al., 
2005a; Xu et al., 2005b; Levenstein et al., 2006). 
Bendall and colleagues have found that under feeder-free culture conditions, the hESC organize 
themselves in order to create a niche in which derived hESC derived fibroblast-like cells are 
dependent on FGF-2 and in response to this factor express IGF-1 reported to promote self-
renewal of undifferentiated hESC (Bendall et al., 2007). 
 
1.1.4.3- Transforming growth factor β (TGFβ) pathway 
TGFβ superfamily members play an important role in a wide range of cellular processes including 
tissue differentiation, morphogenesis, proliferation, migration and apoptosis in embryonic 
development, as well in adult homeostasis and response to disease and injury (Massague, 1990). 
The TGFβ superfamily of ligands include TGFβ, Activin, Nodal, Bone morphogenetic proteins 
(BMP) and Growth/Differentiation factors (GDF), among others. All of these have been 
associated with ESC (Valdimarsdottir and Mummery, 2005). These ligands bind to heteromeric 
complex of serine/threonine kinase receptors called TGFβ type I and type II receptors. The type I 
receptor acts downstream of the type II receptor and transduces the signal through the 
phosphorylation of Smads (Massague, 2000; Piek et al., 1999), wich play theirs role in the 
nucleus acting as transcription factors or target genes.  
It has been shown that maintenance of  hESC in an undifferentiated state requires the action of 
the TGFβ/Nodal/Activin branch of the TGFβ superfamily (Amit et al., 2004; Ludwig et al., 2006b; 
Vallier et al., 2005; Vallier et al., 2004). It has been suggested that TGFβ1 prevents differentiation 
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along the primitive endoderm lineage (Poon et al., 2006). On the other hand, BMP signaling 
needs to be repressed to prevent differentiation into to primitive endoderm or along the 
trophoblast lineage (Pera et al., 2004; Xu et al., 2002c). While TGF, Activin, and Nodal bind to a 
set of receptors that stimulates the activation of SMAD 2/3, BMP4 binds to different receptors and 
activates the SMAD 1/5/8 signaling (Valdimarsdottir and Mummery, 2005). 
Culture medium supplemented with Activin A can maintain hESC in the undifferentiated state for 
over 20 passages without the need for feeder layers or conditioned medium from MEF (Beattie et 
al., 2005; Xiao et al., 2006). The bone morphogenetic protein antagonist, Noggin, in combination 
with FGF-2, was shown to maintain the pluripotency of hESC in the absence of feeder layers 
(Wang et al., 2005). These three growth factors are all expressed in MEF, suggesting that they 
may be important factors secreted by MEF for maintaining undifferentiated hESC. 
 
1.1.4.4- MEF secreted factors 
A great deal of research is focusing on the identification of factors that are secreted by MEF. 
Conditioned medium from MEF is sufficient for the maintenance of hESC on Matrigel. This 
suggests that secreted factors produced by MEFs can activate the molecular programs required 
for maintaining hESC in an undifferentiated state. The identification of these factors, signaling 
pathways and downstream target genes is fundamental for the future of hESC research, 
especially because the ultimate goal is to produce chemically defined and xeno-free media to 
culture these cells. A genome-wide expression profiling performed by Greber and colleagues 
revealed that FGF-2 acts on MEF to regulates the expression of key members of the TGFβ 
pathway (upregulates Inhba, Tgfb1, Grem1, and downregulates Bmp4) that are most likely to 
influence hESC self-renewal (Greber et al., 2007). They also showed that FGF-2 has similar 
effect on hESC, suggesting that TGFβ ligands act in an autocrine manner. 
 
1.1.4.5- Other factors 
Another study claimed that activation of the canonical Wnt pathway is sufficient to maintain self-
renewal of both hESC and mESC and this was achieved by using a specific pharmacological 
inhibitor of glycogen synthase kinase-3 (GSK-3), 6-bromoindirubin-3'-oxime (BIO) (Sato et al., 
2004). However, data reported  by others (Dravid et al., 2005) and in our laboratory (Kathryn 
Davidson, personal communication) do not support the findings claimed by Sato and colleagues. 
Wnts seem to promote proliferation and inhibition of apoptosis of hESC rather than promoting 
self-renewal. 
Pebay and colleagues (Pebay et al., 2005) have also reported a system for the maintenance of 
stem cells. They have shown that sphingosine-1-phosphate and PDGF, two known mitogens 
components of serum, can maintain hESC self-renewal in a serum-free culture medium but still in 
the presence of feeder layers. They suggested that this is mediated by activation of the 
extracellular signal-regulated kinases (ERKs).  
In summary, different pathways seem to be required for ESC maintenance, proliferation and 
repression of differentiation.  
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1.1.5- Strategies to improve clonal survival 
hESC are very difficult to clone and frequently die or differentiate when dissociated to single cells 
or small clumps. This limits the application of the most useful genetic techniques. In order to solve 
this problem some groups are developing strategies to improve clonal survival.  
In 2006, Peter Donovan’s group reported that hESC express receptors of tropomyosin-related 
kinases (TRK) family, which are mediators of antiapoptotic signals. They further showed that 
three TRK ligands, brain-derived neurotrophic factor, neurotrophin 3 and neurotrophin 4, mediate 
hESC survival trough the phosphatidylinositol-3-kinase pathway (Pyle et al., 2006) for 15-20 
passages. More recently, has been reported that Y-27632, an inhibitor of a selective Rho-
associated kinase also known as ROCK inhibitor, when supplemented to a serum-free media to 
increases cloning efficiency of hES cells from 1% to 27% by inhibiting dissociation-induced 
apoptosis (Watanabe et al., 2007).  
 
1.1.6- Cell cycle of hESC 
When in culture the majority of mammalian cells undergo a limited number of cell divisions until 
they reach a state of irreversible proliferation, called replicative senescence (Hayflick and 
Moorhead, 1961). The number of division that the cells undergo before they senescence is called 
the Hayflick limit and this is dependent on the cell type or species. This limit suggests that there is 
something like a mitotic clock regulating the number of divisions. Loss of genomic and 
mitochondrial genomic integrity, epigenetic alterations, oxidative damage, progressive loss of 
DNA repair ability and erosion of telomeres have been implicated in senescence. hESC 
(Thomson et al., 1998), as well as transformed cells, have bypassed senescence and appear to 
be immortal in culture. ESC also display constitutive replication, which is a common of aspect of 
early embryo development in many species. This may reflect the requirement of establishing 
sufficient cell numbers to initiate gastrulation (Burdon et al., 2002). 
The cell cycle of hESC still has the four cell cycle phases G1, S, G2, and M, however the duration 
of G1 is dramatically shortened (Becker et al., 2006). By measuring Bromodeoxyuridine (BrdU) 
incorporation and subsequent fluorescence-activated cell sorting (FACS) analysis this study was 
able to show that 65% of asynchronously growing human ES cells are in S phase. The duration of 
the S is approximately 8 h, G2 approximately 4 h, and M phases approximately 1 h are similar in 
ES and somatic cells, but G1 phase has a duration of only 2.5-3 h that is significantly shorter than 
what is commonly observed for somatic cells (Becker et al., 2006). 
In the case of mESC, Burdon and colleagues have suggested that G1 control pathways that 
operate in other types of cell are reduced or absent in ESC and that the uncoupling from G1 
regulation might be involved in sustaining the undifferentiated state cells possibly by constraining 
the temporal opportunity for both chromatin remodeling and the establishment of heritable 
transcription programs (Burdon et al., 2002). 
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1.1.7- Epigenetics 
Epigenetic modifications, such as autosomal imprinting and X-chromosome inactivation, are 
crucial for proper development and cell fate determination. A number of genetic diseases and 
cancers have been associated with loss of imprinting.  
Additionally, epigenetic mechanisms contribute to the repression of inappropriate developmental 
programs in time and space while ensuring heritability of existing or newly acquired phenotypic 
states. Several studies have been done to evaluate the epigenetic status of mESC and hESC, 
including the assessment of the abundance of modified histones and enzymes responsible for 
modifications, Polycomb group (PcG) protein binding patterns, replication timing and chromatin 
accessibility (reviewed by Spivakov and Fisher, 2007). 
Determining how these epigenetic features relate to the transcriptional signatures of ESC, and 
whether they are also important in other types of stem cell, is a key challenge for the future 
(Spivakov and Fisher, 2007).  
Rugg-Gunn PJ and colleagues (Rugg-Gunn et al., 2005) examined the allele-specific expression 
of six imprinted genes and the methylation profiles of three imprinting control regions. They 
identified generally monoallelic gene expression and normal methylation patterns. During 
prolonged passage, one cell line became biallelic with respect to H19, but without loss of the 
gametic methylation imprint. The authors of this study claimed a significant degree of epigenetic 
stability in hESC (Rugg-Gunn PJ et al., 2005). 
As mentioned before, a more recent study has reported DNA methylation instability in hESC 
epigenome induced by culture conditions (Allegrucci et al., 2007) and that the unstable loci have 
been previously been associated with tumour phenotype.  
 
1.1.8- hESC signature and gene expression profiling 
In order to define the gene expression signature of undifferentiated hESC, to compare this 
signature between different stem cell lines and to shed more light on the common regulatory 
networks that are operational in ESC, a large number of high throughput studies have been 
performed on these cells. Serial analysis of gene expression, massively parallel signature 
sequencing, transcriptional profile analysis by microarrays and proteomic approaches are the 
most commonly carried out.  
Many gene expression profiling studies have been performed on hESC. These microarray studies 
have revealed that hESC are enriched for genes that encode for certain transcription factors (for 
example, Oct4, Nanog, Sox2, FoxD3, Rex1, SRY), DNA modifying enzymes (for example, TERF1, 
CHK2, DNMT3), surface markers (for example, connexin43), growth/differentiation factors (FGF-2, 
CER1, GDF3), receptors (FGFR1, FGFR2, TDGF1, FZD5, FZD), and genes involved in the 
control of the cell cycle, apoptosis, and DNA repair, among others with known and unknown 
function (Abeyta et al., 2004; Bhattacharya et al., 2005; Bhattacharya et al., 2004; Ginis et al., 
2004; Rao et al., 2004; Richards et al., 2004). 
Ginis and colleagues (Ginis et al., 2004) compared gene expression profiles of hESC and mESC 
by immunocytochemistry, reverse-transcriptase polymerase chain reaction (RT-PCR), and 
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membrane-based focused cDNA array analysis. Many genes were found to be commonly 
expressed in ESC of these two species. Genes that showed differences in their expression were 
vimentin, beta-III tubulin, alpha-fetoprotein, eomesodermin, HEB, ARNT, and FoxD3 as well as 
the LIFR complex LIFR/gp130. Differences in genes related to cell cycle regulation, control of 
apoptosis, and cytokine expression were also found. The profile of gene expression observed in 
H1 cells was similar to that of two other hESC lines tested (line I-6 and clonal line-H9.2) and to 
feeder-free subclones of H1, H7, and H9. This indicates that differences between hESC and 
mESC in terms of pluripotency marker expression were species-specific and not due to 
differences in culture conditions. 
One of the limitations/problems of most of microarray studies performed on hESC is the fact that 
hESC are analyzed as if they were a homogenous population. Because such populations include 
both undifferentiated and differentiated cells, microarray analysis will reflect this heterogeneity. 
Enver and colleagues developed the first microarray analysis using Affymetrix analysis on hESC 
sorted by flow cytometry based on presence or absence of the cell surface glycoprotein SSEA3 
(Enver et al., 2005). The found that 468 genes were uniquely expressed in normal SSEA3+ and 
proposed a cellular differentiation hierarchy for HESC culture maintenance: normal SSEA3+ cells 
represent pluripotent stem cells while normal SSEA3- cells have exited this compartment, but 
retain multilineage differentiation potential. As mentioned before Laslett and colleagues also took 
heterogeneity in account and went further in dividing hESC into more subpopulations based on 
their immunoprofile (GCTM-2 and CD9 immunostaining) and performed their transcriptional 
analysis on a Compugen platform (Laslett et al., 2007). They divided the population in 4 
subpopulation expressing different levels of antigens mentioned above (P7, expresses the 
highest level of stem cells antigens, P6, P5 and P4, negative cells for cell surface markers) and 
showed that these subpopulations exhibit different gene expression profiles. Comparing this 
study to the first mentioned, the greatest overlap observed was between SSEA3+ versus SSEA3- 
and P7 versus P4. 
 
1.1.9- International Stem Cell Initiative: an attempt to compare different hESC cell lines 
The International Stem Cell Initiative is an international consortium that is comparing the 
properties of 75 hESC from laboratories around the world (Andrews et al., 2005). 
The characterization studies included flow cytometry analysis of cell surface markers, reverse 
transcriptase polymerase chain reaction (RT-PCR) of genes characteristic of hESC and their 
early differentiation derivatives, as well as to investigate the change on gene expression during 
embryonic body formation, a simple differentiation protocol. The results of these collaborative 
studies were recently published. They reported that 59 hESC lines from 17 laboratories worldwide, 
despite diverse genotypes and different techniques used for derivation and maintenance, 
exhibited similar expression patterns for several markers (such as SSEA-3,  SSEA-4, TRA-1-60, 
TRA-1-81, GCTM2, GCT343, CD9, Thy1, tissue-nonspecific alkaline phosphatase, class 1 HLA, 
Nanog, Oct4, TDGF1, DNMT3B, GABRB3 and GDF3). However, the lines showed differences in 
expression of several lineage markers and although several imprinted genes showed generally 
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similar allele specific expression patterns, some gene-dependent variation was observed. In 
addition, some female lines expressed readily detectable levels of XIST while others did not. 
Fortunately, the study did not detect contamination of the lines with mycoplasma, bacteria or 
cytopathic viruses. 
 
1.1.10- In vitro Differentiation of hESC 
There are many studies demonstrating that hESC can differentiate into multiple cell lineages 
(Table 1.2). These protocols involve either spontaneous differentiation, mainly through the 
formation of embryoid-bodies (EB), directed differentiation using growth factors and/or 
extracellular matrices, or even co-culture with other cell types. hESC have been shown to be able 
differentiate into cell types of ectodermal, endodermal, mesodermal and extraembryonic lineages.  
EB formation was the first method used to induce differentiation in ECC (Martin and Evans, 1975) 
and mimics the process of formation of germ layers from the ICM. Other protocols explore the 
role of known morphogens implicated in embryonic development, such as BMP4, Activin (at 
higher concentrations than the reported to promote maintenance of hESC), Retinoic acid (RA) 
and Wnt. 
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TABLE 1.2- Published differentiation of hESC (Adapted from Hoffman and Carpenter, 2005) 
Cell 
lineage 
Cell type Cell 
line  
Note Reference 
General differentiation 
 Endoderm, 
ectoderm and 
mesoderm 
derivatives   
H9.1 Formation of EBs followed by treatment with 
growth factor  and analysis of expression of 
mRNA   
(Schuldiner et 
al., 2000) 
  H9 Expression of several markers by PCR and 
immunostaining 
(Itskovitz-
Eldor et al., 
2000) 
  H13 Gene expression profile by microarray 
during differentiation 
(Dvash et al., 
2004) 
Ectoderm  
 Neurons H9 RA and NGF neuronal differentiation (Schuldiner et 
al., 2001) 
 Neurons and glia H1,H7,H
9 
Differentiation into enriched populations of 
functional neurons and neural progenitors 
(Carpenter et 
al., 2001) 
 Neurons and glia H1,H9, 
H9.2 
Differentiation into neural progenitors, 
neurons and glia. Transplantation into 
neonatal rats 
(Zhang et al., 
2001) 
 Neurons and glia HES-1 Differentiation into neural progenitors, 
neurons and glia. Transplantation into 
neonatal rats 
(Reubinoff et 
al., 2001) 
 Neurons BG01, 
BG02 
Differentiation into neural precursors and 
neurons 
(Schulz et al., 
2003) 
 Neurons HES-1 Differentiation into dopaminergic neurons 
Transplantation into Parkinsonian rats, 
resulting in functional improvement 
(Ben-Hur et 
al., 2004) 
 Neural precursors HES-2, 
HES-3 
Differentiation into neural precursors (Pera et al., 
2004) 
 Neurons H1, H9, 
HES-3 
Differentiation into midbrain dopaminergic 
neurons 
(Perrier et al., 
2004) 
 Neurons BG01, 
BG03 
Differentiation into dopaminergic neurons (Schulz et al., 
2004) 
 Neurons BG01 Differentiation into dopaminergic neurons (Zeng et al., 
2004) 
 Neurons MB03 Differentiation into dopaminergic neurons (Park et al., 
2004) 
 Neurons H1,H9 Differentiation into motoneurons neurons (Li et al., 
2005) 
 Oligodendrocytes H7 Differentiation into enriched populations of 
oligodendrocytes and myelination after 
transplantation 
(Nistor et al., 
2005) 
Endoderm 
 Insulin positive 
cells 
H9 Direct differentiation (Assady et al., 
2001) 
 Insulin-producing 
cells 
H9, H9.2, 
H13, I6 
Direct differentiation (Segev et al., 
2004) 
 Hepatocyte-like 
cells 
H1, H9 Direct differentiation (Rambhatla et 
al., 2003) 
 Hepatocyte-like 
cells 
N/A Direct differentiation (Lavon et al., 
2004) 
Mesoderm     
 Cardiomyocytes H9.2 Evaluation of structural and functional 
properties  
(Kehat et al., 
2001) 
 Cardiomyocytes H9.2 High resolution electrophysiology (Kehat et al., 
2002) 
 Cardiomyocytes H1,H7,H9  Differentiation into enriched populations of 
functional cardiomyocytes 
(Xu et al., 
2002a) 
 Cardiomyocytes HES-2 Differentiation into cardiomyocytes and their 
characterization 
(Mummery et 
al., 2002), 
(Kehat et al., 
2003) 
 Cardiomyocytes H1,H7,H9, 
H14 14 
Evaluation of electrophysiological and 
pharmacological properties 
(He et al., 
2003) 
 Cardiomyocytes HES-2 Differentiation into cardiomyocytes by co-
culture with END-2 cells 
(Mummery et 
al., 2003) 
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 Cardiomyocytes H9.2 Evaluation of ultrastructural and proliferative 
characteristics 
(Snir et al., 
2003) 
 Cardiomyocytes H9.2 Evaluation of electrophysiological and 
pharmacological properties 
(Satin et al., 
2004) 
 Cardiomyocytes H1 Demonstration of functional integration after 
transplantation into guinea pig model 
(Xue et al., 
2005) 
 Hematopoietic 
colony-forming 
cells 
H1, H1.1, 
H9.2 
Differentiation of multipotent hematopoietic 
precursors 
(Kaufman et 
al., 2001) 
 Hematopoietic 
progenitor cells 
H1, H9 Differentiation of multipotent CD45
+
 
hematopoietic precursors 
(Chadwick et 
al., 2003) 
 Hematopoietic 
progenitor cells 
H1, H9 Differentiation of multipotent CD34
+
 
hematopoietic precursors 
(Vodyanik et 
al., 2005) 
 Hemangioblasts H1, H7,  
H9, MA01, 
MA03, 
MA40 and 
MA09) 
Differentiation into multiple hematopoietic 
lineages and endothelial cells. 
Transplantation into rats and mice injured 
models, resulting in vascular repair 
(Lu et al., 
2007) 
 Leucocytes H1 Differentiation into antige-presenting 
leucocytes 
(Zhan et al., 
2004) 
 Endothelial cells H9 Isolation and characterization of hESC-
derived endothelial cells 
(Levenberg et 
al., 2002) 
 Endothelial  H1, H9 Identification of primitive endothelial-like 
cells that generate endothelial and 
hematopoietic cells  
(Wang et al., 
2004) 
 Endothelial  H9.2 Evaluation of endothelial markers during 
spontaneous differentiation  
(Gerecht-Nir 
et al., 2005) 
 Vasculogenesis H9.2, 
H13 
Vasculogenesis using alginate scaffolding (Gerecht-Nir 
et al., 2004b) 
 Vasculogenesis H9.2, 
H13, I6 
Vasculogenesis in teratomas (Gerecht-Nir 
et al., 2004a) 
Extraembryonic  
 Trophoblast H1, H7, 
H9, H14 
Differentiation into trophoblasts (Xu et al., 
2002c) 
 Trophoblast H1 Identification of trophoblast cells in EB (Gerami-Naini 
et al., 2004) 
Germ cells 
 Germ cells HSF-1, 
HSF-6, 
H9 
Spontaneous differentiation of stem cells (Clark et al., 
2004) 
 
As seen from studies above, hESC have been vigorously investigated as a source for cell 
replacement therapies, and it is apparent that they can differentiate into a wide range of specific 
cell types. In order to deliver on their promise, large amounts of high quality hESC will be needed 
that are genetically stable, free of animal products and manipulated to evade the immune system 
through either somatic cell nuclear transfer or other technologies. A deeper understanding of the 
molecular mechanisms that control the genetic stability of hESC is required.  
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1.2- GENETIC STABILITY: HESC AS A MODEL 
Arguably the ES/EC cell pair, and the phenomenon of culture adaptation of ES cells, provides  
a rare, if not the only, circumstance in which one can readily access the normal  
counterpart of a tumour stem cell and observe progressive changes as the  
‘normal’ stem cell converts to a malignant state (Baker et al., 2007). 
 
Although the original reports on hESC indicated that they can maintain a normal diploid karyotype 
during long term propagation in vitro, there is evidence that this depends on culture conditions. 
Different laboratories have reported that hESC cultured for long periods of time tend to gain 
chromosomal abnormalities, resembling the ones observed in hECC (reviewed by Grandela and 
Wolvetang, 2007). The most frequently observed karyotypic abnormalities are gain of 
chromosome 17q, 12 and the X chromosome (Brimble et al., 2004; Draper et al., 2004; Mitalipova 
et al., 2005), while there also seems to be a high proportion of partial or total chromosome 1 
duplication. It has been postulated that increased dosage of those chromosomes might give the 
cells some sort of selective advantage. 
Draper and colleagues (Draper et al., 2004) were the first to report gain of chromosome 17q and 
chromosome 12 in H7 and H14 cell lines cultured with KSR (Invitrogen/GIBCO) instead of FCS 
and passaged with an enzymatic method (Collagenase IV). They performed interphase 
fluorescence in situ hybridization (FISH) and showed that after 22 passages trisomy 17 was 
observed in 76% of the cells and after an additional 17 passages, in 95% of the cells, again 
indicating that such cells possess enhanced survival or proliferation properties. Buzzard and 
colleagues (Buzzard et al., 2004) cultured six NIH-registered hESC lines (hES1-6) between 34 
and 140 passages using mechanical method of passaging cells rather than enzymatic or 
chemical methods of cell dissociation. They reported just one karyotype abnormality was 
detected in an early passage hES5, demonstrating that hESC are not necessarily predisposed to 
karyotypic abnormalities even grown for extended time. Another group studied three cell lines 
(BG01, BG02 and BG03) and showed that karyotypic changes also give rise to differences in 
expression of genes, especially those involved in pluripotency (Mitalipova et al., 2005). They 
reported that bulk passaging (nonenzymatic- Cell Dissociation Buffer- or enzymatic- colagenase, 
trypsin) methods can compromise the genetic stability of hESC, in contrast to manual methods.  
Because classical G-band karyotyping can only give a rough idea of chromosomal stability, 
techniques with higher resolution should be used to detect smaller chromosomal and gene 
alterations/mutations. Other studies have attempted to overcome that problem by using 
techniques, like SNP, to track down these alterations on hESC, especially those that are cultured 
for long periods of time. Maitra and colleagues (Maitra et al., 2005) compared nine hESC lines 
(BG01, BG02, BG03, H1, H7, H9, HES-2, HES-3, SA001 and SA002) derived and cultured in 
different laboratories at both early and late passage, and found the former contain one or more 
genomic alterations commonly observed in human cancers, mitochondrial DNA sequence 
mutations and gene promoter methylation. Enver et al (2005) investigated the adaptation process 
by comparing early passage (normal) and late passage (adapted) sublines of H7. The karyotype 
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of early passage cells was normal, whereas the adapted showed an extra copy of chromosome 1 
and chromosome 17q amplification. A slightly higher proportion of SSEA-3+ cells were found in 
the adapted cultures as compared to the normal ones (83 and 64%, respectively). This group also 
showed X-inactivation in adapted cells suggesting that epigenetic changes are also associated 
with adaptation. Thus the mechanism of adaptation may be similar to the early events involved in 
oncogenesis and tumour progression. Baker and colleagues (Baker et al., 2007) have made an 
attempt to link culture adaptation and malignancy. In agreement with other laboratories they also 
observed a nonrandom gain of certain regions in the three mainly affected chromosomes in hESC 
(12, 17 and X). They hypothesized that these chromosomes may contain candidate genes that 
could be important for the observed culture adaptation and/or play a role in stem cell 
maintenance in vitro and cell tumorogenesis in vivo. One of these candidate genes present in 
terminal half of q arm of chromosome 17 is BIRC5, also known as Survivin. Survivin can act as 
an antiapoptotic gene and also plays a role in chromosome segregation and is expressed in a 
large number of tumour types such as neuroblastomas and associated with highest-risk tumours 
and poor survival outcome. Gain of chromosome 12 was also frequently observed in both hESC 
and testicular germ cell tumours (TGCT). Nanog, a pluripotency gene, is located on 12p13 and 
overexpression of this gene promotes self-renewal and prevents differentiation and thus providing 
hESC with an anti-differentiation and proliferative advantage in culture. Another amplified region 
on chromosome 12, 12p11.2-12 that is also frequently amplifies in TGCT harbours the oncogene 
K-RAS and SOX5, a gene involved in cell fate determination. Reduced apoptosis has been 
observed in malignant cells with amplification of this genomic region (Roelofs et al., 2000), and it 
is possible that amplification of this region may confer a similar survival advantage to hESC. 
Multiple studies have found that hESC acquire additional copies of chromosome X and often 
TGCT have more than one X chromosome. Enver et al further identified ELK1, A-RAF, the 
androgen receptor and its interacting protein NONO, as potential candidate genes on X that could 
be involved in hESC adaptation. The non random gain of chromosomes 12, 17 and X observed in 
different hESC lines in different laboratories around the world lends support to the hypothesis that 
there may be genes on these chromosomes that confer a growth or anti-differentiation advantage 
to hESC in culture. Generating small clumps or single cells from hESC colonies in general leads 
to apoptosis and differentiation. The fact these abnormalities occur more frequently in bulk 
cultured cells suggests that the seeding of small clumps of hESC puts selective pressure on 
hESC that favors hESC with such genetic abnormalities. In this context increased expression of 
genes that inhibit apoptosis and differentiation of hESC, such as CD30, a biomarker for 
transformed human pluripotent stem cells, (Herszfeld et al., 2006), prior to overt genetic 
abnormalities may increase the likelihood of acquiring further abnormalities.  
Because of their pre-existing capacity for self-renewal and unlimited replication, stem cells are 
also appealing candidates as the “cell of origin” for cancer (Beachy et al., 2004; Reya et al., 2001). 
Investigating the adaptation process by which cells go from normal to transformed can give 
insights to mechanisms responsible for the development of cancers. However, it is still to be 
addressed experimentally if a mutation or other genetic or epigenetic change that gives a 
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selective advantage to undifferentiated hESC will have an effect on the behavior of their 
differentiated progeny (Baker et al., 2007).   
If one wants to limit the appearance of abnormal hESC within the culture it is crucial to investigate 
the response of hESC to genomic insults or DNA damage. In response to DNA damage various 
mechanisms can be activated: DNA repair, transcriptional response, DNA damage checkpoints 
with cell cycle arrest, or if the damage is irreparable, apoptosis. This study will focus mainly on 
apoptosis.  
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1.3- APOPTOSIS 
Programmed cell death is critical for development and homeostasis in metazoans 
(Vaux and Korsmeyer, 1999).  
 
The phenomenon of apoptosis was first described by Carl Vogt in 1842, and its name, introduced 
by Kerr, Wyllie and Currie in 1972, is derived from the ancient Greek meaning the ‘‘falling off of 
petals from a flower’’ or ‘‘shedding of leaves from a tree in autumn’’. This term was used to 
describe a common type of programmed cell death that was observed in various tissues and cell 
types. The dying cells shared many morphological features, that were distinct from the features 
observed in cells undergoing necrotic cell death, and this could be a result of common and 
conserved endogenous cell death programme. Apoptosis is a form of caspase-mediated cell 
death with particular morphological features and usually does not lead to inflammation (Fink and 
Cookson, 2005). Unlike apoptosis, necrosis denotes a form of cell death usually accompanied by 
inflammation (Savill, 1997), is not energy dependent, does not involve caspase activity or gene 
regulation.Table 1.3 shows differences these two processes. 
 
TABLE 1.3- Comparison between apoptosis and necrosis (Adapted from Academic Pathology, 
Queen's University Belfast, 2003) 
Apoptosis Necrosis 
Physiological or pathological Always pathological 
Energy dependent Energy independent 
Cell shrinkage Cell swelling 
Membrane integrity maintained Membrane integrity lost 
Characteristic nuclear changes Nuclei lost 
Apoptotic bodies form Do not form 
DNA cleavage No DNA cleavage 
Evolutionarily conserved Not conserved 
Dead cells ingested by neighbouring cells Dead cells ingested by neutrophils and 
macrophages 
 
Apoptosis should not be used synonymously with programmed cell death (PCD), which can occur 
via apoptosis, but is rather used to identify a specific morphology of cell death. The term PCD 
refers to time- and position-programmed cell death during development of an organism. However, 
apoptosis can be induced by anti-cancer drugs, toxins and other types of stresses (Lawen, 2003). 
One of the main reasons for the interest in this process is due to its involvement in many 
diseases, such as neurodegenerative and autoimmune diseases (if it occurs too much) and 
cancer (if it occurs too little).  
 
1.3.1- Apoptosis in development and homeostasis 
During animal development, there are numerous structures or specific populations of cells that 
are formed that are later removed by apoptosis. This allows greater flexibility because primordial 
structures can be adapted for different functions at various stages of life or in different sexes 
(Meier et al., 2000). A classical example of this is the development of the Müllerian duct (that 
gives rise to the uterus and oviduct in females) that is removed in males, and the Wolffian duct 
(that gives rise to the male reproductive organs) that is deleted in females. Other examples are 
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cavitation, neural tube and kidney formation, mammary gland development and the separation of 
the digits.  
In the adult a balance between the number of cells that divide and die must be kept relatively 
constant in order to maintain homeostasis. Furthermore, cells need to be replaced when they are 
malfunctioning or eliminated if they can potentially become tumorigenic. 
During early human development a high degree of genetic abnormality occurs, since the majority 
of first trimester miscarriages are attributed to chromosomal defects (Metcalfe et al., 2004). 
Preimplantation embryos undergo apoptosis at the blastocyst stage, primarily in the ICM. As 
many as 7-8% of these cells undergo apoptosis at any one time (Hardy et al., 1989) and coupled 
with the observation that aneuploid cells can be present in the human ICM (Evsikov and 
Verlinsky, 1998), this emphasizes the potential role of apoptosis in eliminating genomic damage 
from foetal development. Dead ICM cells usually display typical morphological features of 
apoptosis and are adequately phagocytozed (Fabian et al., 2005). Furthermore, the incidence of 
apoptosis in in vitro produced embryos can be increased in suboptimal culture conditions, 
resulting for example from inappropriate composition of culture medium or inappropriate culture 
density of embryos. Although apoptosis may be necessary to eliminate genetic damage, it must 
also be tightly regulated in order to prevent inappropriate loss of normal cells.  
 
1.3.2- Apoptosis in ESC  
DNA damage response and cell-cycle regulation differ markedly between mESC and somatic 
cells (Hong and Stambrook, 2004). Spontaneous mutation frequency in mouse somatic cells is 
approximately 100-fold higher than in mESC cells. mESC cells also lack a G1 checkpoint as 
mentioned before and are hypersensitive to ionizing radiation and other DNA-damaging agents 
(Hong and Stambrook, 2004). These characteristics facilitate apoptosis and the removal of cells 
with a mutational burden from the population. 
Sumi and colleagues using an inducible system to promote the sustained activation of proto-
oncogene c-myc found that this results in apoptosis and differentiation into extraembryonic 
lineages of hESC (Sumi et al., 2007). These effects were transcription dependent, but blocking 
caspase activity or knocking-down p53 were not sufficient to prevent induction of differentiation 
markers by c-myc activation.  
It is anticipated that a detailed understanding of apoptosis pathways in hESCs will be useful for 
future cell replacement therapies using hESCs since it may allow for the selective elimination of 
unwanted cell lineages prior or subsequent to lineage specific differentiation. An example of the 
usefulness of such information apoptosis was demonstrated by Bieberich and colleagues (2004) 
in mice, who showed that ceramide-induced apoptosis eliminates residual pluripotent ESC, 
prevents teratoma formation, and enriches the embryoid body-derived cells for cells that undergo 
neural differentiation after transplantation (Bieberich et al., 2004).  
During transplantation of ESC derivatives, most of the cells die, restricting the contribution of the 
graft to recovery in injury or disease models. A study performed by Wei and colleagues (Wei et al., 
2005) circumvented this limitation by overexpressing the anti-apoptotic gene Bcl2 in mESC. The 
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cells were then differentiated with RA down to neural lineages and transplanted into the post-
infract brain of adult rats. After transplantation, ESC derived cells with the Bcl2 gene showed 
increased expression markers for neural cells, and the survival of these cells and functional 
recovery of ischaemic rats that received them was also increased. There was no formation of 
tumours, possibly because overexpression of Bcl2 did not completely prevent apoptosis in the 
host brain.  
Another problem is the low survival of hESC that are frozen using conventional slow-cooling 
cryopreservation protocols. They die predominantly by apoptosis rather than necrosis (Heng et 
al., 2006). A study used the caspase inhibitor zVAD-fmk to enhance the survival rate of these 
cells after thawing 2007 from 9.9% to 18.7% and this was not accompanied by a significant 
enhancement in spontaneous differentiation of hESC (Heng et al., 2007). 
There is little published work on apoptotic signaling pathways in hESC and no information on the 
molecular mechanism of DNA damage-induced apoptosis in these cells prior to the body of work 
presented in this thesis. 
 
1.3.3- Major molecular regulators of apoptosis 
 
1.3.3.1- Bcl2 family 
The Bcl2 family of proteins are the central regulators of caspase activation, and its anti- and pro-
apoptotic members are key arbiters of the life-or-death decision (Cory and Adams, 2002). The 
first member to be identified was Bcl2 at the chromosomal breakpoint of t(14;18) bearing human 
follicular B cell lymphoma (Bakhshi et al., 1985; Cleary and Sklar, 1985; Tsujimoto et al., 1985). 
Later it was shown that this proto-oncogene, instead of promoting cell proliferation, inhibits 
apoptosis following physiological and pathological stimuli (McDonnell et al., 1989; Vaux et al., 
1988).  
In mammals, the Bcl2 family has at least 20 members which share at least one conserved Bcl2 
homology (BH) domain. The anti-apoptotic members are Bcl-xL, Bcl-w, A1 and Mcl1, and these 
possess four conserved Bcl2 homology domains, BH1 through BH4. The pro-apoptotic proteins 
are divided in two categories: multidomain or BH1–3, containing BH1, BH2, and BH3 regions 
(Bax, Bak) and BH3-only proteins (PUMA, Noxa, Bnip3, Bik, Bim, Bad, Bmf, and Hrk) (Kuwana et 
al., 2005). Both types of pro-apoptotic proteins are required to initiate apoptosis. Some groups 
have classified the BH3 only proteins in 2 groups: the direct activators and derepressors. The 
direct activator BH3 peptides (like Bid and Bim) can directly activate Bax and sequester anti-
apoptotic family members, were the only ones to induce direct cytochrome c release from the 
mitochondria. The derepressor BH3 peptides, which cannot activate Bax directly, just have the 
ability to sequester anti-apoptotic family members (Kuwana et al., 2005). 
Similar to their role in the blastocyst stage of the embryo, members of Bcl2 family are essential 
for the survival of both adult and embryonic stem cells. In hematopoietic stem cells (HSC), growth 
factors including stem cell factor increased transcription of the Mcl1 gene and Mcl1 was required 
to increase survival of purified bone marrow progenitors (Opferman et al., 2005). In fact, Mcl1 is 
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the most abundantly and consistently
 
expressed Bcl2 family member detected in the 
preimplantation embryo (Jurisicova and Acton, 2004) and is the only pro-survival Bcl2 family 
member
 
whose disruption results in preimplantation embryonic
 
lethality (Rinkenberger et al., 
2000). Although Bcl2 is not usually express in mESC, LIF and Bcl2 overexpression are sufficient 
to expand these cells in vitro under serum- and feeder-free conditions (Yamane et al., 2005). The 
antiapoptotic effect of Bcl2 allows cells to survive and, because no serum or feeders are present, 
it is possible to assess the effect of single growth factors, cytokines, and small molecules on the 
proliferation and differentiation of ESC. The authors of this study also suggest that Bcl2 possible 
blocks ERK signaling pathway, which in mESC leads to differentiation. 
 
1.3.3.2- Caspases  
Caspases are a family of evolutionarily conserved cysteinyl proteases that are involved both in 
apoptosis and inflammation through aspartate-specific cleavage of a wide range of cellular 
substrates (Lamkanfi et al., 2007). During the apoptotic process, caspases are associated with 
cellular dismantling, whereas in inflammation they mediate the proteolytic activation of 
inflammatory cytokines. In mammals, at least 15 members of the caspase family have been 
identified (Martinon and Tschopp, 2004). The first caspase identified was ICE, which 
proteolytically activates the proform of the cytokine interleukin (IL)-1β to its active form (Cerretti et 
al., 1992). A later study has shown that it can also activate IL-18 (Akita et al., 1997). Other 
studies, mainly through exhaustive functional analysis of conditional caspase-deficient mice or 
derived cells, have suggested a broader role for these proteases such has cell differentiation, 
proliferation and NF-κB activation (reviewed by Lamkanfi et al., 2007).  
Caspases can be categorized in initiator and effector caspases and these have distinct structural 
domains. Initiator caspases have prodomains that interact with other molecules to aggregate 
caspases into homo- or heterophilic polymers required for caspase activation. Two such 
prodomains are the caspase activation and recruitment domain (CARD) and the death effector 
domain (DED) (Zheng et al., 2000). DEDs consist of six or seven anti-parallel α-helices that 
provide homotypic interaction required to recruit procaspases to receptor-adaptor protein 
complexes (eg, the death-inducing signaling complex, DISC, with Fas) (Kischkel et al., 1995). 
CARD has been observed to have a structure similar to DED, thereby allowing interaction with 
and subsequent activation of caspase proforms. On the other hand, effector caspases have short 
prodomains (they lack CARD and DED). Usually initiator caspases are of low abundance, but 
their function is amplified by the proteolytic activation of more abundant effector caspases that do 
not possess the long CARD or multiple DEDs. Upstream initiator caspases, such as caspase-8 
and caspase-9, in turn proteolytically activate caspase-3, -6, and -7 (Slee et al., 2001). Initiator 
caspases may themselves function as effector caspases in the death process. For example, 
caspase-8 acts on members of the Bcl2 family.  
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1.3.4- Biochemistry of apoptosis 
Apoptosis is associated with biochemical and physical changes involving the cytoplasm, nucleus 
and plasma membrane. It involves a cascade of events that lead to the death of the cell and, 
ultimately, to the formation of apoptotic bodies that can be engulfed and degraded by neighboring 
cells avoiding inflammation.  
 
1.3.4.1- Apoptotic pathways 
Apoptosis can be triggered in a cell through either the extrinsic pathway or the intrinsic pathway 
(Figure 1.3). The extrinsic pathway is initiated through the stimulation of the trans-membrane 
death receptors, such as the tumour necrosis factor (TNF) and Fas receptors, located on the cell 
membrane. On the other hand, the initiation of the intrinsic pathway occurs through the release of 
signal factors by mitochondria within the cell. 
 
1.3.4.1.1- The Extrinsic Pathway 
The extrinsic pathway, or receptor-mediated pathway, is activated by ligands, which are released 
by other cells that bind to transmembrane death receptors on the target cell to induce apoptosis. 
This pathway is mainly involved in the inflammatory response and regulation of immune function. 
Typical death receptors are tumour-necrosis factor receptor (TNF-R) and Fas (also called Apo-1 
or CD95), which are part of the TNF-R family and contain a cytosolic death domain (DD) (Wong 
et al., 1992; Csipo et al., 1998). In case of TNFα, its binding to TNF-R1 on the target cell will 
trigger multiple receptors to aggregate on the surface of the target cell (reviewed by Chen and 
Goeddel, 2002). The aggregation of these receptors in their cytoplasmic domains recruits an 
adaptor protein known as TNF receptor-associated death domain (TRADD) that by it self recruits 
other proteins such as Fas-associated death domain (FADD). FADD, in turn, recruits caspase-8 
or caspase-10, initiator caspases, to form the death-inducing signal complex (DISC). Through the 
recruitment of caspase-8 to DISC, caspase-8 will be activated and it is now able to directly 
activate caspase-3 to initiate degradation of cellular targets. Active caspase-8 can also cleave Bid 
protein to tBid, which acts as a signal on the membrane of mitochondria to facilitate the release of 
cytochrome c in the intrinsic pathway. A functional damage to selective components of the 
mitochondrial electron transport chain (particularly those that increase the production of oxygen 
radicals) and structural alterations in mitochondrial morphology has been shown to mediate TNF 
citotoxicity (Schulze-Osthoff et al., 1992). The mitochondria can be also source of second 
messenger molecules responsible for gene-inductive effects of TNF (Schulze-Osthoff et al., 1993). 
 
1.3.4.1.2- The Intrinsic Pathway 
The intrinsic pathway, also called the mitochondrial pathway, is triggered by cellular stress, 
specifically mitochondrial stress caused by factors such as DNA damage (Rich et al., 2000), heat 
shock and cytotoxic drugs (Liu et al., 1996). When an apoptotic signal is received, proapoptotic 
proteins in the cytoplasm, such Bax and Bak, bind to the outer membrane of the mitochondria to 
signal the release of the internal content. Following the release cytochrome c from the 
  
   
 - 26 - 
CHAPTER 1: Introduction 
intramembrane space to the cytosol, it binds to the Apoptotic Protease Activating Factor-1 (Apaf-
1) (Adrain et al., 2006; Adrain and Martin, 2001; Hill et al., 2003). This complex will catalyze the 
activation of pro-caspase-9, an initiator caspase, forming together a complex called the 
Apoptotosome (around 1 MDa), which in turn activates caspase-3, the effector caspase that 
initiates cleavage of cellular substrates. In addition to the release of cytochrome c, the apoptosis 
inducing factor (AIF) (Joza et al., 2001) and Smac/DIABLO (Du et al., 2000; Verhagen et al., 
2000), a protein that inhibits the inhibitor of apoptosis (IAP), can also be released from the 
mitochondria. 
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FIGURE 1.3- Schematic representation of intrinsic and extrinsic apoptotic pathways. See 
text for details. 
 
One of the most important mediators of extrinsic or intrinsic signal and apoptotic responses that 
decide the future of the cell is the tumor suppressor p53. This study focuses mainly on p53 
responses to DNA damage through the intrinsic pathway. 
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1.4- TUMOUR SUPPRESSOR P53 
Although the p53 tumor suppressor was identified nearly three decades ago and  
plays a pivotal role in human cancer, its complexity continues 
 to surprise the research community (Mills, 2005). 
 
The tumour suppressor p53 is considered a critical regulator of genomic integrity because of its 
ability to trigger apoptosis and/or cell cycle arrest in response to genotoxic stress. Indeed, 
mutations of the p53 gene occur in approximately 50% of human
 
cancers (Hollstein et al., 1991; 
Hussain and Harris, 1998; Levine, 1997). p53 can be involved in maintaining genetic stability in 
several ways. p53 exerts control over both the G2/M and the G1 cell cycle checkpoints. p53 
inactivation can synergize with oncogene activation leading to aneuploidy and chromosome 
imbalance. If the p53 pathway is altered in ESC and an oncogene gets activated, these cells may 
have a survival or growth advantage and can take over the culture. p53 can also affect genetic 
stability through its ability to regulate centrosome duplication via either transactivation dependent 
mechanisms involving p21, or transactivation independent mechanisms, by interacting directly 
with other centrosomal proteins at the centrosome. Indeed, Survivin, an IAP and a chromosomal 
passenger protein whose deregulation leads to aneuploidy, is negatively regulated by p53 
(reviewed by Sah et al., 2006). As mentioned earlier, Survivin is also one of the candidate ESC 
transforming genes on the frequently duplicated chromosome 17. 
The p53 protein consists of 393 amino acids and is commonly divided into three functional 
domains: the acidic amino-terminal domain (required for transcriptional activation), the central 
core sequence-specific DNA-binding domain (where most interactions between p53 and target 
proteins occur) and the carboxy-terminal end (contains the tetramerization domain, a nuclear 
export signal and nuclear localization signals). p53 can be post-translational modified in many 
ways on many residues (reviewed by Bode and Dong, 2004). p53 has a short half-life and is 
normally maintained at low levels levels in unstressed mammalian cells through continuous 
ubiquitylation by RING-finger ubiquitin E3 ligase Mdm2 (one of its downstream targets) and 
subsequent protesomal degradation. This creates an autoregulatory feedback loop to regulate 
expression and activity of this tumour suppressor.  
 
1.4.1- p53 knockout mice 
p53 knockout mice are viable and fertile but are prone to the spontaneous development of a 
variety of neoplasms (Donehower et al., 1992). At first glance the viability of these animals 
indicates that p53 function is not essential for embryonic development. However, a fraction of 
p53-deficient embryos in fact do not develop normally (Sah et al., 1995). These animals display 
defects in neural tube closure resulting in an overgrowth of neural tissue in the region of the mid-
brain, a condition known as exencephaly. Additionally, a significant proportion of female p53-/- 
mice die during embryogenesis or in the period between birth and weaning, being subject to a 
spectrum of abnormalities (Armstrong et al., 1995). However, mice lacking Mdm2, a negative 
regulator of p53, die at an early embryonic stage, but can be rescued in a p53-null background 
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(Jones et al., 1995; Montes de Oca Luna et al., 1995). This implies that at an early embryonic 
stage p53 is functional and its functional activity has to be controlled to allow survival of embryos 
and subsequent development. Embryonic phenotypes of homozygotes deficient for either gene 
appear more obvious upon challenge. Lack of either of these genes is sufficient to rescue 
blastocysts from cell death induced by hyperglycaemia (Keim et al., 2001; Moley et al., 1998). 
Suppression of hyperglycaemia-induced
 
cell death is dependent on both Bax and p53, and is 
accompanied
 
by a decrease in the number of embryo resorptions, directly
 
implicating cell death in 
postimplantation embryonic loss (Moley, 2001). 
 
1.4.2- p53 in apoptosis 
There are different apoptotic pathways controlled by p53. In response to cellular stress, p53 
transactivates proapoptotic genes (PUMA, Noxa, Bax, p53 AIP1, Apaf-1 and PERP) activating 
the receptor-mediator (extrinsic) pathway, the mitochondrial (intrinsic) pathway and the ER 
pathway (Figure 1.4). p53 can also repress the transcription of relevant prosurvival genes (Bcl2 
and IAPs). Bioinformatic studies predict that more than 4000 human genes contain putative p53 
binding sites (Lu, 2005). The activity of p53 is controlled in different ways depending on the cell 
context either trough post-translational modifications (phosphorylation, sumoylation, acetylation) 
or through the activity of cofactors and inhibitors, like Mdm2 (Bourdon et al., 2003). Several in 
vivo studies reported that a fraction of induced p53 translocates to the mitochondria. A study 
published by Erster et al (Erster et al., 2004) showed that in sensitive organs, like the thymus, 
mitochondrial p53 accumulation in vivo
 
occurs soon after a death stimulus, triggering a rapid first
 
wave of apoptosis that is transcription independent and may
 
precede a second slower wave that 
is transcription dependent. At the mitochondrion p53 interacts with Bcl2 family of regulators of 
mitochondrial permeability (Chipuk et al., 2004; Leu et al., 2004). 
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FIGURE 1.4- Schematic representation of apoptotic pathways controlled by p53. 
DNA damage and other stress signals converge on p53 signaling by activation of protein kinases 
and/or acetyltransferases, which phosphorylate or acetylate p53, respectively. The inactivation of 
p53 by Mdm2 is counteracted by mechanisms involving post-translational modification of p53 or 
the Mdm2 inhibitor ARF. These posttranslational modifications generally result not only in 
stabilization, but also in activation of p53 in the nucleus, where p53 interacts with sequence-
specific DNA binding sites in its target gene promoters. Through its activity as a sequence-
specific transcriptional activator, p53 increases the expression of pro-apoptotic Bcl-2 family 
proteins. p53 can also have a direct apoptogenic role on the mitochondria, interacting with Bcl2 
family of regulators of mitochondrial permeability. Released apoptogenic factors facilitate the 
activation of the effector caspases through the Apaf-1–caspase 9-apoptosome. 
 
p53 can be activated pharmacologically by the topoisomerase II inhibitor etoposide. This is an 
antineoplastic drug that has been widely used to induced apoptosis in response to DNA damage 
(Karpinich et al., 2002). Topoisomerase II is a nuclear enzyme that functions during
 
both DNA 
replication and transcription (Hande, 1998). Topoisomerase II
 
prevents "knots" from forming in 
DNA by allowing the passage of
 
an intact segment of the helical DNA through a transient double
 
strand break (Burden and Osheroff, 1998). Topoisomerase II inhibitors such as etoposide
 
stabilize the complex formed by topoisomerase II and the 5'-cleaved
 
ends of the DNA, thus 
forming stable (nonrepairable) protein-linked
 
DNA double strand breaks (Burden and Osheroff, 
1998). Cells are apparently able to
 
recognize such DNA damage and, in turn, to eliminate the 
injured
 
cells by
 
apoptosis. This is known to be p53-mediated via the mitochondrial death pathway. 
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Etoposide is extensively used to investigate the p53 mediated apoptosis of hESC all throughout 
this study.  
 
1.4.3- p53 family and differentiation 
p53 and its related family members, p63 and p73, have also been implicated in cellular 
differentiation. All three genes are involved in cell cycle arrest and apoptosis after DNA damage. 
Despite the fact that they share sequence homology with p53, enabling them to bind to p53 DNA-
binding sites, to transactivate p53-responsive genes, and exhibit partial functional similarity, 
mouse knockout studies revealed an unanticipated functional diversity among them. p63 and p73 
knockouts exhibit severe developmental defects but no increased cancer susceptibility, while p53 
knockouts display high incidence of tumours and a less profound developmental phenotype. p63-
deficient mice are born alive but their limbs are absent or truncated due failure in the formation of 
the apical ectodermal ridge, a structure required for limb outgrowth along the proximal-distal axis 
(Mills et al., 1999). Their skin lacks stratification and does not express differentiation markers. 
These mice do not have ectodermal structures that are produced through epidermal-
mesenchymal interactions during embryonic development, like hair follicles, teeth and mammary 
glands. These observations indicate that p63 plays an essential role in the maintenance of 
progenitor-cell populations that are required to sustain epithelial development and morphogenesis. 
Indeed, p63 is considered to be an important keratinocyte stem cell marker (Pellegrini et al., 
2001). P73-null mice exhibit hippocampal dysgenesis, hydrocephalus, chronic infections and 
inflammation, as well as defects in pheromone sensory pathways (Yang et al., 2000). Unlike p53, 
the genes encoding p63 and p73 are rarely mutated in human cancer (Mills et al., 1999; Moll and 
Slade, 2004; Yang et al., 2000). There are also alternative splicing isoforms of all these genes 
that encode natural truncated forms involved in regulation of target gene expression (Benard et 
al., 2003; Bourdon et al., 2005; Dohn et al., 2001; Liu et al., 2004; Wu et al., 2003). 
Several reports have shown that endogenous p53 levels and activities are modulated upon 
differentiation. It has been reported that p53 expression and activity was upregulated during 
maturation of human hematopoietic cells (Kastan et al., 1991) and differentiating epidermal 
keratinocytes (Weinberg et al., 1995). p53 has also been shown to enhance macrophage 
differentiation (Matas et al., 2004). Recently, Brynczka and colleagues (Brynczka et al., 2007) 
have studied the transcriptional role of p53 during NGF-induced differentiation of the PC12 line 
into neuron-like cells. They claimed that receptor-mediated p53 transcriptional activity is involved 
in cell differentiation and suggested a contributory role for p53 in neuronal development. 
Overexpression of p53 in some cell types induces differentiation, such as leukemic K562 cells, 
HL-60 cells, Friend virus transformed erythroleukemic cells or squamous carcinoma (Banerjee et 
al., 1995; Brenner et al., 1993; Ehinger et al., 1995; Feinstein et al., 1992; Soddu et al., 1994) or 
even in non- transformed cells of the myeloid and muscle lineages (Soddu et al., 1996). Although 
these results suggest that p53 has a regulatory role in differentiation, the possibility that the 
reported effects are due to a proliferation inhibition by p53 in some cell lines cannot be excluded. 
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1.4.4- Role of p53 in hESC 
Transcriptional profiling analysis performed on ESC have shown a consistent expression of p53 
and other proteins involved in apoptosis (Bhattacharya et al., 2005; Ginis et al., 2004; Ramalho-
Santos et al., 2002). Array analysis of H1 cells indicated (Ginis et al., 2004) that ESC express 
p53, the negative regulator of p53 HDM2, the pro-apoptotic downstream target of p53 Bax, as 
well as the Bax related genes Bak, HRK and the Bcl2 family member Mcl1. Therefore the basic 
machinery for cytochrome c release and apoptosome activation is present. 
The precise role of p53 in both mESC and hESC apoptosis remains unclear. While some argue 
that p53 is non-functional in undifferentiated mESC (Aladjem et al., 1998) others show that p53 
does have a role to play in both UV-induced apoptosis (Chao et al., 2000; Xu et al., 2002b). 
Sabapathy and colleagues (Sabapathy et al., 1997) have also reported that undifferentiated 
mESC express high levels of functional p53 in a wild-type conformation, and upon differentiation 
p53 levels suffer a reduction and the protein undergoes a conformational change to a mutant 
form. Furthermore, its functional activity is lost upon differentiation and these cells become less 
sensitive to UV irradiation as compared with undifferentiated mESC. Both undifferentiated and 
differentiated cells derived from mESC lacking p53 display enhanced proliferation, and apoptosis 
accompanying differentiation is reduced. The authors of this study claimed that functional 
inactivation of p53 protects differentiating cells from apoptosis. 
Interestingly, Lin and colleagues (Lin et al., 2005) have shown that in mESC p53 becomes 
activated in response to DNA damage and induces differentiation by suppressing Nanog 
expression. This may represent an alternative mechanism for p53 to maintain genetic stability in 
ESC.  
Recently, a study has shown that hESC undergo p53 mediated-apoptosis induced by UV through 
a mitochondrial pathway (Qin et al., 2006). These authors further reported that relatively high rate 
of spontaneous apoptosis of hESC in culture (10-15 % daily) is controlled by p53. However, 
according to these authors, despite the accumulation of p53 and occupancy of this transcription 
factor on the promoter of gene targets, it fails to activate the transcription of its target genes. They 
further demonstrated that knocking down p53 expression also slows the differentiation rate of 
hESC after treatment with Activin. At present it remains to be established whether this 
spontaneous apoptosis is due to suboptimal culture conditions or is an intrinsic feature of hESC 
that is involved in eliminating cells with acquired DNA damage.  
Because of present difficulty of gene targeting by homologous recombination in hESC to generate 
specific knock-out alleles, an alternative and more feasible way of investigating the role of p53 in 
hESC is the use of RNA interference (RNAi) to downregulate the expression of this tumour 
suppressor. 
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1.5- RNA INTERFERENCE: SHRNA AND LENTIVIRUS  
Just when scientists thought they had deciphered the roles played by the cell's leading  
actors, a familiar performer has turned up in a stunning variety of guises. 
 RNA, long upstaged by its more glamorous sibling, DNA, is turning out 
 to have star qualities of its own (Couzin, 2002). 
 
The mechanism of RNAi was discovered in 1998. The combination of RNAi and ESC 
manipulation will be useful not also for advancement of basic research but also helping 
developing new therapies that are currently not possible due to technical limitations (reviewed by 
Heidersbach et al., 2006). 
RNAi was first described by Fire and colleagues (Fire et al., 1998) and is a conserved mechanism 
of post-transcriptional gene silencing which acts through degradation of messenger RNA (mRNA) 
transcripts by the action of homologous short RNA species. This mechanism plays a role in 
different processes such as the response to viral infections and in development. In 2006, Andrew 
Fire and Craig C. Mello shared the Nobel Prize in Physiology or Medicine for their work on RNAi 
in C. elegans. 
 
1.5.1- Mechanism of RNAi 
Most of the understanding on the mechanism of RNAi comes from studies on plants, C. elegans 
and Drosophila.  
The first observations in C. elegans showed that exposure to double stranded RNAs (dsRNAs, 
generally ranging from 500 to 1000 nucleotides) resulted in loss of corresponding mRNA. 
Promoter and intronic sequences failed to trigger silencing. In plants, it was also observed that 
exposure to dsRNAs resulting from transcription of viral RNA in the cytoplasm also triggered 
depletion of mRNA sequences without an apparent effect on the rate of transcription. This was 
suggestive that RNAi induced degradation of homologous mRNAs results in a measurable 
decrease in gene-specific expression and this was confirmed in subsequent studies (Hannon, 
2002).  
In mammalian cells, RNAi can be triggered by dsRNA or dsRNA domain-containing molecules 
that are processed by the endoribonucleases Drosha and Dicer (Figure 1.5). In the nucleus, 
Drosha processes endogenously expressed RNAs with dsRNA domains, mostly micro RNA 
(miRNA) precursors (Bartel, 2004). In the cytoplasm, these precursors are further processed by 
Dicer to yield miRNAs. Dicer is also responsible for the processing of other dsRNAs molecules 
from exogenous sources into small duplex RNAs, called small interfering RNAs (siRNAs) 
(Bernstein et al., 2001; Elbashir et al., 2001; Zhang et al., 2004). Dicer-processed RNAs are 
unwound, and one strand of the duplex is integrated into a ribonucleoprotein complex (RNP) 
containing members of the Argonaute family of proteins (Hammond et al., 2000; Hammond et al., 
2001; Nykanen et al., 2001; Pham et al., 2004). This RNP complex is known as RNA-induced 
silencing complex (RISC) in the case of siRNAs (Hammond et al., 2000; Hammond et al., 2001). 
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The siRNA strands subsequently guide the RISCs to complementary RNA molecules, where they 
cleave and destroy the complementary mRNA.  
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Exogenous Delivery 
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FIGURE 1.5- Mechanism of RNAi (adapted from Heidersbach et al., 2006). 
In the nucleus, miRNA begin to be processed to from long primary miRNAs by Drosha. This 
enzyme cleaves the long pre-cursor into short nucleotide (pre-cursor) hairpins which are then 
transported to cytoplasm. In the cytoplasm, the enzyme Dicer recognizes the pre-cursor and 
cleaves it into a 19–21nucleotides RNA duplex. Exogenous delivered shRNAs are also 
recognized by Dicer. A single strand of the duplex originating from a Dicer-processed precursor 
or an exogenous siRNA is incorporated into the RISC. In case of perfect pairing between the 
siRNA and its target mRNA, RISC cleaves the target. 
 
 
1.5.2- Tool to study gene function  
The selective and robust effect of RNAi on gene expression (similar in what occurs in loss-of-
function mutation), prompted the use of this methodology as a valuable research tool for in vitro 
and in vivo gene function analysis. Since RNAi often does not totally abolish the expression of the 
gene of interest, this technique is sometimes referred as a "knockdown", as opoposed to 
"knockout" procedures in which expression of a gene is entirely eliminated. 
Some studies have report that in many types of mammalian cells exposure to long dsRNA leads 
a non-specific response directed by dsRNA dependent protein kinase (Kumar and Carmichael, 
1998). This is mediated by the interferon pathway and will activate apoptotic cell death. This 
limitation was bypassed by the introduction, or expression, of shorter dsRNA species (less than 
21 bp) into cells (Elbashir et al., 2001). This breakthrough made possible the use of RNAi-based 
tools for the large-scale screens in mammalian systems. Nevertheless, there are some 
mammalian cell types, like the mouse oocytes/zygotes, ESC and ECC, that do not induce the 
interferon pathway in response to long dsRNA (Billy et al., 2001; Wianny and Zernicka-Goetz, 
2000; Yang et al., 2001).  
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RNAi is carried out by transfection of siRNAs and, more recently, by transcription of short hairpin 
RNAs (shRNAs) from expression vectors and retroviruses. The introduction of synthetic siRNA or 
expression of shRNA is very similar to what was described above for the processing of 
endogenous miRNA. However, certain cell types are resistant to transfection based approaches, 
both in vitro and in vivo (McCaffrey et al., 2002). To circumvent this limitation, lentiviral vectors 
were used to stably deliver shRNAs. The main advantages of lentiviruses are their high efficiency 
in delivering shRNA to target cells, their ability to infect both dividing and non-dividing cell, stem 
cells, zygotes, and their differentiated progeny (Rubinson et al., 2003) and their ability to escape 
transgene silencing that is observed with oncoretrovirus-based vectors in HSC and ESC (Zaehres 
and Daley, 2006). This permits a rapid and efficient analysis of gene function and can be applied 
in potential therapies. However, a recent study has reported that transgenes delivered lentiviral 
vectors can be suppressed in a promoter-dependent manner in hESC (Xia et al., 2007). This 
suppression is higher then that observed in mESC. Because silencing has not been observed in 
transient transfection of hESC with shRNA expression vectors, suppression of the transgene 
occurs right after transduction and integration. Therefore, caution should be taken in selection of 
optimal promoters when using lentiral vectors in hESC. 
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1.6- AIMS AND HYPOTHESIS 
 
The general aims of this thesis are  
I) the identification of apoptotic pathways in hESC. 
II) the elucidation of the role of p53 in apoptosis of hESC. 
III) the investigation of the role of p53 in differentiation of hESC. 
 
Hypothesis: p53 is required for hESC apoptosis and has a role in cell differentiation. 
 
Chapter 3 of this thesis describes the etoposide-induced apoptosis of hESC mediated by p53 
using existing apoptosis assays, flow cytometric analysis, Western blotting and 
immunofluorescence. This chapter also describes a model of p53-mediated apoptosis in hESC. 
Chapter 4 of this thesis analyses the phenotype of hES cell lines (HES-2 and HES-4) that have 
been genetically modified with stable lentiviral U6 driven shRNA vectors designed to 
downregulate p53 and describes the transcriptome analysis of GFP and p53 shRNA transduced 
hESC. This Chapter also addresses the role of p53 on spontaneous and induced differentiation, 
as well as teratoma formation. 
In Chapter 5 the general significance of the results reported in this thesis and the future directions 
are presented. 
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This chapter has been divided into two sections dealing with cell culture and molecular 
techniques. Supplier and catalogue numbers are included. Culture medium composition, 
biological reagents, and specific working solutions are detailed within the methodology section in 
which they are used or referenced. General laboratory solutions and buffers are described in 
Appendix I. 
 
Section 2.1: 
This section describes methods used in culture of mammalian cells. Methods adapted from 
published protocols or from manufacturer’s guidelines are described in the text unless otherwise 
stated.  
 
Section 2.2:  
This section describes methods employed for molecular biology analysis. Commercially available 
kits or preparations were used according manufacturer’s instructions and are described in the 
text. 
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Section 2.1- Cell Culture Methods 
hESC lines HES-2, HES-3 and HES-4 were provided by this laboratory (Reubinoff et al., 2000). 
HES-2 and HES-3 are karyotypically female lines while HES-4 is of male karyotype. HT1080 is a 
human fibrosarcoma cell line, HepG2 is a human hepatocellular liver carcinoma cell line and 
CFPac-1 is a ductal pancreatic adenocarcinoma derived from a metastatic lesion in the liver of 
Caucasian male with cystic fibrosis. The 293FT cell line is a human embryonic kidney cell line, 
genetically modified and carries the pUC-derived plasmid (pCMVSPORT6TAg.neo.). 
 
2.1.1- Commonly Used Tissue Culture Solutions, Reagents and Materials  
General laboratory reagents utilized were of tissue culture grade and were supplied by Sigma-
Aldrich and tissue culture grade plastic ware was supplied by Falcon (Becton Dickinson), unless 
otherwise stated. Polypropylene 1.7 ml microtubes (Axygen, Union City CA, USA) [Cat No: 
MCT175-C] for use in tissue culture were autoclaved in a glass beaker covered in aluminium foil 
or ultra wrap (Dräger Medical, Lübeck, Germany) and subsequently opened strictly in the hood. 
When possible, items utilized in tissue culture that were not purchased as tissue-culture grade 
(such as glass coverslips, slides, and forceps for example) were baked at 180°C for 2 hours to 
sterilize prior to use. 
 
2.1.1.1- Growth factors 
All growth factors were supplemented fresh from stock solutions into cell culture medium 
immediately prior to use. 
 
Fibroblast Growth Factor-2 (FGF-2) human recombinant protein expressed in E. coli (R&D 
Systems, Minneapolis, USA) was obtained as 25 µg of lyophilized powder [Cat No: 233-FB] 
stored at -20°C. The powder was reconstituted as stock solution in 500 µl sterile PBS
-
 (Gibco) 
with 0.1% BSA fraction IV (Sigma-Aldrich), to produce a 50 ng/µl stock concentration of growth 
factor, stored at -20°C for up six month in 50 µl aliquots. When required, a vial of FGF-2 was 
thawed and added to experimental media without serum (SR culture media) at 4 ng/ml. The 
remainder of the contents was stored up to 2 weeks at 4°C. This reagent was used from 1 
September 2004 to 9 November 2006 and from 9 August 2007 until 26 September 2007. 
 
Recombinant Human Fibroblast Growth Factor- Basic- (Chemicon International) [Cat No: GF003] 
was obtained as 50 µg of lyophilized powder and stored at -20°C. The powder was reconstituted 
as stock solution in 1 ml sterile PBS- (Gibco) with 0.1% BSA fraction IV (Sigma-Aldrich), to 
produce a 50 µg/ml stock concentration of growth factor, stored at -20°C for up six month in 50 µl 
aliquots. When required, a vial of FGF-2 was thawed and added to experimental media without 
serum (SR culture media) at 4 ng/ml. The remainder of the contents was stored up to 2 weeks at 
4°C. This reagent was used from 9 November 2006 till 9 August 2007. 
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2.1.1.2- Extracellular matrices 
 
Gelatin, Type A from porcine skin (Sigma-Aldrich) [Cat No: G1890] 1% (w/v) stock solution was 
prepared by adding 5 g gelatin to 500 ml sterile distilled water (Gibco) [Cat No: 15230-204] in a 
500 ml glass bottle, mixing well and autoclaving. The solution was kept at room temperature (RT) 
and diluted to a 0.1% gelatin working concentration when required.  
 
Matrigel
TM
 Basement Membrane Matrix (BD Biosciences, MA, USA) [Cat No: 354234] is a 
solubilized basement membrane preparation extracted from EHS mouse sarcoma, a tumour rich 
in extracellular matrix proteins. The matrix is stable for minimum of 3 months when stored at -
20°C. Each lot is supplied at different concentration. Matrigel is diluted into cold DMEM/F12 
(Gibco). The coating concentration is 0.0347 mg/cm
2
 and the minimal time of 3 hours in the 
incubator at 37°C or overnight (ON). The coating mixture is then aspirated and the dish is pre-
equilibrated with conditioned media from MEF (CM) before seeding cells. 
 
2.1.1.3- Enzymes and dissociation solutions 
Cell Dissociation Buffer enzyme free Hanks'-based (Gibco) [Cat No: 13150016] was stored at 4°C 
and used undiluted. Dissociation Buffers are membrane-filtered isotonic and enzyme-free 
aqueous formulations of salts and chelating agents in either Ca
2+
- and Mg
2+
- free Hanks' 
balanced salt solution or Ca
2+
- and Mg
2+
- free phosphate-buffered saline. They are used for 
gentle dissociation of mammalian cells from support substrates and each other in particular for 
studies requiring intact cell surface proteins such as ligand binding flow cytometry and 
immunohistochemistry. 
 
Collagenase Type I (Worthington Biochemical Corporation, Lakewood, NJ USA) [Cat No: 
L5004196] powder was stored at 4°C. A 4 mg/ml solution was prepared fresh as needed by 
gently dissolving 0.04 g of powder in 10 ml at RT DMEM/F12 (Gibco) [Cat No: 11320-033]. The 
powder was allowed to dissolve for 5 min and the solution was filtered sterilized using a pre-wet 
0.22 µm filter and stored at 4°C. 
 
Dispase (Gibco) [Cat No: 17105-041] was stored at 4°C. A 10 mg/ml solution was prepared as 
needed by dissolving 0.1 g (1 vial) of the powder into 10 ml of 37°C pre-warmed hESC serum 
medium. The powder was allowed to dissolve for 5 min and pipetted up and down a couple of 
times. Dispase was allowed to dissolve for further 10-20 min at RT and filtered sterilized using a 
pre-wet 0.22 µm filtered, then stored at 4°C. 
 
TrypLE Express Stable Trypsin Replacement Enzyme (Gibco) [Cat No: 12604-013] was used 
neat and stored at 4°C. 
 
Trypsin-EDTA (0.25% Trypsin, EDTA 1X liquid) (Gibco) [Cat No: 25200-056] containing 2.5 g/L 
Trypsin and 0.38 g/L EDTA•4Na in Hanks’ Balanced Salt Solution was divided into 2 ml aliquots 
and stored at -20°C. To prepare a 0.05% (w/v) Trypsin/EDTA working solution it was diluted with 
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8 ml of PBS
-
 (Gibco). The remaining volume of 0.05% working solution was stored at 4°C and 
used or discarded within one week. 
 
2.1.1.4- Miscellaneous Culture Components, Solutions and Materials 
 
Bovine Serum Albumin (BSA) (Sigma-Aldrich) [Cat No: A8806] was used in reconstitution of FGF-
2. To prepare a solution containing BSA, powder was weighed, allowed to dissolve undisturbed in 
the solvent for 10-15 minutes, and filtered through a 0.22 µm syringe filter unit. 
 
Capillaries, glass (Harvard Apparatus, Holliston MA, USA) [Catalog number 30-0039] were pulled 
over a low Bunsen burner flame to generate finely edged tips for cutting hESC colonies. 
 
Dimethylsulfoxide (DMSO) (Sigma-Aldrich, Steinheim, Germany) [Cat No: D2650] was used at a 
final concentration of 10% (v/v) in freezing medium for cryostorage of cell lines in liquid nitrogen. 
 
Distilled water (Gibco) [Cat No: 15230-162] 
 
Fetal calf serum (FCS) used for MEF and hESC culture was batch tested and supportive batches 
were ordered in bulk to provide reagent for up to several years. Different types of FCS were used 
for specific tissue applications: for MEF culture JRH Biosciences FCS [Cat No: 12003-500N] and 
CSL Biosciences FCS (Parkville VIC, Australia) [Cat No: 09702301] while for hESC culture 
Hyclone FCS (Logan UT, USA) [Cat No: SH30070-03] and JRH Biosciences FCS (Brooklyn VIC, 
Australia), [Cat No: 12203-100M]. 
 
Fugene 6 Transfection Reagent (Roche Applied Science) [Cat No: 11 814 443 001] was obtained 
in 1 ml volume and stored at 4°C. 
 
Geneticin 50 mg/ml (Gibco) [Cat No: 10131-035], also known as G418 sulfate, is an 
aminoglycoside used as a selective antibiotic for genetically modified cell lines which contain the 
neomycin resistance gene. Working concentration in cell culture media was 500 µg/ml.  
 
Pasteur pipettes, glass disposable (Chase Scientific Glass, Rockwood, Tennessee) [No. 93, 9 
inch length, flint glass] were packed into metal canisters and baked at 180°C for 2 hours to 
sterilize. Glass Pasteur pipettes were attached to a vacuum tap with tubing and used to aspirate 
media from tissue culture flasks. 
 
Mitomycin C (Sigma-Aldrich, Steinheim, Germany) [Cat No: M0503] was received as 2 mg 
lyophilized powder and stored at 4°C. A 0.5 mg/ml stock solution was made by adding 4 ml of 
sterile distilled water (Gibco) [Cat No: 15230-204] into each Mitomycin C vial and allowed to 
dissolve completely. The solution was filter sterilized using a pre-wet 0.22 µm filter into a 15 ml 
Falcon tube. The tube was protected from light with aluminum foil and stored at 4°C. The working 
solution was used at 10 µg/ml in MEF culture media immediately before adding to MEF. 
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Phosphate Buffered Saline (Na
+
/Mg
+2
 free) (PBS-) (Gibco) [Cat No: 15230-162] 
 
Phosphate Buffered Saline (Na
+
/Mg
+2
) (PBS+) (Gibco) [Cat No: 15230-162] 
 
Trypan blue dye (Sigma-Aldrich, Steinheim, Germany) [Cat No: T8154] was diluted 1:2 in PBS or 
medium to examine cell viability when counting on a hemocytometer. 
 
2.1.1.5- Medium solutions 
Media for cell culture was prepared in disposable tissue culture grade plastic ware (Millipore, 
Billerica MA, USA). All media was either sterile filtered through a 0.22 µm GP Express PLUS 
membrane filter unit (Millipore) [Cat No: SCGPT02RE and SC00B05RE] or sterility tested for a 
minimum of 2 days before use. The media was light protected with aluminum foil, stored at 4°C 
and pre-warmed to 37°C prior to addition to live cells.  
The following components were ordered in large volumes, aliquoted under sterile conditions, and 
stored at the temperature recommended by the manufacturer: FCS, KSR, non-essential amino 
acid (NEAA) solution, L-glutamine (L-Glut) solution, and Penicillin/Streptomycin (Pen/Strep) 
solution. 
 
Serum based hESC Culture Medium (500 ml)                                
DMEM high glucose (Gibco) [Cat No: 11960-044]   382 ml   
FCS (for hESC Culture)       100 ml (20%) 
NEAA solution (10 mM) (Gibco) [Cat No: 11140-050]   5 ml (0.1 mM) 
L-Glut solution (200 mM) (Gibco) [Cat No: 25030-081]   5 ml (2 mM) 
Pen/Strept solution (Gibco) [Cat No: 15070-063]    2.5 ml 
(Pen: 25U/ml; 
         Strep: 25ug/ml) 
β-Mercaptoethanol (55Mm) (Gibco) [Cat No: 21985-023]   0.9 ml (0.1 mM) 
Insulin-Transferrin-Selenium-A (Gibco) [Cat No: 51300]   5 ml  
         (Insulin: 10mg/L; 
         Transferrin: 5.5mg/L; 
         Na-Selenite: 6.7ug/L;  
         Na-Pyruvate: 110mg/L) 
 
 
hESC Serum Replacement (SR) Culture Medium (500ml)      
DMEM/F12 (Gibco) [Cat No: 11320-033]     389.1 ml 
KSR (Gibco) [Cat No: 10828-028]      100 ml (20%)  
NEAA solution (10 mM) (Gibco) [Cat No: 11140-050]    5 ml (0.1 mM) 
L-Glut solution (200mM) (Gibco) [Cat No: 25030-081]   5 ml (2 mM) 
β-Mercaptoethanol (55 mM) (Gibco) [Cat No: 21985-023]   0.9 ml (0.1 mM) 
 
*FGF-2 was supplemented fresh into the media volume used each day at final concentration of 4 
ng/ml (stock at 50 µg/ml). 
 
 
MEF Feeder Cell Culture Medium (500 ml)        
DMEM (Gibco) [Cat No: 1190-044]     442.5 ml 
FCS (for MEF culture)       50 ml (10%) 
L-Glut solution (200 mM) (Gibco) [Cat No: 25030-081]   5 ml (2.0 mM) 
Pen/Strept solution (Gibco) [Cat No: 15070-063]    2.5 ml  
(Pen: 25U/ml; 
Strep: 25ug/ml) 
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Conditioned medium (CM) from MEF          
Serum replacement culture medium plus 4 µg/ml FGF-2 as added to a T75 of MEF at full density 
(6x10
4 
cells/cm
2
) and collected 24 h after. The CM medium was filtered sterilized using a 0.22 µm 
filter and FGF-2 (4 ng/ml) was added before use with Matrigel cultures. SR medium was replaced 
on the flask of MEF feeders each day to continue producing conditioned medium. 
 
 
Complete medium for 293 FT and HT1080        
DMEM high glucose (Gibco) [Cat No: 11960-044]   415 ml 
FCS (JRH Biosciences) [Cat No: 12003-500N]    50 ml (10%) 
NEAA solution (Gibco) [Cat No: 11140-050]     5 ml (0.1 mM) 
L-Glut solution (200 mM) (Gibco) [Cat No: 25030-081]   15 ml (6 mM) 
Sodium Pyruvate (Gibco) (100 Mm) [Cat No: 11360070]   5 ml (1mM) 
Pen/Strept solution (Gibco) [Cat No: 15070-063]    5 ml  
 
* Geneticin® (Gibco) [Cat No: 10131-035] was added fresh at final concentration of 500 µg/ml 
(Stock at 50 mg/ml) 
 
 
Complete medium for CFPac-1 (500 ml)         
Iscove's modified Dulbecco's medium      440 ml 
FCS (JRH Biosciences) [Cat No: 12003-500N]    50 ml (10%) 
L-Glut solution (200 mM) (Gibco) [Cat No: 25030-081]    10 ml (4 mM) 
1.5 g/L sodium bicarbonate 
 
Complete medium for HepG2  (500 ml)        
Dulbecco's modified Eagle's medium and Ham's F12 medium  
FCS (JRH Biosciences) [Cat No: 12003-500N]    50 ml (10%) 
L-Glut solution (200 mM) (Gibco) [Cat No: 25030-081]   7.5 ml (2.5 mM) 
HEPES (1M) (Gibco) [Cat No: 15630-080]    7.5 ml (15 mM) 
Sodium pyruvate (100 mM) (Gibco) [Cat No: 11360070]   2.5 ml (0.5 m  
Geneticin® (500 µg/ml) (Gibco) [Cat No: 10131-035]   4 ml (0.4 mg/ml) 
1200 mg/L sodium bicarbonate  
 
Freezing Medium for hESC serum-free culture (10 ml)       
FCS (for hESC culture)        9 ml (90%) 
DMSO (Sigma-Aldrich) [Cat No: D2650]      1 ml (10%) 
 
Freezing Medium for 293FT and HT1080, HepG2 and CFPac-1 (10 ml)     
Complete medium       9 ml 
DMSO (Sigma-Aldrich) [Cat No: D2650]      1 ml (10%) 
 
 
2.1.2- hESC and other cell lines Culture Methods 
Cell cultures were maintained at 37°C with 5% CO2 in a humidified Steri-Cycle CO2 incubator 
(Thermo Electron Corporation, Marietta OH, USA). Tissue culture procedures were performed in 
air handling class II biological safety cabinets (DCE-BRT Environmental Ltd., Leicester, UK and 
Bioair Instruments Aura 2000 MAC, Laf Technologies Pty Ltd & Bio Cabinets Australia Pty Ltd, 
Ringwood, VIC Australia) or an HWS-series laminar flow workstation (Clyde-Apac, Woodville, SA 
Australia). These will be referred as “hoods”. Standard aseptic techniques were rigidly followed in 
culturing cell lines. 70% ethanol in deionized water was used to disinfect surfaces and equipment 
as needed. Cultured cells were examined by phase-contrast microscopy using an Olympus IX71 
inverted microscope with attached Olympus DP12 digital camera system (Olympus Corporation, 
Tokyo, Japan). Routine centrifugation of cells was performed in a Sigma 2-4 centrifuge (Sigma-
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Aldrich Laborzentrifugen, Harz, Germany) or Sigma 2-5 centrifuge. Hoods were exposed to UV 
lamps after use for a minimum of 20 minutes. Pipettes (Gilson, Middleton WI, USA), pipet-aids 
(Falcon Express Pipet-aid) (Beckton Dickinson, Franklin Lakes NJ, USA) and other equipment 
used for tissue culture methods were used generally only in the laboratory dedicated for tissue 
culture to minimize the risk of contamination. 
 
2.1.2.1- Gelatinizing Tissue Culture Plates 
Sufficient volume of 0.1% Gelatin was added to cover culture surface area and incubated at RT 
for minimum of 1 hour. Then gelatin was aspirated and cells were plated. 
 
2.1.2.2- Expansion and culture of MEF feeder support cells 
The derivation, culture and preparation of MEF feeder cells for hESC propagation were routinely 
carried out by laboratory technical staff Linh Nguyen, Karen Koh, Irene Tellis, Pegah Jamshidi, 
Tracey Lomas, Lisa Kass and Sheetal Saini. 
 
2.1.2.2.1- Subculturing MEF feeder cells 
1. MEF were subcultured when flasks reach 80-90% confluency. The T-175 flasks containing 
MEF were washed twice with 10-15 ml PBS
-
 (Gibco) and trypsinized by incubating the cells 
for 5 minutes at 37°C. 
2. The flasks were tapped firmly against an open palm until cells detach from flask wall. 10 ml 
MEF medium were added to stop the action of the trypsin. The cells were dissociated into a 
single cell suspension by mixing up and down in a serological pipette, and then transferred to 
a 50 ml Falcon tube. The flask was washed with another 10 ml MEF media and added to tube 
and then centrifuged for 2 minutes at 500 x g. 
3. The supernatant was aspirated and the pellet was gently flicked to disperse cell pellet. The 
cells were resuspended in 10-20ml MEF media and split evenly among several T175 at a 
ratio of 1:3-1:6. Generally, MEF at early passage (P0, P1, or P2) could be split higher at 1:5 
or 1:6 (from an 80-90% confluent flask). Later passage MEF (P3, P4) of the same confluency 
were split 1:3 or 1:4. MEF were expanded to a maximum of four passages (P4) before 
mitomycin C treatment for hESC co-culture. 
 
2.1.2.2.2- Mitomycin C inactivation of MEF feeder cells 
1. Mitomycin C (MC) (200 mg) (Sigma-Aldrich) was added to 200 ml FCS/DMEM and the 
solution was sterilized through a 0.2 µm cellulose acetate filter (Millipore). This solution can 
be stored at 4°C and used to mitotically inactivate MEF cells for 4 weeks. 
2. MC-FCS/DMEM was warmed to 37°C and enough added to MEF cell containing flasks to 
cover the cells with a thin film of medium. The treated flasks were placed in an incubator at 
37°C for 2-3 hours. 
3. While the MEF feeder cells were being inactivated, designated tissue culture vessels for MEF 
were coated with 0.1% (v/v) gelatine solution for at least 1 hour. 
4. At the end of inactivation process, the MC-FCS/DMEM medium was aspirated and the MEF 
cells washed 3 times with 10 ml PBS
-
. A volume of 5ml of trypsin/EDTA solution per T-75 
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flask (1.5 ml per T-25 flask) was added to the cells and incubated at 37°C for 5 min. The cells 
were tapped gently for easier dislodgment. 
5. The trypsin/EDTA was inactivated with 10 ml of FCS/DMEM and cells were gently 
resuspended into a single cell suspension using a 5 ml pipette tip using the medium speed on 
a Falcon Express Pipet-aid (Beckton Dickinson, Franklin Lakes NJ, USA). 
6. The cell suspension was transferred to a 15 ml Falcon conical tube and pelleted for 2 min at 
500 x g. The cell pellet was then resuspended in a 10 ml of fresh FCS/DMEM medium and 
the cell number/ml counted using a haemocytometer. 
7. Gelatin was removed from gelatin-coated plastic tissue culture flasks and a PBS
-
 wash was 
applied to remove excess gelatine solution. The appropriate volume of mitomycin C treated 
MEF was added to tissue culture flask (6x10
4 
cells/cm
2
 for conventional serum grown hESC, 
2x10
4 
cells/cm
2
 for SR/FGF-2 grown hESC).  
8. Plating of hESC on feeder cell layers was possible a minimum of 3 hours after MEF seeding, 
although typically MEF cells wee used after an ON attachment period. The feeders were 
used for hESC cultures within one week of mitotic inactivation.  
 
2.1.2.3- Expansion and culture of hESC 
The hESC lines were cultured using both conventional mechanical excision of the colony for 
growth in the presence of serum medium and mouse embryonic fibroblast feeder cells MEF 
(6x10
4 
cells/cm
2
) (Reubinoff et al., 2000; Thomson et al., 1998). Alternatively cells were cultured 
using SR supplemented medium with FGF-2 on one third of the conventional mouse embryonic 
fibroblast feeder cell line density (2x10
4 
cells/cm
2
) (Amit et al., 2000) passaged with Colagenase I 
or cells were plated on Matrigel (BD Biosciences) with MEF-conditioned serum replacement 
medium as described by (Xu et al., 2001). hESC lines were used only up to passage 18 when 
cultured as per Amit et al (2000) or Xu et al (2001). hESC colonies were routinely transferred on 
day 7. All hESC lines used for this work were proven to be mycoplasma-free, of normal karyotype, 
and capable of forming teratomas representative of all three germ layers. 
 
2.1.2.3.1- Propagation of hESC in serum containing medium 
Mechanical dissection of hESC colonies was performed using a Leica MZ6 stereomicroscope 
(Leica Microsystems, Wetzlar, Germany) with a microscope warm stage (LEC Instruments, 
Scoresby, VIC Australia; model LEC916) set up in a laminar flow workstation. The standard 
tissue culture vessel for hESC propagation in serum containing medium is a polystyrene 61x15 
mm centre-well organ culture plate (Beckton Dickinson, Franklin Lakes NJ, USA).  
1. Glass capillaries (Clark Electromagnetics Industries) were prepared by pulling over a low 
Bunsen burner flame, generating finely edged tips for cutting selected areas of colonies. 
Although glass capillaries generally delivered better results, a 27-30 gauge syringe needle 
(Beckton Dickinson, Franklin Lakes NJ, USA) was also be used for colony cutting. 
2. Day 7 hESC serum cultures were examined under an inverted microscope and plates 
harbouring undifferentiated colonies were selected for transfer. The plates were washed 
twice with 1 ml PBS
+ 
per dish. 
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3. A pulled glass capillary was placed into a micropipette holder and used to make cuts to 
undifferentiated colony areas (alternatively a 27.5 gauge needle can be used). This work was 
conducted under a Leica MZ6 dissection microscope (3.2 X magnification) on a heating stage 
inside the hood Colonies were typically cut into square pieces approximately 0.5 mm
2 
and 
proportions of the colonies that were overtly differentiated were avoided. 
4. The media from each plate was aspirated and colonies washed with 1 ml PBS
+ 
per culture 
dish. A volume of 1 ml of Dispase II (10 mg/ml) dissolved in hESC serum medium was 
applied to each dish for 5 min at 37°C in a CO2 incubator. Dispase dislodges the cut colony 
pieces from the culture dish. 
5. The colony pieces were picked up using a 20 µl pipette (Gilson) and transferred to a dish 
filled with 1ml PBS
+
. Another wash was conducted to remove Dispase by transferring then 
pieces into a second dish containing 1 ml PBS
+
. 
6. The washed pieces were carefully placed on a newly prepared MEF feeder cell coated plate 
(at 6x10
4
 cell/cm
2
 density) filled with fresh hESC serum medium. Approximately 6-9 colony 
pieces were seeded per dish equidistant from each other. The dishes were placed carefully at 
37°C in a CO2 incubator, making sure that pieces did not move and clump together. 
7. Media changes were conducted every second day until the next transfer event by aspirating 
old serum medium and adding a new pre-warmed 1 ml aliquot per organ culture dish. 
 
2.1.2.3.2- Establishing serum-free cultures (bulk cultures) 
1. Serum hESC medium was aspirated from 4-6 organ culture dishes bearing undifferentiated 
hESC colonies grown for 7 days. 
2. The culture dishes were washed with 1 ml sterile PBS
+
 solution. A volume of 1 ml of Dispase 
(10 mg/ml) dissolved in hESC serum medium was applied to each dish for 5 min at 37°C in a 
CO2 incubator. 
3. The hESC colonies were dislodged and aspirated using a 200 µl pipette (Gilson) into a 500 µl 
volume of transfer medium [30% (v/v) FCS-hESC medium, 70% (v/v) SR medium with FGF-2] 
in a sterile polypropylene 1.7 ml microtube. 
4. Using a 200 µl pipette (Gilson) the colonies were triturated into a fine cell clumps. 500 µl of 
cell clumps was then injected using a 1000 µl pipette (Gilson) into a T-25 tissue culture flask 
containing 4.5 ml of transfer medium. The flask was labelled accordingly: the name of the 
hESC line and the existing serum grown passage number + 1 SR/FGF-2 passage number, 
for example HES4 p32+1. The T-25 tissue culture flask was placed at 37°C in a CO2 
incubator, agitated repeatedly to prevent hESC clumps sticking together and left ON. 
5. The next day, transfer medium was aspirated along with free floating cell debris and 7 ml of 
SR hESC medium with FGF-2 (4 ng/ml) was added to a T-25 flask. The flask was examined 
for attached cell clumps. The media was changed daily Monday-Friday and once over the 
weekend. The cells were routinely monitored under a microscope for the extent of 
differentiation in culture and scored as poor, average or good. Poor = overt differentiation, 
Average = some differentiated areas, Good = minimal differentiation 
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2.1.2.3.3- Subculturing hESC in serum-free conditions 
Bulk cultures were routinely split with Collagenase type I on Day 7 or when hESC culture reached 
approximately 80-90% confluency. Flasks with fresh MEF (plated at 2x10
4
/cm
2 
density) with SR 
media plus 4 ng/ml FGF-2 were pre-equilibrated in the morning.  
1. Collagenase type I (4 mg/ml) (w/v) (Worthington) was dissolved in unsupplemented 
DMEM/F12 media at RT. The enzyme solution was filtered through a 0.22 µm filter (Millipore), 
ensuring sterility. 
2. Existing culture medium was aspirated and the flasks washed with 5 ml of PBS
-
. The wash 
solution was removed and 1-2 ml of 4 mg/ml Collagenase type I was added to a T25 flask 
and incubated at 37°C for 15-20 min. 
3. The flask was tapped until MEF were released leaving only hESC colonies slightly curled on 
flask surface.  
4. Then hESC colonies were flushed from flask surface with 5ml of SR media (without FGF-2) 
using a 5 ml pipette and a cell suspension was collect into a 15 ml Falcon tube. The larger 
cell clumps were dissociated by pipetting up and down several times. 
5. Cell suspension was filtered using a 70 µm BD Falcon Cell Strainer [Cat. No: 352350] to 
avoid the carrying over of larger clumps of differentiated hESC.  
6. The cells were spun for 2 min at 500 x g and the supernatant aspirated. The cells were 
resuspend with 2-3 ml of SR media plus 4 ng/ml FGF-2. The split ratio depends on a number 
of factors such as flask confluency and cell health, morphology and growth rate patterns. 
Such characteristics may vary from week to week and can be observed over several 
passages. 
 
2.1.2.3.4- Freezing hESC in serum-free conditions 
1. hESC colonies were harvested from tissue culture flasks, triturated and purified according to 
the protocol on section 2.1.2.2.3. Cell material from confluent T-25 tissue culture flask was 
used for the freezing procedure. 
2. hESC clumps were resuspended again in 5 ml SR medium with FGF-2 and centrifuged at 
500 x g for 2 min. The medium was aspirated and the cell pellet gentle flicked to ensure 
dispersal of cell clumps. 
3. 1 ml of ice-cold Freezing medium [90% DMEM/FCS medium, 10% DMSO (v/v)] was added, 
gentle resuspending the cell clumps using a sterile plastic 2 ml pipette. 
4. The aliquots were pipetted into 1ml cryovials (Falcon). The vials were closed tightly and the 
lids wrapped in parafilm followed by immediate transfer to a Nalgene 1°C isopropanol 
freezing container. The container was placed at -80°C ON. 
5. The next day, the cryovials were removed from -80°C and placed into liquid nitrogen for long 
term storage. 
 
2.1.2.3.5- Thawing hESC grown in SR with FGF-2 
1. The designated hESC containing cryovial was removed from liquid nitrogen and its cap 
loosened to allow trapped nitrogen gas to escape. 
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2. The cell content was thawed by immersing the bottom half of cryovial in 37°C water bath and 
swirling the tube repeatedly. Care was taken not to immerse the whole tube in the water bath 
as this can compromise sterility. 
3. Immediately after thawing, the content was transferred into a 15 ml centrifuge tube (Falcon) 
and 10 ml of SR medium at RT was added drop by drop to the tube and immediately 
centrifuged at 500 x g for 2 min. 
4. The DMSO containing supernatant was removed and the cell pellet resuspended in 5 ml of 
fresh SR medium with FGF-2. This cell washing step was repeated once again. 
5. The tube was centrifuged and the 5 ml of wash medium aspirated. The pellet was 
resuspended in 5 ml of pre-warmed SR medium with FGF-2 and transferred into a T-25 flask 
containing fresh MEF feeders. The flasks were placed at 37°C in a CO2 incubator, agitated 
again repeatedly to prevent hESC clumps sticking together and left to attach and resume 
growth. 
  
2.1.2.3.6- Culturing hESC in MEF-free conditions on Matrigel 
Serum-free cultures of hESC on low density MEF were split onto Matrigel-coated vessels for 
short term (1 week maximum) experiments. hESC were not serially subcultured under MEF-free 
conditions. The same protocol was followed as in section 2.1.2.3.5 for subculture of hESC in 
serum-free conditions, except that collagenase-treated hESC clumps were seeded onto Matrigel-
coated vessels with MEF CM instead of onto flasks containing MEF. Approximately 30,000 hESC 
per cm
2 
were seeded on flasks coated with Matrigel (with coating concentration of 0.0347mg/cm
2
) 
and pre-equilibrated with MEF conditioned media supplemented with 4 ng/ml FGF-2. Media was 
changed daily. 
 
2.1.2.4- Growth and Maintenance of 293FT cell line  
Cell line 293 FT was purchased from Invitrogen (Cat No: R700-07) and was used for the 
production of lentiviral stocks.  
 
2.1.2.4.1- Thawing Cells 
1. A vial of frozen cells (supplied in a vial containing 3x10
6 
cells/ml) removed from liquid nitrogen 
and thawed quickly in a 37°C water bath. 
2. Just before the cells were completely thawed, the outside of the vial was decontaminated 
with 70% ethanol, and the cells transferred to a sterile 15 ml tube containing PBS. Briefly the 
cells were centrifuged at 500 x g for 2 min and the cells resuspended in 2 ml complete 
medium without Geneticin®. 
3. The cells were transferred to a T-75 cm2 flask containing 10 ml of complete medium without 
Geneticin®. 
4. The flask was incubated overnight at 37°C to allow the cells to attach to the bottom of the 
flask. 
5. The next day, the medium was aspirated off and replaced with fresh, complete medium 
containing 500 µg/ml Geneticin®. 
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6. The cells were incubated and checked daily until 80-90% confluent. 
 
2.1.2.4.2- Subculturing Cells 
1. All medium was removed from the flask and the cells were washed once with 10 ml PBS to 
remove excess medium and serum. Serum contains inhibitors of trypsin. 
2. 2 ml of trypsin/EDTA solution were added to the monolayer and incubated 3 minutes at room 
temperature until cells detached. The cells were checked under a microscope to confirm 
detachment.  
3. 8 ml complete medium containing Geneticin ® were added and the cell suspension was 
transferred to a 15 ml sterile, conical tube. 
4. The number of viable cells was determined using the trypan blue exclusion method. 
5. The cells were seeded at 3x10
6 
cells/cm
2
 density diluted in pre-warmed complete medium 
containing 500 µg/ml Geneticin®. The flask was incubated at 37°C. 
6. The cells were maintained as adherent monolayer cultures in complete medium containing 
500 µg/ml Geneticin®. 
 
2.1.2.5- Differentiation of hESC Activin A and BMP4 
Activin A and BMP4 were used to differentiate hESC. 
1. Briefly, hESC were seeded on Matrigel with CM from MEF. 
2. When cells reached about 70% confluency, Activin A (20 ng/ml and 40 ng/ml) was added to 
cells in serum-free medium published by Ng et al. (2005) and BMP4 (25 ng/ml and 50 ng/ml) 
was added to cells in SR medium. 
3. The media was changed every two days and these factors were added at each change. 
4. After 7 days of exposure to Activin A and BMP4, the cells were harvested and total mRNA 
was isolated (described in section 2.2.9 of this Chapter). 
 
2.1.2.6- Teratoma formation 
The ability of hESC to form teratomas is the best test of pluripotency presently available. The 
cells are implanted for testing beneath the testis capsule of SCID mice between 5-6 weeks of age. 
The first part of the procedure, carried out to exteriorise the testis, is similar to the procedure used 
in vasectomy. The examination of teratomas was carried out by Professor Stephen Fox from the 
Peter MacCallum Cancer Centre (Melbourne, Australia). 
1. The cells were prepared about 15-20 min before surgery. Between 2 to 3 organ culture 
dishes (8 hESC colonies/dish) were needed to inject into 2 mice. Tumours can be formed 
using 8 hESC colonies (containing about 50,000 cells in total) per mouse. 
2. The cells were washed twice with PBS
+
. Using a pulled glass pipette a cut was made around 
colonies which were harvested Dispase. 
3. The colonies were collected and washed twice. The colonies were then transferred into a 
microcentrifuge tube and broken up by pipetting up and down with a 200 microliter Gilson 
pipettor. 
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4. The cells were centrifuged and resuspended in 50 µl of hESC injection buffer (DMEM, 25 Mm 
HEPES, 10% FCS) and kept on ice. 
5. Using aseptic technique within a laminar flow hood, the animal give strain sex and age of 
mice was anesthetised with avertin. 
6. The abdomen was swabbed with alcohol, and a small longitudinal incision was cut through 
the skin and abdominal wall just bellow the level of origin of the hindlimb. The animal was 
transferred to the stage of a dissecting microscope. 
7. The scrotum of the mouse was squeezed to bring the testes into the abdominal cavity. A 
piece of fat was visible inside the incision towards the caudal part of the mouse and just a bit 
lateral to the midline and this tissue was drawn outside the abdomen with a forceps and the 
vas deferens and testis followed. 
8. A small artery clamp was used to gently put traction on the testis, which was fully outside the 
body. A 26 gauge needle was used to make a small hole in the testis capsule in a region 
where there are no major blood vessels. 
9. The cell inoculum was injected using a pulled glass pipette, approximately 10 µl/testicle. The 
cells were inserted into the testis about halfway to avoid escaping of cells.  
10. After the testis was returned well inside the abdominal cavity, the procedure was repeated 
with the other testis. Then the internal and external incisions were closed separately with 6-0 
silk.  
11. The mice were monitored until they awakened from the anaesthetic, and checked again the 
following day. 
12. The animals were monitored weekly beginning at around four weeks for tumour development. 
Clinical examination was carried out by bringing the testis down into the scrotum and 
palpating it. Lesions become apparent by about five weeks as swellings. The mice were 
humanely euthanized, and the tumours were removed, fixed in formalin and sent for routine 
histological processing. 
13. Sections of teratomas were stained with hematoxylin and eosin (H&E) and examined under a 
bright field microscope. 
 
2.1.2.7- Karyotyping analysis  
hESC lines were sent to karyotyping analysis to Cytogenetics Labotory, Monash Medical Centre, 
Clayton, Victoria, Australia. 
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Section 2.2- Molecular Biology Methods and Materials 
 
2.2.1- Commonly Used Molecular Biology Reagents and Equipment 
General laboratory reagents utilised were of molecular biology grade and were supplied by 
Sigma-Aldrich, Merk or Invitrogen unless otherwise stated. Composition of commonly used 
molecular biology reagents and commercial suppliers is described with their methodology in this 
chapter. Wherever possible, composition of reagents supplied in kits or reaction mixes have been 
detailed in the text.  
Equipment used in specific laboratory procedures is outlined in the relevant sections of the text. 
The Eppendorf 5417R and 5415D microcentrifuges (Eppendorf) were routinely used for 
centrifugation of 0.5-1.7ml tubes. For procedures involving larger volumes or temperature 
controlled conditions, a Multifuge 3 S-R centrifuge (Heraeus, Germany) was utilised. Bacterial 
plates were incubated in a Memmert incubator Beschickung LM 100-800 
(Schawabach/Germany). 
 
2.2.2- Imunological Material and Methods 
 
2.2.2.1- Mounting materials 
Vectashield ® Mounting Medium (Vector Laboratories, CA, USA) [Cat No: H-1000]. The mounting 
medium was applied neat as a thin film of solution over slides. 
 
Glass coverslips 22x60 mm (Menzel-Glaser, Mannheim, Germany) [Deckglaser # 1] and (HD 
Scientific Supplies Pty Ltd). 
 
Blue Glass 12 well slides (IGN Industries, Victoria, Australia) 
 
Nail polish, clear (L’Oreal, Paris, France) 
 
2.2.2.2- Nuclear Dyes 
 
4’,6-Diamidino-2-Phenylindole (DAPI) (Sigma-Aldrich, Steinheim, Germany) [Cat No: D9542]. The 
stock solution was diluted 1:2000 in ddH2O to a final working concentration of 10 µg/ml. DAPI 
was applied to cell DNA on slide preparations by covering the slide surface with 0.5 ml working 
solution and incubating for 2 min at RT. 
 
Propidium iodide (PI) (Sigma-Aldrich, Steinheim, Germany) [Cat No: 70335] PI was used to label 
cell viability (0.5 µg/ml). 
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2.2.2.3- Primary antibodies 
 
 
TABLE 2.1- Primary antibodies names, source, dilution used and application 
Reagent Source Dilution Application 
CD9 mouse monoclonal IgG2a 
(Clone TG30) anti-human 
antibody 
Hybridoma supernant 
prepared in the laboratory 
Applied neat IC, FL 
GCTM-2 mouse monoclonal IgM 
anti-human antibody 
Hybridoma supernant 
prepared in the laboratory 
Applied neat IC, FL 
Mitochondrial marker mouse 
monoclonal IgG1 (clone 1E6) 
anti-human antibody 
Hybridoma supernant 
prepared in the laboratory 
Applied neat IC 
Mouse Monoclonal IgG2b anti-
human Oct3/4 (C-10) antibody  
(Santa Cruz Biotechology, CA, 
USA) [Cat No: sc-5279] 
1:40 
1:200 
IC, FL  
WB 
Mouse Monoclonal IgG2a anti-
human p53 (DO-1) antibody 
(Santa Cruz Biotechnology, 
CA, USA) [Cat No: sc-126] 
1:50 
1:1000 
IC 
WB 
Mouse Monoclonal IgG1 p53 
(PAb 1801) antibody 
(Abcam) 
[Cat No: ab28] 
1:100 IC 
Mouse Monoclonal IgG1 Mcl1  
(RC13) antibody 
(Abcam) 
[Cat No: ab3184] 
1:50 
1:1000 
IC 
WB 
Mouse IgG1 anti-
human/rat/mouse Hdm2 (clone 
SMP14), ascites fluid  
(Sigma-Aldrich) 
[Cat No: M4308] 
1:50 
1:1000 
IC 
WB 
Rabbit polyclonal IgG anti-
human Hdmx antibody 
(Abcam) 
[Cat No: ab16058] 
1:50 
1:1000 
IC 
WB 
Rabbit polyclonal IgG anti-
human Bax antibody 
(DAKO) 
[Cat No: A3533] 
1:50 
1:1000 
IC 
WB 
Rabbit polyclonal anti-
human/mouse/rat Cleaved 
Caspase-3(Asp175) antibody 
(Cell Signaling) 
[Cat No: 9661] 
1:50 
1:1000 
IC 
WB 
Mouse Monoclonal IgG1 anti-
human/canine/rat/mouse β-
Tubulin (clone SAP.4G5), ascites 
Fluid 
(Sigma-Aldrich) 
[Cat No: T7816] 
1:5000 WB 
Mouse Monoclonal IgG1 anti- 
human Lamin B Antibody 
(Calbiochem) 
[Cat No: NA12] 
1:1000 WB 
Mouse Monoclonal IgG1 anti-
human/canine/rat/mouse 
GAPDH (Clone 6C5) antibody  
(Ambion)  
[Cat No: 4300] 
1:4000 WB 
Mouse Monoclonal IgG1 anti-
human/canine/rat/mouse 
Cytochrome c antibody 
(BD Pharmingen) [Cat No: 
556433] 
1:200 WB 
Rabbit polyclonal IgG anti-
human PUMA antibody 
(Calbiochem) 
[Cat No: PC686] 
1:1000 WB 
Mouse Monoclonal IgG1 anti-
human Noxa antibody 
(Abcam) 
[Cat No: ab13654] 
1:1000 WB 
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Rabbit polyclonal IgG anti-
human Bcl2 (∆C21) antibody 
(Santa Cruz Biotechnology) 
[Cat No: sc-783] 
1:50 
1:1000 
IC 
WB 
Mouse Monoclonal IgG1 Nanog 
antibody  
eBioscience  
[Cat No: 14-5769] 
1:1000 WB 
Mouse Monoclonal IgG1 p21 
antibody 
(BD Pharmingen) 
[Cat No: 554228] 
1:1000 WB 
Abbreviations: FC = flow cytometry, IC = immunocytochemistry, WB = western blotting 
 
 
2.2.2.4- Isotype controls 
 
 
TABLE 2.2- Isotype controls names, source, dilution used and application 
Reagent Source Dilution Application 
Purified mouse IgG1 BD Pharmingen  
[Cat No: 553447] 
* FL 
Purified mouse IgG1 
 
DAKO  
[Cat No: X 0931] 
* IC 
Purified mouse IgG2a BD Pharmingen  
[Cat No: 553447] 
* FL 
Purified mouse IgG2a 
DAKO 
[Cat No: X 0943] 
* IC 
Purified mouse IgG2b 
BD Pharmingen 
[Cat No: 559530] 
* FC 
Purified mouse IgG2b 
DAKO 
[Cat No. X  0944] 
* IC 
Purified mouse IgM 
BD Pharmingen 
[Cat No. 553472] 
* FC 
* The dilution of isotype-matched negative control antibodies is the same as dilution of primary antibody for 
each experimental application. 
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2.2.2.5- Secondary antibodies 
 
TABLE 2.3- Secondary antibodies names, source, dilution used and application 
Reagent Source Dilution Application 
Alexa Fluor ® 488 conjugated 
goat anti-mouse IgG1 
Molecular Probes, 
Eugene, USA 
[Cat No: A21121] 
1:500 IC, FL 
Alexa Fluor ® 488 conjugated 
goat anti-mouse IgG2a 
Molecular Probes, 
Eugene, USA 
[Cat No: A21131] 
1:500 IC, FL 
Alexa Fluor ® 488 conjugated 
goat anti-mouse IgG2b 
Molecular Probes, 
Eugene, USA 
[Cat No: A21141] 
1:500 IC 
Alexa Fluor ® 488 conjugated 
goat anti-mouse IgM 
Molecular Probes, 
Eugene, USA 
[Cat No: A21042] 
1:500 IC 
Alexa Fluor ® 568 conjugated 
goat anti-mouse IgG1 
Molecular Probes, 
Eugene, USA 
[Cat No: A21124] 
1:500 IC 
Alexa Fluor ® 568 conjugated 
goat anti-mouse IgG2b 
Molecular Probes, 
Eugene, USA 
[Cat No: A21144] 
1:500 IC 
Alexa Fluor ® 568 conjugated 
goat anti-Rabbit (H+L) 
Molecular Probes, 
Eugene, USA 
[Cat No: A11011] 
1:500 IC 
Alexa Fluor ® 647 conjugated 
goat anti-mouse IgG2b 
Molecular Probes, 
Eugene, USA 
[Cat No: A21242] 
1:2000 FL 
Alexa Fluor ® 647 conjugated 
goat anti-mouse IgM 
Molecular Probes, 
Eugene, USA 
[Cat No: A21238] 
1:2000 FL 
HRP conjugated polyclonal 
rabbit anti-mouse Ig-HRP 
(Dako Cytomation, 
Glostrup, Denmark) 
[Cat No: P0260] 
1:1000 WB 
HRP conjugated goat anti-
mouse Ig-HRP 
(Jackson Immuno 
Research Laboratories, 
PA, USA) 
[Cat No: P0161] 
1:1000 WB 
HRP conjugated polyclonal 
goat anti-rabbit IgG 
(Dako Cytomation, 
Glostrup, Denmark) 
[Cat No: P0448] 
1:1000 WB 
Abbreviations: FC = flow cytometry, IC = immunocytochemistry, WB = western blotting. 
 
 
2.2.2.6- Western blotting solutions 
  
Skim milk powder (Coles Supermarket, Clayton, Victoria, Australia) was prepared fresh at 5% 
(w/v) in TBS-T (see Appendix I for solution preparation) for blocking of western blots. 
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30% Acrylamide/Bis Solution (Bio-Rad) [Cat No. 161-0156] is obtained as a 30% Solution of 
Acrylamide/Bis at a 29:1 w/w ratio and stored at 4˚C in dark. 
 
Restore Western Blot Stripping Buffer (Pierce) [Catalog number 21059] was stored at RT and 
applied neat for removal of primary and secondary antibody probes from PVDF and nitrocellulose 
blots to enable re-probing. 
 
2.2.3- Indirect immunofluorescence microscopy methods 
Fluorescent immunostained samples were analyzed and photographed using an Olympus BX51 
microscope and ULH100HG epifluorescence system with DP70 camera. For confocal 
microscopy, a Leica TCS NT laser scanning confocal microscope attached to an inverted Leica 
DMIRB/E fluorescence was used. 
 
2.2.3.1- Fixation and permeabilization of cells  
Various cell lines were fixed onto slides or coverslips. 
 
2.2.3.1.1- Ethanol (EtOH) or Methanol (MeOH) fixation protocol 
1. The cells were washed gently cells twice with cold PBS
-
, taking care not to flush cells off the 
surface of the slide or coverslip. 
2. Ice-cold EtOH or MeOH was added and incubated 5 minutes on ice.  
3. EtOH or MeOH were aspirated, and the preparations were air dried and either stained or 
wrapped in plates in parafilm and store at -20˚C until needed. 
 
2.2.3.1.2- Paraformaldehyde (PFA) fixation protocol 
1. Medium was aspirated from the slides/coverslips and these were rinsed well with ice cold 
PBS. 
2. 4% PFA (see Appendix I for solution preparation) solution was added to the slides and left for 
15 minutes at RT°C. 
3. PFA solution was aspirated from the Plate or slide chamber and slides were washed with 
PBS. 
4. Immediately following fixation, the samples were processed, beginning with the 
permeabilization step. 
 
2.2.3.1.3- Permeabilization (for PFA-fixed specimens) 
PFA-fixed cells to be used for immunostaining were first permeabilized to allow the antibody 
access across the cell and nuclear membranes.  
1. A PBS solution containing 0.1% Triton X-100 was incubated over the cells for 5 min on ice. 
2. Samples were washes twice with PBS before antibody labeling. 
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2.2.3.2- Antibody labelling and examination of cells  
1. The majority of staining was performed on 8-well chamber slides or coverslips. In this last 
case coverslips were put on top of inverted microtube lids that served as a platform. 
2. A blocking solution (usually 10% SR medium) was added and incubated with the cells at RT 
for 15 minutes. 
3. Primary antibody was diluted and placed on slides according to manufacturer’s directions. In 
some cases a range of antibody dilutions was performed to determine an optimal 
concentration for staining. Coverslips required 100 µl solution while chamber slides required 
50 µl per well. 
4. Coverslips or slides were incubated for 2 hour at RT or at 4˚C ON. 
5. Slides were washed three times with PBS and similarly incubated with the appropriate 
secondary antibody at RT 30 minutes or at 4˚C ON. 
6. Slides were washed three times with PBS as previously and subsequently counterstained 
with DAPI (1 µg/ml). 
7. Cells were mounted under a glass coverslip (Menzel Glaser) with Vectashield mounting 
solution (Vector Labs) to minimise bleaching of fluorescence, sealed with nail polish and 
analyzed and photographed an Olympus BX51 microscope and ULH100HG reflected 
fluorescence system with DP70 camera or on the Leica confocal system. 
8. The slides were archived at 4˚C and protected from light. 
 
2.2.4- Flow cytometry methods 
Indirect immuno-labeled hESC were analyzed with CXP software (Beckman Coulter) using a 
Cytomics FC 500 series flow cytometry system (Beckman Coulter) or a BD FACSVantage SE 
flow cytometer with FACSDiva option (Beckton Dickinson Biosicences). Fluorescence-activated 
cell sorting (FACS) and In situ Cell proliferation assay were carried out on the FACSDiva 
instrument with the assistance of Andrew Fryga and Darren Ellemor. 
 
2.2.4.1- Apoptosis and flow cytometry analysis 
Etoposide (Sigma-Aldrich) [Cat No: E1383], gamma-irradiation, human TNF alpha (Sigma-Aldrich) 
[Cat No: T0157], serum removal and hydrogen peroxide were used as apoptosis-inducing agents. 
Cyclic pifithrin-α (cPFT, 25 µM, (Sigma-Aldrich) [Cat No: P4236], pifithrin-µ (PFT-mu, 10 µM) 
(Calbiochem) [Cat No:506155] and Bongkrekic acid (BA, 50 µM, Sigma-Aldrich) [Cat No: B6179] 
were added 1 h before the treatment with etoposide. zVAD-fmk (25 µM, Sigma-Aldrich) [Cat No: 
V116], Cycloheximide (40, 10 and 4 µM, Sigma-Aldrich) [Cat No: C7698], Leptomycin B (5 ng/ml, 
Sigma-Aldrich) [Cat No: L2913] and Cyclosporine A (10 µM, Sigma-Aldrich) [Cat No: 30024] were 
added 30 min before the treatment with etoposide. 
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2.2.4.1.1- Annexin V staining 
Annexin-V-Fluos binds in a Ca
2+
 -dependent manner to negatively charged phospholipid surfaces 
and shows high specificity to phosphatidylserine, which during early stages of apoptosis 
translocates from the inner part of the plasma membrane to the outer layer becoming exposed at 
the external surface of the cell (Vermes et al., 1995). Annexin-V-FLUOS Staining Kit (Roche 
Applied Science) [Cat No: 11858777001] was used for detection and quantification of apoptosis. 
1. hESC cells were cultured for 5 days on Matrigel with MEF conditioned medium supplemented 
with FGF-2 and treated exposed to hydrogen peroxide or DMEM/F12 alone for 22 h. 
2. After treatments, floating cells were collected and adherent cells were harvested with Cell 
Dissociation Solution (Gibco) (2ml/T25). These cells were pooled and pelleted by 
centrifugation for 2 min at 500 x g. 
3. The cells were washed with PBS
-
 and resuspended at 1x10
6
 cells/ml. 
4. The cells were centrifuged for 2 min at 500 x g and the cell pellet was resuspended in 100 µl 
of Annexin-V-FLUOS labelling solution containing PI. 
5. The suspension was incubated for 20 min at RT. 
 
2.2.4.1.2- OCT4-Terminal deoxynucleotidyl Transferase Biotin-dUTP Nick End Labeling (TUNEL) 
detection assay 
This flow cytometry immunoassay quantifies DNA strand breaks by using terminal 
deoxynucleotidyl Tranferase (TdT), which catalyses polymerization of labelled nucleotides to free 
3’-OH DNA ends. In Situ Cell Death Detection Kit, Fluorescein from (Roche Applied Science) [Cat 
No: 11684795910] was used for detection and quantification of apoptosis. Simultaneously, cells 
can be characterized further for expression of the marker Oct4.  
1. hESC cells were cultured for 5 days Matrigel with MEF conditioned medium supplemented 
with FGF-2. To test the sensitivity of hESC to apoptosis-inducing agents, cells were treated 
with Etoposide (Sigma-Aldrich) and gamma-irradiation. The cells were analysed for apoptosis 
at different doses of agent and different time points. cPFT (25 µM, Sigma-Aldrich), PFT-mu 
(10 µM, Sigma-Aldrich) and BA (50 µM, Sigma-Aldrich) were added 1 h before the treatment 
with etoposide. zVAD-fmk (25 µM, Sigma-Aldrich) and Cycloheximide (4 µM, Sigma-Aldrich) 
were added 30 min before the treatment with etoposide. 
2. After treatments, floating cells were collected and adherent cells were harvested with Cell 
Dissociation Solution (Gibco) (0.5 ml/well of 6-well plate or 2ml/T-25). These cells were 
pooled and pelleted by centrifugation.  
3. The cells were washed with PBS
-
 and resuspended at 1x10
6
 cells/ml. 
4. Cells were divided in 1 ml aliquots and resuspended in 500 µl of freshly prepared Fixation 
solution [PFA 2% in PBS
-
 (pH 7.4)]. The cells were incubated at RT for 1h. (Note: before 
adding PFA cells were in a small volume of PBS to avoid clump formation). After fixation, the 
cells were centrifuged at 375 x g for 2 min and the fixation solution was gently aspirated. 
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5. The cell pellet was resuspended in 200 µl of Permeabilization solution [Triton X-100 0.1% in 
PBS
-
] for 2 min on ice. The cells were centrifuged at 375 x g for 2 min and the 
permeabilization solution was aspirated. 
6. The cells were washed twice with PBS
-
. 
7.  Using a P200 micropipette, 45 µl of Label Solution ® (Roche Applied Science) [Cat No: 
11684795910] containing fluorescein conjugated nucleotides was then mixed with 5 µl of 
Enzyme Solution ® containing terminal deoxynucleotidyl transferase from calf thymus, 
recombinant in E. coli, in storage buffer (Roche Applied Science). The cell pellet was 
resuspended in this reaction mixture and the cells incubated for 1h at 37 °C. 
8.  The pellet was briefly resuspended in 200 µl of PBS, the cells were centrifuged at 375 x g for 
2 min and the wash solution was aspirated. 
9. The cells were resuspended in 200 µl of SR medium with 1:40 of monoclonal antibody Oct3/4 
C-10 (Santa Cruz) and incubated on ice for 1h. Purified mouse IgG2b (BD Pharmingen) was 
used as isotype control at same concentration as Oct3/4 antibody. The cells were pelleted for 
2 min at 375 x g and washed with 500 µl. 
10. After pelleting, cells were resuspended in 200 µl of SR with 1:1000 of appropriate secondary 
antibody Alexa Fluor anti-mouse IgG2b 647 (Molecular Probes- Invitrogen) and incubated on 
ice for 1h. 
11. Cells were again washed with in PBS, resuspended in 500 µl PBS
 
and samples were then 
ready for flow cytometry analysis. Cells were gated initially using forward and right angle light 
scatter and AF488 and AF647 fluorescence signals were collected. Data were analyzed and 
present using CXP Analysis Software (Beckman Coulter).  
2.2.4.1.3- Measurement of mitochondrial membrane potential 
MitoProbe
TM
JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolylcarbocyanine iodide) 
assay kit for flow cytometry (Molecular Probes, Invitrogen) [Cat No: M34152] as used to measure 
mitochondrial membrane potential and as performed accordingly to manufacturer instructions.  
1. Cell Dissociation Solution (Gibco) was used to harvest cells and then these were washed 
with PBS.  
2. Cells (1x10
6
 cells) were incubated with 1 µM JC-1 (reconstituted in DMSO) diluted in KSR 
medium for 30 min at 37 ºC in the dark.  
3. Cells were washed with PBS, resuspended in PBS and analyzed by flow cytometry 
(Cytometrics FC 500 System, Beckman Coulter).  
4. As a positive control, cells were incubated with 100 mM of CCCP (carbonyl cyanide 3-
chlorophenylhydrazone), a mitochondrial membrane-potential disrupter, for 5 min prior the 
addition of JC-1. 
 
2.2.4.1.4- Cell staining for viability 
LIVE/DEAD® Fixable Dead cell stain kit (green fluorescence, Molecular Probes, Invitrogen) [Cat 
No: L23101] was used to distinguish apoptosis from necrosis and the assay was performed 
accordingly to manufacturer instructions.  
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1. Cells were harvested with Cell Dissociation Solution (Gibco) and washed with PBS.  
2. Cells (1x10
6
 cells) were incubated with 1 µl of fluorescence reactive dye (reconstituted in 
DMSO) diluted in SR medium for 30 min on ice in the dark.  
3. Cells were washed with PBS, resuspended in PBS, fixed in 4% PFA solution and analyzed by 
flow cytometry (Cytometrics FC 500 System, Beckman Coulter). 
 
2.2.4.1.5- Cell proliferation assay 
In Situ Cell Proliferation Kit, FLUOS (Roche Applied Science) [Cat. No: 11810740001] was used 
to measure cell proliferation (incorporation of BrdU) and the assay was performed according to 
the manufacturer’s instructions. 
1. BrdU labeling was performed by diluting BrdU labeling reagent 1:1000 in the culture medium 
for 2h in the incubator at 37 °C and 5% CO2. 
2. Culture medium was aspirated and the flasks washed with 5 ml of PBS
-
. The wash solution 
was removed and TrypLE Express Stable Trypsin Replacement Enzyme (Gibco) was applied 
to form a thin film over a confluent T-25 flask (1 ml) or a well of a 6-well plate (Matrigel 
cultures- 0.5 ml).  
3. BrdU labelled cells were washed in PBS. 
4. The cells were resuspended in 250 µl of TG30 monoclonal antibody supernant containing 
mouse anti CD9 (1:1) and incubated on ice for 30 min. Purified mouse IgG2a (BD Pharmingen) 
was used as an isotype control (1:125). Cells were pelleted for 2min at 375 x g and washed 
with 500 µl of PBS. 
5. After pelleting, cells were resuspended in 200 µl of SR with 1:1000 of secondary antibody 
Alexa Fluor anti-mouse IgG2a (Molecular Probes- Invitrogen) and incubated on ice for 30 min. 
Then cells were washed twice with PBS. 
6. The cells were fixed with fixative solution (70% Ethanol in 50 mM Glycine buffer, pH 2.0) and 
then cells were washed twice with PBS.  
7. The cells were incubated in denaturation solution (4 M HCl) and then cells were washed 
twice with PBS and the pH was measured to make sure that was above 6.5. 
8. To block, cells were incubated with incubation buffer for 10 min at RT. 
9. The cells were resuspended in 50 µl of anti-BrdU-FLUOS antibody working solution (1:5 anti-
BrdU-FLUOS in incubation buffer) for 45 min at 37°C and then washed twice with PBS. 
10. Before analysis on the flow cytometer, cells were resuspended in 500 µl PBS
-
 containing 5 
µg/ml of PI. 
11. Data were analyzed and present using CXP Analysis Software (Beckman Coultier). 
 
2.2.4.1.6- Preparation of cells for FACS 
1. Culture medium was aspirated and the flasks washed with 5 ml of PBS
-
. The wash solution 
was removed and Cell Dissociation Buffer solution (Gibco) was applied to form a thin film 
over a confluent T-25 flask (1 ml) or a well of a 6-well plate (Matrigel cultures- 0.5 ml). The 
cells were treated for 5 min in an incubator at 37 °C and 5% CO2. 
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2. The Cell Dissociation Buffer solution was aspirated from flasks and hESC colonies were 
sloughed off by gently and repeatedly spraying the entire culture flask or well with SR 
medium at RT using a 5 ml sterile pipette attached to a Drummond Scientific Co. express 
pipet-aid on the high speed setting (Becton Dickinson). 
3. The wash medium (5 ml) was aspirated, transferred to a sterile 15 ml Falcon tube and 
centrifuged 2 min at 375 x g. The medium as aspirated and the cells were washed with SR 
medium. 
4. The cells were resuspended in 500 µl of monoclonal antibody GCTM-2 and TG30 supernant 
(TG30) (1:1) and incubated on ice for 30 min. Purified mouse IgG2a and IgM (BD Pharmingen, 
Cat # 559530) were used as isotype controls (1:125). Cells were pelleted for 2min at 375 x g 
and washed with 500 µl of PBS. 
5. After pelleting, cells were resuspended in 200 µl of SR with 1:1000 of appropriate secondary 
antibodies Alexa Fluor anti-mouse IgG2a and anti-mouse IgM 647 (Molecular Probes- 
Invitrogen) and incubated on ice for 30 min. 
6. PI (1:1000 from a 1 mg/ml stock solution) was added to determine cell viability.  
7. Cells were again washed with in PBS
-
, resuspended in 500 µl PBS
-
 and samples were then 
ready for flow cytometry analysis. Cells were gated initially using forward and right angle light 
scatter and AF488 and AF647 fluorescence signals were collected. Data were analyzed and 
present using CXP Analysis Software (Beckman Coultier).  
8. Double positive cells were sorted and colleted to a tube containing SR medium. 
9. Samples were then processed for RNA extraction. 
 
2.2.5- SDS-PAGE and Western Blotting 
Sodium dodecyl sulfate - Polyacrylamide Gel Electrophoresis (SDS-PAGE) followed by western 
blotting was used to determine the size and presence of proteins expressed in various cell lines.  
 
2.2.5.1- Preparation of samples 
1. Laemmli buffer was prepared (see Appendix I for solution preparation). 
2. Cells were harvested with Cell dissociation buffer (Gibco) and washed once with 1ml PBS 
(Gibco). 
3. The PBS was aspirated the carefully and 250 µl of Laemmli buffer was added per sample 
(per well of 6 well plate). 
4. Samples were then transferred to tubes and these were covered with boiling caps and boiled 
for 10 minutes on a heating block. 
5. Samples were stored at -20˚C for later use. 
 
2.2.5.2- Preparation of  SDS-PAGE Gels 
SDS-PAGE gels were prepared in two stages: a resolving gel and a stacking gel. The resolving 
gel was made with 30% acrylamide/bis solution (Bio-Rad) [Cat No. 161-0156] at a range of 8 to 
15% final concentration of acrylamide depending on protein size (Table 2.4). Stacking gel was 
made up at acrylamide concentration of 4% (Table 2.5). 
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TABLE 2.4- Solutions for preparing resolving gels for SDS-PAGE 
8% 10% 12% 15% 
Resolving gel 
10 ml 10 ml 10 ml 10 ml 
MQ H2O 4.6 4.0 3.3 2.3 
1.5 M Tris pH 8.8 2.5 2.5 2.5 2.5 
30% acrylamide/bis  2.7 3.33 4.0 5.0 
10% SDS 0.1 0.1 0.1 0.1 
10% APS 0.1 0.1 0.1 0.1 
TEMED 0.006 0.004 0.004 0.004 
 
TABLE 2.5- Solutions for preparing stacking gels for SDS-PAGE 
4% 
Stacking gel 
4 ml 
2.7 
0.5 M Tris pH 6.8 0.67 
30% acrylamide/bis 0.5 
10% SDS 0.04 
TEMED 0.04 
10% APS 0.004 
 
1. To prepare 10 ml of 12% resolving gel the following reagents were combined: 4ml of 30% 
acrylamide solution, 2.5ml of 1.5M Tris HCl (pH 8.8), 100µl SDS (10% stock) and ddH2O to 
10ml. 4 µl of the polymerizing agent TEMED (Bio-Rad) [Cat No: 161-0801] was added along 
with 100µl of freshly made 10% Ammonium Persulfate (APS) (Sigma-Aldrich) [Cat No: 
A3678]. The solution was mixed and immediately poured into the gel cast before being 
overlaid with 1-2ml isopropanol. The resolving gel was allowed to set at RT for approximately 
20 min. 
2. The isopropanol was poured off the resolving gel and allowed to evaporate off before the 
stacking gel was cast. 4% stacking gel is composed of  1 ml of 30% acrylamide solution, 1 ml 
of 0.5M Tris HCl (pH 6.8), 60 µl SDS (10% stock) and ddH2O to 6 ml. The polymerizing 
agents were added as for the resolving gel before casting. 
 
2.2.5.3- Electrophoresis of SDS-PAGE gels 
1. The samples were denatured by boiling at 100°C for 2 min. 
2. The samples were briefly centrifuged at 10,000 x g for 1- 2 min before loading (10-22 µl of 
sample per lane) in duplicate. A protein size standard ladder, Kaleidoscope™ Prestained 
Standards (Bio-Rad) [Cat No: 161-0324] was run on each gel to allow determination of 
sample molecular weight. 
3. Protein samples were electrophoresed at 100 V in 1x Running Buffer [25 mM Tris, 192 mM 
Glycine, 0.05% SDS] for 1.5-2 h until the dye front reached the end of the gel.   
4. Gels were carefully removed from the casting plates and prepared for transfer. 
 
2.2.5.4- SDS-PAGE Semi-Dry Transfer  
Gels were placed into a Semi-phor semi-dry transfer apparatus (Hoefer Scientific Instruments) 
(Amersham Biosciences) and transfer of proteins was conducted according to manufacturer’s 
instructions. 
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1. A PVDF transfer membrane (Amersham Pharmacia Biotech) [Cat No: RPN303F] previously 
washed 5 min in MeOH for 5 min, transferred to MilliQ H2O for 5 min and finally incubated in 
running buffer for 30 min. 
2. The gel was removed and assembled with transfer membrane as recommended by the 
manufacturer of the apparatus (2x blotting paper, membrane, gel, 2x blotting paper, cover). 
3. A 100 mA current, approximately 10-15V, was applied for 1 h at RT. When finished, the 
apparatus was dismantled. 
 
2.2.5.5- Immunohybridization and detection of proteins 
1. A blocking agent, 5% skim milk in PBS-Tween 0.01% (PBS-T), was incubated with the 
membranes for 1 h or overnight at 4˚C to prevent non-specific hybridization. 
2. The membranes were incubated with a primary antibody specifically directed to the protein of 
interest diluted in 5% skim milk in PBS-T for 1 hour at RT or overnight at 4˚C on the rocker. A 
heat sealer was used to make a bag for each blot to be probed. For most full sized blots, 2.5 
ml solution was applied to cover the blot. 
3. Membranes were washed 3x 5 min with PBS-T. 
4. HRP labeled secondary antibody was diluted in 5% skim milk in PBS-T for 1 hour at RT on 
rocker.  
5. Membranes were washed 2x 5 min with PBS-T and 1x5 min with PBS. 
 
2.2.5.6- Detection of proteins  
The proteins were then detected using ECL Plus Western Blotting Detection Reagents 
(Amersham Biosciences) [Cat No: RPN2132] or ECL Western Blotting Substrate (Pierce) [Cat No: 
32106]. Bio-Rad Gel ChemiDoc
TM
 XRS System was used to acquire the images. 
1. Once detection reagents were warmed to RT, the two detection solutions were mixed 
according to the manufacturer’s instructions. The final volume of detection reagent required is 
0.1 ml/ cm
2
 (for normal sized blot approximately 1-2ml). In case of ECL Plus Western Blotting 
Detection Reagents (Amersham Biosciences, the solutions A and B were mixed in a ration of 
40:1. When ECL Western Blotting Substrate (Pierce) was used equal volumes of solutions 1 
and 2 were mixed. 
2. Excess wash buffer was drained from washed membranes and these were placed on the 
black tray within the gel-doc system. 
3. The detection reagents were pipetted on top of membrane covering it surface. The tray was 
placed into the gel-doc system and 5 minutes were allowed for occurrence of the substrate 
reaction before proceeding with imaging. 
4. Blots were exposed for different intervals of time, depending on primary antibody used, and 
images were acquired using Gel ChemiDoc
TM
 XRS System (Bio-Rad). Lastly, software based 
densitometric analysis (Gel-Pro Analyser version 3.1, MediaCybernetics) was performed on 
cross-reactive bands and the β-tubulin loading controls. 
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2.2.5.7- Stripping and re-probing membrane 
1. Blots were washes with PBS-T and were incubated with Restore PLUS Western Blot 
Stripping Buffer (Pierce) [Cat No: 21059] for 15 minutes at RT on a rocker. 
2. The membranes were blocked with 5% skim milk in PBS-T for 1 hour at RT or ON at 4˚C on 
the rocker and then probed with the next antibody according to the protocol described in 
section 2.2.7.3. 
 
2.2.6- Cell subfractionation 
Cell subfractionation was performed to obtain cytosolic fraction to determine release of 
cytochrome c from the mitochondria. 
1. hESC were washed with PBS and permeabilized with 20 µg/ml digitonin (Sigma-Aldrich) [Cat 
No: D141] for 10 min at 37
o
C. 
2. The cytosolic/soluble fraction was collected with a P1000 micropipette to a 1.7ml tube and 
boiled in 3x Laemmli sample buffer.  
3. Cells were washed twice with PBS and boiled in Laemmli sample buffer (non-soluble fraction). 
4. Samples were then processed and analysed through SDS-PAGE and Western blotting. 
 
2.2.7- DNA laddering protocol 
DNA laddering is a technique used to identify DNA cleavage that occurs during apoptosis.  
1. After treatment with etoposide for different time points, cells hESC and apoptotic bodies were 
collected then pelleted and the supernant was discarded. 
2. The cells were resuspended on ice in 20 µl of lysis buffer (50 mM tris-HCl (pH 8.0), 0.5% 
SDS, 0.5 mg/ml proteinase K added fresh) and pipetted to ensure complete lysis 
3. The lysate was incubated at 55
o
C for 60 min. 
4. The cell debris was pelleted and then 5 µl of 1 mg/ml RNase A was added to the supernatant. 
The suspension was incubated at 55
o
C for another 60 min. 
5. The sample was spun briefly to pellet any further cell debris and the supernatant was 
collected.  
6. The lysate was heated to 70
o
C for a few minutes and mixed with 10 µl of loading buffer  with 
1% low melting point agarose (Scientifix) [Cat No: 9040A]. 
7. The samples were run on a 2% agarose gel (Quantum Scientific) [Cat No: 200-0011] 
containing 0.5 µg/ml ethidium bromide and run at 40V for 2h using a Bio-Rad power pack 
until appropriate separation of bands had occurred.   
8. The DNA laddering was visualized and photographed under UV light in a Gel ChemiDoc
TM
 
XRS System (Bio-Rad). 
 
2.2.8- Lentiviral-mediated delivery of shRNA 
HES-2 cells and HES-4 were transduced with lentivirus carrying short hairpin RNA (shRNA) 
designed to knockdown p53 or GFP using the BLOCK-it
TM
 Lentiviral RNAi Expression System 
(Invitrogen) [Cat No: K4944-00], as described by the manufacturer. The p53 and GFP shRNA 
sequences used were the following: 
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p53A top strand  
5’-CACGCGCACAGAGGAAGAGAATCTCGAAAGATTCTCTTCCTCTGTGTGCGC-3’ and 
p53A bottom strand 
5’-AAAAGCGCACAGAGGAAGAGAATCTTTTCGAGATTCTCTCTTCCTCTGTGCGC-3’. 
p53B top strand  
5’-CACCGTCTGTGACTTGCACGTACCGAAGTACGTGCAAGTCACAGAC-3’ and 
p53B bottom strand 
5’-AAAAGTCTGTGACTTGCACGTACTTCGGTACGTGCAAGTCACAGAC-3’. 
GFP top strand  
5'-CACCGAAGAAGTCGTGCTGCTTCATCGAAATGAAGCAGCACGACTTCTTC-3' and  
GFP bottom strand  
5'-AAAAGAAGAAGTCGTGCTGCTTCATTTCGATGAAGCAGCACGACTTCTTC-3'. 
 
Cells were plated on Matrigel and infected with lentivirus. Apoptosis assays and Western blotting 
analysis were performed as described above. 
 
2.2.8.1- Producing lentivirus in 293FT cell line 
 
TABLE 2.6- Optimized transfection conditions for production of lentiviral stocks in 293FT cells 
Conditions         Amount 
Tissue culture plate size                          T75  
Number of 293FT cells to transfect                  6 x 10
6
 cells  
Amount of ViraPower™ Packaging Mix                     11.5 µg  
Amount of pLenti6/BLOCK-iT™-DEST expression plasmid                                 4 µg 
Amount of Fugene 6 Transfection Reagent                      36 µl 
 
1. Fugene 6 Transfection Reagent was pipetted directly into 800 µl of DMEM High glucose 
without allowing contact with the walls of the plastic tube and incubated 5 min at RT. 
2. Then 4 µg of pLenti6/BLOCK-iT™-DEST expression plasmid and 9 µg of ViraPower™ 
Packaging Mix were added to Fugene 6 Transfection Reagent and the complex was mixed 
and incubated for 20 min at RT. 
3. The complex was added to the cells in a drop-wise manner. The flasks were swirled to 
ensure distribution over the entire plate surface. Antibiotics were omitted from the culture 
medium of 293FT cells during production of virus. 
4. The next day the media containing the DNA-Fugene 6 complexes was removed and replaced 
with complete media containing sodium pyruvate. 
5. Virus-containing supernatants were harvested 48-72 hours posttransfection by removing 
medium to a 15 ml sterile, capped, conical tube and filtered sterilizing it using a 0.45 µM filter. 
6. The viral supernatants were pipetted into cryovials in 1 ml aliquots and stored at -80°C. 
 
2.2.8.2- Titering Lentiviral Stock 
2.2.8.2.1- Determining Antibiotic Sensitivity 
1. HT1080 cells and HES cells were plated at approximately 25% confluence. Set of 6 plates 
were prepared. The cells were allowed to adhere ON. 
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2. The next day, the culture medium was substituted with medium containing varying 
concentrations of Blasticidin (0, 2, 4, 6, 8, 10 µg/ml Blasticidin) (Invitrogen) [Cat. No: R210-
01]. 
3. The selective media was replenished every 3-4 days, and the percentage of surviving cells 
was observed. 
4. The appropriate concentration of Blasticidin that kills the cells within 10-14 days after addition 
of antibiotic was determined. 
 
2.2.8.2.2- Transduction and Titering Procedure 
1. The day before transduction (Day 1), the HT1080 cells were trypsinized, counted and plated 
in 2 x 10
5
 cells per well a 6-well plate such that they were 30-50% confluent at the time of 
transduction. The cells were incubated at 37°C ON. 
2. On the day of transduction (Day 2), the lentiviral stock was thawed and 10-fold serial dilutions 
ranging from 10
-2
 to 10
-6 
were preapared. For each dilution, the lentiviral construct was diluted 
into complete culture medium to a final volume of 2 ml. 
3. The culture medium was removed from the cells. Each dilution was mixed gently by inversion 
and added to one well of cells. 
4. Polybrene® (Sigma-Aldrich) [Cat No: 10768-9] was added to each well to a final 
concentration of 6 µg/ml. The plate was swirled gently to distribute the added solutions and 
incubated at 37°C ON. 
5. The following day (Day 3), the media containing virus was removed and replaced with 2 ml of 
complete culture medium. 
6. The following day (Day 4), the medium was removed and replaced with complete culture 
medium containing the appropriate amount of Blasticidin (10 µg/ml) to select for stably 
transduced cells. 
7. Medium was replaced with fresh medium containing Blasticidin every 3-4 days. 
8. After 10-12 days of selection (day 14-16), no live cells were seen in the mock well and 
discrete Blasticidin-resistant colonies appeared in one or more of the dilution wells. The 
medium was removed and the cells washed twice with PBS. 
9. Crystal violet solution was added (1 ml for 6-well dish) and incubated for 10 minutes at RT. 
10. The crystal violet stain was removed and the cells washed with twice with PBS. 
11. The blue-stained colonies were counted and the titer of the lentiviral stock was determined. 
 
2.2.8.3- Transducing hESC with lentivirus 
1. On the day of transduction, the lentiviral stock was thawed. 
2. The culture medium was removed from the HES-2 and HES-4 cells on Matrigel.  
3. To each well was added Polybrene® was added to a final concentration of 6 µg/ml. 
4. An appropriate lentiviral stock dilution was added. As control no viruses was added to a well. 
The plate was swirled gently to mix and incubated at 37°C ON. 
5. On the following day, the media containing virus was removed and replaced with 2 ml of 
culture medium. 
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6. The following day, the medium was removed and replaced with complete culture medium 
containing the appropriate amount of Blasticidin (2.5-7.5 µg/ml) to select for stably 
transduced cells. 
7. The medium was replaced with fresh medium containing Blasticidin every day. 
8. After 10-12 days of selection (day 14-16), the absence of live cells in the mock well was 
confirmed The cells were harvested and subcultured with serum-free medium on 2x10
4
 
cell/cm
2
 density of MEF. 
 
2.2.9- Total RNA isolation 
RNA isolation was conducted with an RNeasy Mini Kit (Qiagen) [Cat No: 74104], according to 
manufacturer’s instructions. Buffer RPE was prepared by adding 4 volumes of EtOH (RNase-
free), as indicated on the bottle, to obtain a working solution and Buffer RLT was made by adding 
10 µl β-ME per 1ml RLT immediately prior to use. 
 
1. Cells were pelleted in a microtube by centrifuging at 375 x g for 2 minutes and then washed 
in PBS. 
2. The cell pellet was resuspended in 350 µl Buffer RLT +β-ME and mixed by pipetting. 
3. The sample was homogenized by passing the lysate through a 21-gauge needle (with 1ml 
syringe) 5-6 times or using a Quiashredder columns (Qiagen) [Cat No: 79654]. 
4. 350 µl (1 volume) of 70% EtOH (RNase-free) were added to the homogenized lysate and 
mixed well by pipetting. 
5. 700 µl sample were applied, including any precipitate that may have formed, to an RNeasy 
mini column placed in a 2 ml collection tube (supplied with the kit). The lid was closed and 
centrifuged for 15 seconds at 10,000 x g. The flow-through was discarded 
6. 350 µl Buffer RW1 were pipetted into the RNeasy mini column and centrifuged for 15 
seconds at 10,000 x g. The flow-through was discarded.  
7. DNAse treatment was performed using RNase-free DNase Set (Qiagen) [Cat. No: 79254]. 70 
µl of buffer RDD was added to a 10 µl aliquot of DNase I and mixed gently by tapping. DNase 
I incubation mix (80 µl) was pipetted directly onto the spin column membrane, incubate at RT 
for 15 min. 
8. 350 µl Buffer RW1 were pipetted into the RNeasy mini column at the end the flow-through 
and collection tube were discarded. 
9. The RNeasy column was transferred to a new round bottom collection tube. 500 µl of Buffer 
RPE were pipetted onto the column, the lid was closed and centrifuged for 15 seconds at 
10,000 x g. The flow-through was discarded. 
10. Another 500 µl Buffer RPE were added to the column, the lid was closed and centrifuged for 
2 minutes at 10,000 x g to dry the RNeasy silica-gel membrane. 
11. To eliminate any possible Buffer RPE carryover, the collection tube was discarded and 
placed the RNeasy column placed in a new collection micro tube. Tubes were centrifuged for 
1 minute at 10,000 x g. 
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12. To elute, the RNeasy column were transferred to a new 1.5 ml snap cap collection tube 
(supplied). 30-50 µl RNase-free water was pipetted directly onto the RNeasy silica-gel 
membrane. The tube was closed and centrifuged for 1 minute at 10,000 x g to elute. 
13. RNA concentration and purity were determined using a ND-1000 spectrophotometer 
(Nanodrop®, Wilmington, DE, USA) using the software ND-1000 v3.2.1 (Nanodrop®, 
Wilmington, DE, USA) and total RNA was stored at -80˚C until needed. 
 
2.2.10- Gene expression profile analysis 
The samples were sorted by flow cytometry for the presence of the ESC markers CD9 and 
GCTM-2. Two separate hESC lines were used (HES-2 and HES-4) and there were 3 replicates of 
each. Expression profiling was performed using Sentrix Human-6 V2 Expression BeadChip 
arrays from Illumina®. RNA was harvested from HES-2 and HES-4, as described above, using 
RNeasy (Qiagen). The aim was to compare hESC which have been transduced with shRNA for 
GFP to the ones transduced with p53 shRNA. Samples were submitted to the SRC Microarray 
facility with collaboration with Sean Grimmond and Gabriel Kolle from the University of 
Queensland, Australia.   
 
1. In brief, all RNA samples were assessed for integrity using the Agilent Bioanalyzer 2100 and 
obtained RNA integrity numbers (RIN scores) above 8.5 as evaluated using the Expert 2100 
software version B.02.02.  
2. For each sample, amplification was performed on 200 ng of total RNA using the Illumina 
TotalPrep RNA Amplification kit (Ambion) [Cat No: IL1791] with a 14 hour in vitro transcription 
reaction period. 
3. Amplified cRNA (1500 ng per array) was hybridized to Human-6.v2 BeadChip arrays 
according to the manufacturer’s guidelines and detected with Fluorolink Streptavidin-Cy3 (GE 
Healthcare Biosciences).  
4. BeadChip arrays were scanned using the Illumina BeadStation Array Scanner and image 
intensity values extracted. The raw intensity values obtained for the scanned array images 
were compiled using the BeadStudio v2.3.41 software from Illumina®. 
 
2.2.10.1- Normalisation of Array data 
1. Normalisation of data was performed in R utilising the BeadExplorer and Affy packages. R is 
a language and environment for statistical computing and graphics (BioConductor: 
http://bioconductor.org).  
2. Raw data from BeadStudio were imported into R using BeadExplorer.  
3. The Affy package was used to background subtract the raw data using Robust MultiChip 
Analysis (RMA) (Irizarry et al., 2003). 
4. The dataset was normalized per chip by Quantile normalization (Bolstad et al., 2003). This 
data was exported into GeneSpring GX v7.3.1 (Agilent) for visualization. 
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2.2.10.2- Generation of significant gene lists 
1. Differential expression analysis was performed using the limma package from BioConductor 
in R.  
2. For each pairwise comparison, data was fitted to the linear model using lmFit and 
significance scores for each probe were calculated using the Empirical Bayes method (Smyth, 
2004). 
3. B-statistical scores were defined for the comparison between GFP and p53 shRNA.   
4. Adjustments to the linear fitting model were made for pairwise effects of the different hESC 
lines. 
5. Significant gene lists for each comparison were defined as a B-statistical score of greater 
than 0 (Greater than 50% chance of true differential expression).  
 
2.2.10.3- Ingenuity Analysis 
Significantly differentially expressed genes between the GFP versus p53 shRNA transduced cell 
lines comparison were uploaded into Ingenuity Pathways Analysis 5.0 (Ingenuity® Systems) on 
the basis of Genbank Accession Number. 
 
 
2.2.11- Reverse transcription reaction 
A High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, USA) [Cat No: 4368814] 
was used to make cDNA from total RNA. 
1. 2x Reverse Trancriptase master mix was prepared combining the reagents in table 2.7 on ice. 
 
TABLE 2.7- Reagents for 2x reverse transcriptase master mix 
Component Volume (µl) 
10X RT Buffer  2.0 
25X Dntp 0.8 
10X Random primers  2.0 
MultiScribe
TM
 Reverse Transcriptase 1.0 
Nuclease-free water 3.2 
Total per reaction 10 
 
2. 10 µl of 2x reverse transcriptase master mix were pipetted into an individual tube. 
3. 10 µl of RNA sample (1 µg of RNA) were added to each tube and mixed by pipetting up and 
down. Tubes were briefly centrifuged. 
4. The samples were run using the program thermal cycling conditions indicated on Table 2.8. 
5. Samples were then diluted 200 times for further analysis. 
 
TABLE 2.8- Thermal cycling conditions for cDNA reverse transcription reaction. 
 Step 1 Step 2 Step 3 Step 4 
Temperature 25°C 37°C 85°C  4°C 
Time 10 min 120 min 5 sec ∞ 
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2.2.12- Quantitative Polymerase Chain Reaction (Q-PCR) 
The TaqMan
®
 Probe Detection assay system from Applied Biosystems was used to perform Q-
PCR or real time PCR. TaqMan
®
 probes (Applied Byosystems) [Cat No: 4331182] used were 
Human Oct4 (Hs01895061_u1), Human Nanog (Hs02387400_g1) and Human p53 
(Hs99999147_m1). Human GAPDH (Hs99999905_m1) and Human β-Actin (Hs99999903_m1) 
were used as an endogenous control. 
 
TABLE 2.9- Reagents for Q-PCR reaction 
Component Volume (µl) 
TaqMan
®
Probe 1.0 
Taqman Universal PCR Master Mix (Applied Biosystems) [Cat No: PN 4304437] 10.0 
Template  9.0  
Total per reaction 20.0 
 
1. Briefly, samples were prepared by mixing all components from Table 2.9. 
2. Samples were loaded in triplicate in a Micro-Amp Optical 96-well Reaction Plate (Applied 
Biosystems) [Cat No: N801-0560] and water was used as a control and then plates were 
sealed.  
3. Samples were run in a 7500 Real-Time PCR System (Applied Biosystems) [Cat No: PN 
4351104] using the program thermal cycling conditions indicated on Table 2.10. 
4. Data was analyzed using 7500 System SDS Software (Applied Biosystems) [Cat No: PN 
4366951]. 
 
TABLE 2.10- Thermal cycling conditions for Q-PCR 
 Step 1 Step 2 Step 3 
Cycles 1 1 40  
Temperature 50°C 95°C 95°C 60°C 
Time 2 min 10 min 15 sec 1min 
 
 
2.2.13- Statistical analysis 
Values were considered to be significantly different when the achieved significance level, or p-
value, was less than 0.05 (p-value < 0.05 was denoted by *) or less than 0.01 (p-value < 0.01 was 
denoted by **) using the Student’s t-test. 
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3.1- hESC exhibit classic apoptotic features 
As mentioned in Chapter 1, there is little published work on the occurrence of apoptosis or 
apoptotic signaling pathways in hESC. So, firstly it was investigated whether hESC display any of 
the hallmarks of apoptosis in response to DNA damage (reviewed by Lawen, 2003). Inhibition of 
topoisomerase II with etoposide is known to induce DNA double strand breaks (Hande, 1998; 
Karpinich et al., 2002a) and thus can be used as a model for environmentally induced DNA 
damage. Therefore, hESC cultures were incubated with etoposide for different lengths of time 
and assessed for the occurrence of the typical hallmarks of apoptosis: mitochondrial cytochrome 
c release to the cytosol, caspase 3 activation, DNA laddering and nuclear condensation. 
Incubation with 340 nM etoposide for 3 hours causes an increase in soluble cytochrome c in the 
cytosol of hESC, without affecting the total amount of intracellular cytochrome c (Figure 3.1A). 
Furthermore, immunofluorescent staining with an antibody specific to activated caspase 3 shows 
that hESC treated with 340 nM etoposide for 3 hours display caspase 3 activation and that this 
activation is inhibited by the general caspase inhibitor zVAD-fmk (Figure 3.1B). By 3 to 4 hours 
after addition of etoposide, hESC start to display the classical 210 bp DNA laddering pattern of 
apoptosis (Figure 3.1C) accompanied by the nuclear condensation and fragmentation typical of 
apoptosis (Figure 3.1D). There is no cell cycle arrest in G0/G1 (Figure 3.2A) and no increase in 
the percentage of necrotic cells (Figure 3.2B) over the time period during which we observe the 
four diagnostic features of apoptosis. These data altogether strongly indicate that hESC can 
undergo apoptosis through the intrinsic pathway (mitochondrial) in a caspase-3-dependent 
mechanism in response to DNA double breaks. 
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FIGURE 3.1- hESC exhibit classic apoptotic features. 
(A) Cytochrome c release. HES-2 cells were treated with 340 nM etoposide for 1, 2 or 3 hours 
and permeabilized with digitonin. Proteins in the soluble (S- supernant) and non-soluble (P- pellet) 
fractions were resolved on separate 15 % polyacrylamide gels and Western blotting was 
performed with p53, cytochrome c, lamin B (nuclear membrane protein) and GAPDH (cytosolic 
protein) antibodies.  
(B) Caspase 3 activation. HES-2 cells were preincubated with 25 µM zVAD-fmk or vehicle for 30 
min and then treated with 340 nM etoposide for 3 hours. PFA-fixed adherent colonies were 
immunostained for cleaved caspase 3 and nuclei visualized with DAPI. Scale bars, 200 µm.  
(C) DNA-laddering. HES-2 cells were treated with 340 nM etoposide for 2 to 18 hours and 
apoptotic bodies and cells were harvested at the indicated time points. DNA was collected and 
separated on a 1.5% agarose gel. A 1 Kb DNA ladder (Invitrogen) was used as a size standard. 
(D) Chromatin condensation HES-2 cells were treated with 340 nM etoposide for 6 hours, fixed 
with PFA 4% and stained with DAPI. The arrow indicates a hESC with the typical condensed 
fragmented appearance of an apoptotic nucleus. Scale bars, 50 µm. 
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FIGURE 3.2- Etoposide treatment does not induce cell cycle arrest or necrosis. 
(A) Etoposide does not induce cell cycle arrest. HES-2 cells were treated with 170 nM etoposide 
for 4.5 and 9 hours and apoptotic bodies and cells harvested at the indicated time points. Cells 
were then fixed with 3.7 % PFA, permeabilized with Triton 0.01% and incubated with DAPI (5 
µg/ml) diluted in PBS. A representative experiment of three independent experiments is shown. 
(B) Etoposide does not induce necrosis. HES-2 cells were treated with 340 nM etoposide for up 
to 6 hours. Apoptotic bodies and cells were harvested at the indicated time points. Cells were 
then incubated with green fluorescence reactive dye (LIVE/DEAD® Fixable Dead cell stain) 
diluted in SR medium for 30 min on ice in the dark, fixed in 4% PFA and analyzed by flow 
cytometry. A representative experiment of three independent experiments is shown.  
 
 
3.2- TNFα-induced apoptosis is not operational in hESC 
In order to investigate if the extrinsic apoptotic pathway is operational in hESC, the response of 
hESC to TNFα was investigated. TNFα however failed to induce apoptosis in hESC at 
concentrations similar to those that induce robust apoptosis in susceptible cell lines (Figure 3.3) 
(Ghosh et al., 2000; Segui et al., 2001). HepG2 cells, a liver cancer cell line, display resistance to 
TNFα-induced apoptosis and only die through extrinsic apoptotic stimuli such as TNFα after 
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preincubation with cycloheximide (CHX) (Santiago-Lomeli et al., 2005). CHX inhibits the NF-κB 
pathway and consequently blocks the expression of survival factors. When the NF-κB activity 
subsides, extrinsic proapoptotic signals can induce cell death. In order to determine whether 
hESC only undergo TNFα-induced apoptosis after CHX treatment, hESC were treated with TNFα 
in the presence of 10 or 40 µM CHX. However, as shown in Fig 3.3, CHX treatment of hESC 
induced a substantial amount of apoptosis by itself. Despite the fact that the percentage of 
apoptotic cells is slightly higher when TNFα is added after preincubation with CHX, this difference 
is not statistically significant (Figure 3.3). Inhibition of NF-κB activity other than through CHX 
treatment should be done to confirm that the NF-κB pathway is indeed involved in the inhibition of 
the activation of the extrinsic apoptotic pathway in hESC. 
0
10
20
30
40
50
60
Ctl CHX 10 CHX 10+
TNF 30
CHX 40 CHX 40+
TNF 30
TNF 30 TNF 50 TNF 100
P
e
rc
e
n
ta
g
e
 o
f 
T
U
N
E
L
 p
o
s
it
iv
e
 c
e
lls
 (
%
)
FIGURE 3.3- TNFα fails to induce apoptosis. 
HES-4 cells grown in serum-free conditions were preincubated with vehicle alone or with inhibitor 
(10 µM and 40 µM CHX were added 1 hour before the treatment with TNFα) and subsequently 
exposed to different concentrations of TNFα (30, 50 and 100 ng/ml) for 24 hours. Floating and 
adherent cells were harvested, stained with TUNEL and analyzed by flow cytometry. Results are 
expressed as percentage means ± S.D. (n=2). 
 
 
3.3- hESC are very sensitive to intrinsic apoptotic stimuli 
To further assess the susceptibility of hESC to various different intrinsic apoptosis inducing 
agents, hESC were subjected to serum removal (Figure 3.4A), addition of hydrogen peroxide 
(Figure 3.4B), gamma irradiation (Figure 3.4C) and etoposide (Figure 3.4D). Each of these 
treatments causes a clear increase in apoptosis. Because this study focuses on the role of p53 in 
hESC and the strict dependence of etoposide-induced apoptosis on p53 in other model systems, 
the kinetics and dose response of hESC to this drug were carefully determined. The data in 
Figure 3.4D-F demonstrate the time and concentration dependence of etoposide-induced 
apoptosis of hESC. hESC are clearly far more sensitive to etoposide-induced apoptosis than 
other human cell lines (Figure 3.5) or primary cell cultures (Karpinich et al., 2002b; Karpinich et 
al., 2006; Liu and Joel, 2003). Indeed, exposure of HES2 hESC to 0.17 µM etoposide for 18 
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hours induces more than 70 % of hESC to undergo apoptosis while the human cell lines HT1080 
(fibrosarcoma), 293FT (human embryonic kidney cell line) and CFPac-1 (pancreatic cancer cell 
line) treated with 0.17 µM etoposide for 24 hours display only 3, 12 and 10 % TUNEL positive 
apoptotic cells, respectively (Figure 3.5). Because of the exquisite sensitivity of hESC to 
etoposide and the well established role of p53 in the apoptotic response of human cells to 
etoposide this drug was selected to further investigate the regulation of apoptosis and mechanism 
of p53-dependent apoptosis in hESC. 
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FIGURE 3.4- hESC are very sensitive serum removal, hydrogen peroxide, gamma-irradiation 
and etoposide. 
(A) Serum removal (SR) from HES-2 cells for 22 hours and the level of apoptosis was quantified 
by Annexin-V-FLUOS Staining Kit (Roche Applied Science). 
(B) HES-2 cells were treated with 200 µM or 500 µM hydrogen peroxide for 22 hours and the 
level of apoptosis quantified by Annexin-V-FLUOS Staining Kit (Roche Applied Science).  
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(C) HES-2 cells were exposed to 1 Gy and 10 Gy and the level of apoptosis was quantified after 
12 hours (In Situ Cell Death Detection Kit, Fluorescein (Roche Applied Science).  
(D) HES-2 and HES-3 cells were exposed to increasing etoposide concentrations between 0.17 
and 17 µM for 18 hours. Floating and adherent cells were harvested after treatment, TUNEL 
stained and analyzed by flow cytometry. Results shown are expressed as percentage means ± 
S.D. (n=3).  
(E) HES-2 and (F) HES-4 cells were exposed to 170 nM etoposide for various time points 
between 3 and 24 hours. Floating and adherent cells were harvested after treatment, TUNEL 
stained and analyzed by flow cytometry. Results shown are expressed as percentage means ± 
S.D. (n=3).  
(p-value < 0.05 by * and p-value < 0.01 denoted by ** compared to control). 
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FIGURE 3.5- hESC are more sensitive to etoposide than human cell lines. 
HES-2 cells, HT1080, 293FT and CFPac-1 were treated with 0.17 or 170 µM etoposide for 24 or 
48 hours. Floating and adherent cells were harvested after treatment, stained with TUNEL and 
analyzed by flow cytometry. (p-value < 0.05 by * and p-value < 0.01 denoted by ** compared to 
HES-2). 
 
 
3.4- Reduced apoptotic response to etoposide in late passage hESC 
As mentioned in Chapter 1, hESC cultured for long periods of time under serum-free conditions 
are likely to adapt to culture conditions. This adaptation process result most likely from genetic 
alterations that promote self-renewal and limit differentiation or apoptosis (Baker et al., 2007; 
Enver et al., 2005). It has been noted that these adapted hESC tend to gain chromosomal 
abnormalities resembling the ones observed in hECCs (Baker et al., 2007). In order to test if 
karyotypically abnormal adapted hESC are more resistant to etoposide-induced apoptosis than 
non-adapted cells, early passage (lower than 10 with normal karyotype) and late passage (higher 
than 80 with an abnormal karyotype (46XX, t(1;6)(p22;q15)) HES-3 cells (cultured per Amit et al, 
2000) were exposed to different concentrations of etoposide (Figure 3.6). Interestingly, late 
passage karyotypically abnormal adapted hESC indeed exhibited reduced apoptotic response to 
etoposide when compared to early passage cells. It remains to be determined whether the 
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reduced propensity to undergo apoptosis of late passage adapted hESC is the cause or the 
consequence of karyotypic abnormalities in hESC. This observation is particularly important when 
comparing apoptosis studies in hESC from other laboratories, with the present data. All the 
experiments performed in this study used early passage hESC (P<18) freshly established from 
standard cultures while most other laboratories routinely use late to very late passage hESC for 
experimentation.  
Nevertheless it is noteworthy that although resistant to low levels of etoposide-induced apoptosis, 
late passage hESC are still more sensitive than the cancer cell lines examined in this study (see 
section 3.3). 
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FIGURE 3.6- Early passage hESC with normal karyotype are more sensitive to apoptosis 
than late passage with abnormal karyotype cells.  
HES-3 cells early (P<10) and late passage (P>80) grown in serum-free conditions were treated 
with 170 or 850 nM etoposide for 18 hours (n=3). Late passage cells were also exposed to 1.7 
and 17 µM etoposide (n=2). Floating and adherent cells were harvested after treatment, TUNEL 
stained and analyzed by flow cytometry.  
 
 
3.5- The state of differentiation of hESC affects their sensitivity to etoposide-induced 
apoptosis 
hESC cultured on MEF feeder cells in the presence of KSR supplemented with 4 ng/ml FGF-2 
(Amit et al., 2004) appear to be a morphologically homogeneous population of undifferentiated 
cells. However, hESC cultured under these conditions are heterogeneous and display various 
degrees of differentiation as judged by the expression of the stem cell marker Oct4 when assayed 
by immunofluorescence or flow cytometry (Figures 3.7, 3.8 and 3.9). Cells at the outer rim of the 
hESC colonies, usually display reduced expression of Oct4.  
Initial observations of hESC treated with etoposide showed that hESC in the center of the colony 
preferentially died (Figure 3.7A). After treatment, cells at the outer rim of the hESC colonies were 
more resistant to etoposide apoptosis than hESC in the center of the colonies (Figure 3.7B) and 
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did no show signs of apoptosis like chromatin condensation (Figure 3.7C). This suggested to us 
that differentiation may modulate the sensitivity of hESC to etoposide-induced apoptosis. 
To quantify this phenomenon, etoposide treated HES-2 and HES-4 cells were double-labeled with 
both TUNEL and antibody directed against the stem cell marker Oct4. As shown in Figure 3.8, the 
survival of Oct4-expressing hESC was reduced from around 70% to less than 10% within 18 
hours after etoposide treatment. Within this timeframe the proportion of surviving Oct4-negative 
cells was not significantly reduced, indicating that differentiated hESC are much more resistant to 
etoposide-induced apoptosis than their less differentiated counterparts. Similar results were 
obtained for both the HES-2 and HES-4 cell lines, though the latter cell line displaying higher 
spontaneous differentiation. As shown in Figures 3.7B, 3.8 and 3.10 the Oct4 immunoreactivity of 
etoposide-treated hESC is lost upon induction of apoptosis. Consequently, the apoptotic hESC do 
not shift horizontally to the TUNEL-positive quadrant of the flow cytometry plot. To show that the 
Oct4-positive hESC preferentially undergo apoptosis, the data are expressed as the absolute 
percentage of surviving TUNEL negative cells (Figure 3.9). The decrease of Oct4-
immunoreactivity is due to a loss of the epitope rather than the entire protein because the total 
amount of Oct4 is not affected by etoposide treatment when analyzed by Western blotting (Figure 
3.8). Furthermore, the reduction in Oct4 immunoreactivity in apoptotic hESC is already observed 
6-9 hours after etoposide treatment, precluding the possibility that this is somehow due to an in 
increase in differentiation. Upon exposure to etoposide, immunodetection of cell surface 
pluripotency markers such as CD9 and GCTM2 is also rapidly lost or takes on an appearance 
that is not characteristic of those markers (Figure 3.10). These data indicate that the dramatic 
alterations in nuclear and plasma membrane that accompany apoptosis interfere with the 
antibody detection of protein epitopes on apoptotic cells. This is possibly due to the activation of 
transglutaminates during apoptosis that cause cross-linking of proteins, turning them insoluble 
and presumably less immunogenic (Melino and Piacentini, 1998,Grabarek et al., 2002). 
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FIGURE 3.7- Oct4 positive cells are more sensitive to etoposide than Oct4 low or negative 
cells.  
(A) HES-4 cells were exposed to vehicle alone or 170 nM etoposide for 18 hours. Scale bars, 200 
µm. 
(B) HES-2 cells were exposed to vehicle alone or 170 nM etoposide for 6 hours. The hESC 
cultures were next fixed with 4% PFA and immunostained with the stem cell marker Oct4. Scale 
bars, 100 µm 
(C) HES-2 cells were exposed 170 nM etoposide for 4 hours. Note the reduced non-uniform 
staining for Oct4 in apoptotic nuclei and that Oct4 positive cells display nuclear condensation and 
many apoptotic bodies (arrows) while differentiated Oct4 negative cells do not show 
morphological signs of apoptosis. Scale bar, 200 µm. 
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FIGURE 3.8- Flow cytometry analysis of Oct4 expression and TUNEL labelling in hESC 
treated with etoposide. 
(A) HES-4 and (B) HES-2 cells were exposed to 170 nM etoposide and harvested at the indicated 
time points. Cells were next labeled with TUNEL, immunostained with the stem cell marker Oct4 
and analyzed by flow cytometry. Results shown are expressed as percentage means ± S.D. 
(n=3).  
(C) and (D) No reduction of expression or specific degradation of Oct4 occurs during apoptosis in 
HES-4 (C) and HES-2 (D). hESC were treated with 170 nM etoposide and apoptotic bodies and 
cells were harvested at the indicated time points. Protein samples were resolved on separate 12 
% polyacrylamide gels at 100 V for 1 hour and analyzed by Western blot with Oct4 and β-tubulin 
antibodies.  
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FIGURE 3.9- Differentiation of hESC reduces their sensitivity to etoposide-induced 
apoptosis. 
(A) HES-2 and (B) HES-4 cells grown under serum-free conditions were treated with 170 nM 
etoposide and harvested after 2, 4, 6, 9, 12 or 18 hours. The etoposide treated hESC were 
double-labeled with TUNEL and the ESC marker Oct4 and analyzed by flow cytometry. The data 
are expressed as the percentage of surviving (TUNEL negative) cells in the Oct4 positive (grey 
bars) and Oct4 negative (white bars) fraction of the hESC culture. Percentage of apoptotic cells is 
shown by the black bars. The results represent the mean ± S.D. (n=3).  
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FIGURE 3.10- Reduction in stem cell markers immunoreactivity in apoptotic hESC.  
HES-4 cells were exposed 170 nM etoposide for 4 hours and stained for GCTM2, CD9 and Oct4. 
Scale bars, 200 µm. 
 
 
3.6- Etoposide-induced apoptosis of hESC requires caspase activation and is partially 
sensitive to cycloheximide 
Cultures of hESC display a high rate of spontaneous apoptosis with 15% of hESC undergoing 
apoptosis daily under optimal culture conditions (Figure 3.4). Caspases are centrally involved in 
the regulation and execution of the apoptotic program (Thornberry and Lazebnik, 1998) and 
caspase 3 is activated in etoposide- treated hESC cultures (Figure 3.1B). To determine whether 
caspases play a functional role in etoposide-induced and spontaneous apoptosis of hESC, hESC 
were incubated with the general caspase inhibitor zVAD-fmk prior to etoposide treatment. As 
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shown in Figure 3.11, zVAD-fmk totally inhibits etoposide-induced, but not spontaneous 
apoptosis of hESC. Similarly, CHX, an inhibitor of protein translation, is able to prevent 50% of 
etoposide-induced apoptosis but has no inhibitory effect on spontaneous apoptosis (Figure 3.11). 
These data therefore indicate that hESC treated with etoposide undergo caspase and protein 
translation dependent apoptosis whereas spontaneous apoptosis proceeds via caspase- and 
translation independent pathways. The possibility that spontaneously apoptosing hESC were 
already committed to die prior to addition of CHX or zVAD-fmk cannot be excluded. 
Cyclosporin A, an inhibitor of both mitochondrial permeability transition and calcineurin (Liu et al., 
1991), induced apoptosis by itself and did not inhibit etoposide-induced apoptosis (Figure 3.11). 
Pre-incubation with leptomycin B, a nuclear export inhibitor (Wolff et al., 1997), cPFT, a purported 
inhibitor of p53 mediated transcription (Komarov et al., 1999), also had no or only a very minor 
inhibitory effect on etoposide-induced hESC apoptosis (Figure 3.11). This is perhaps not 
surprising since the efficacy of cPFT as an inhibitor of p53 transactivation activity is highly 
questionable (Walton et al., 2005). PFT-mu, a compound that inhibits association of p53 with 
mitochondria (Strom et al., 2006), was found to reduce etoposide-induced apoptosis of hESC by 
50 % (Figure 3.11). 
Bongkrekic acid, an inhibitor of the adenine nucleotide translocator and mitochondrial 
permeability transition pore formation (Pastorino and Hoek, 2000; Scarlett et al., 2000), was not 
able to inhibit spontaneous or etoposide-induced apoptosis of hESC (Figure 3.12A). In agreement 
with this observation, there was no detection of loss of mitochondrial membrane potential, 
measured by JC-1 uptake, during the first 4 hours of induction of apoptosis with etoposide (Figure 
3.12B), despite the fact that cytochrome c release in the cytosol was already detected at 3 hours.  
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FIGURE 3.11- zVAD-fmk and cycloheximide inhibit etoposide-induced apoptosis of hESC. 
(A) HES-2 cells and (B) HES-4 grown in serum-free conditions were preincubated with vehicle 
alone or with inhibitor (25 µM cPFT, 10 µM PFT-mu and 50 µM BA were added 1 h before the 
treatment with etoposide; 4 µM CHX, 25 µM zVAD-fmk, 5 ng/ml Leptomycin B and 10 µM 
Cyclosporine A were added 30 min before the treatment with etoposide) and subsequently 
exposed to 170 nM etoposide for 18 hours. Floating and adherent cells were harvested, stained 
with TUNEL and analyzed by flow cytometry. Results are expressed as percentage means ± S.D. 
(n=6 for HES-2 control and etoposide treated cells and n=3 for rest of samples). (p-value < 0.05 
by * and p-value < 0.01 denoted by ** compared to treated control cells). 
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FIGURE 3.12- Bongkrekic acid was not able to inhibit apoptosis of hESC and there was no 
detection of loss of mitochondrial membrane potential during initial steps of apoptosis. 
(A) HES-2 cells were preincubated with vehicle alone or with inhibitor (50 µM BA was added 1 h 
before the treatment with etoposide) and subsequently exposed to 170 nM etoposide for 4.5 and 
9 hours. Floating and adherent cells were harvested, stained with TUNEL and analyzed by flow 
cytometry. Results are expressed as percentage means ± S.D. (n=3). 
(B) HES-2 cells were exposed to 170 nM etoposide for timepoints indicated in graph. Floating and 
adherent cells were harvested, stained with MitoProbe
TM
JC-1 and analyzed by flow cytometry. As 
a positive control, cells were incubated with 100 mM of CCCP for 5 min prior the addition of JC-1. 
Results are expressed as percentage means ± S.D. (n=3). 
 
 
3.7- Expression analysis of several pro- and anti-apoptotic proteins in hESC 
Gene expression profiling studies of ESC have shown robust expression of p53 and other 
proteins involved in apoptosis (Bhattacharya et al., 2005; Ginis et al., 2004; Ramalho-Santos et 
al., 2002). Array analysis of H1 cells indicated (Ginis et al., 2004), that hESC express p53, Mdm2, 
a negative regulator of p53, Bax a pro-apoptotic downstream target of p53, as well as the Bcl-2 
family member Mcl-1. To determine whether hESC express established regulators of p53-
dependent apoptosis, immunostaining of in situ fixed hESC cultures to detect proteins that are 
known to possess apoptotic or anti-apoptotic activities was performed. Figure 3.13 shows that 
p53, Hdm2, Hdm4, Mcl1, Bax and p14ARF are expressed in the HES-4 cell line, whereas Bcl2 
was undetectable. hESC grown under serum and serum-free conditions display similar 
expression patterns for p53, Mcl1 and Bax (Figure 3.13A and 3.13B). In addition to confirming 
   
 - 88 - 
CHAPTER 3: Characterization of hESC apoptosis 
p53 protein expression, the subcellular localization of p53 in hESC was also examined. In the 
majority of undifferentiated hESC, p53 has a cytoplasmic localization with only few cells at the 
edge of the colonies displaying nuclear p53 staining detected by the DO-1 antibody. Similar 
results were obtained using a different anti-p53 antibody (pAB1801, Figure 3.13C). The high 
levels of cytoplasmic expression of p53 in untreated hESC was confirmed by Western blotting of 
cytosolic protein extracts from hESC (Figure 3.1A).  
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FIGURE 3.13- hESC exhibit a cytoplasmic localization of p53 and express Mcl1, Bax, 
p14ARF, Hdm4 and Hdm2. 
(A) HES-2, HES-3 and HES-4 colonies grown under standard culture conditions and serum-free 
conditions were fixed and immunostained for p53 (antibody DO-1). Scale bars, 100 µm. 
(B) HES-4 colonies grown under standard culture conditions and serum-free conditions were 
fixed and immunostained for Mcl1 and Bax standard culture conditions and serum-free conditions. 
Scale bars, 100 µm. 
(C) HES-4 colonies grown under standard culture conditions were fixed and immunostained for 
Hdm2, Hdm4, p14ARF and p53 (antibody pAB1801). Scale bars, 100 µm. 
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3.8- Etoposide-induced apoptosis in hESC dramatically alters subcellular localization of 
p53, Bax and Mcl1 
In untreated undifferentiated hESC, p53 resides mainly in the cytoplasm in two forms, a soluble 
fraction and a particulate fraction, as judged by immunofluorescent detection (Figure 3.13) and 
cell fractionation (Figure 3.1A). Four hours after etoposide treatment co-localization of p53 with 
the mitochondrial marker antibody 1E6 (Banbury, 1994) was detected, suggesting that p53 is 
targeted to this organelle (Figure 3.14B). During incubation with etoposide, the subcellular 
localization of the mitochondria themselves changes from a small punctuate distribution 
throughout the cytosol to large aggregates of mitochondria in a peri-nuclear region that stain 
strongly for p53. Simultaneously an increasing proportion of hESC display nuclear staining for 
p53 (Figure 3.14). These observations suggest that p53 both translocates to the nucleus and 
associates with the mitochondria in response to etoposide treatment. One of the pre-requisites of 
mitochondrial permeability transition and cytochrome c release is thought to be the insertion of 
Bax into the outer mitochondrial membrane. When the subcellular localization was examined of 
Bax and Mcl1 between 3 and 18 hours after etoposide treatment, Bax increasingly co-localized 
with Mcl1 in perinuclear structures reminiscent of the mitochondrial aggregates described above 
(Figure 3.15).  
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FIGURE 3.14- hESC treated with etoposide show redistribution of cytosolic p53 to 
mitochondria and nucleus. 
(A) HES-2 cells were exposed to 340 nM etoposide for 3 or 18 hours, PFA-fixed and 
immunostained for p53 and nuclei (DAPI). A representative example of 3 independent 
experiments is shown. Scale bars, 100 µm. (B) Confocal microscope images of HES-2 cells 
treated with 340 nM etoposide for 4 hours. p53 relocalizes from the cytosol to the nucleus as well 
as to the mitochondria (1E6 is a mitochondrial marker). Scale bars, 50 µm. 
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FIGURE 3.15- Upon treatment with etoposide, Bax and Mcl1 co-localize. 
HES-4 cells were exposed to 340 nM etoposide for 3 and 18 hours, PFA-fixed and 
immunostained for Mcl1, Bax and nuclei (DAPI). Upon induction of apoptosis with etoposide Mcl1 
and Bax co-localize in a perinuclear region in structures reminiscent of mitochondrial aggregates. 
Scale bars, 100 µm (control and 3 hours etoposide 340 nM) and 50 µm (18 hours etoposide 340 
nM). 
 
 
3.9- Altered expression of key apoptosis regulators upon etoposide and gamma 
irradiation-induced apoptosis in hESC 
In most model systems, etoposide-induced apoptosis is dependent on p53 (Karpinich et al., 
2002a, Lowe et al., 1993, Yin et al., 2000). In agreement with these previous observations, an 
increase in p53 expression was detected as early as 3 hours after etoposide addition to hESC. 
Expression of p53 then peaks around 6-9 hours of exposure to etoposide and wanes thereafter 
(Figure 3.16A). PUMA, one of the downstream targets of p53, is upregulated between 4.5 hours 
and 6 hours after exposure to etoposide, as is nuclear p53. Furthermore, consistent with the 
release of cytochrome c at 3 hours after exposure to etoposide, increased activation of caspase 3 
is maintained for  6 to 8 hours after etoposide addition. Similar kinetics of upregulation was 
observed for Hdm2. In contrast, no alteration in Mcl1, Hdm4, Noxa or Oct4 expression were 
found in etoposide treated hESC (Figure 3.16A). However, Nanog is downregulated in hESC after 
etoposide-induced upregulation of p53, in agreement with the previously reported (Lin et al., 2005) 
ability of p53 to supress Nanog expression in mESC. Only a slight upregulation of the p53 target 
Bax in response to etoposide treatment was detected, as well as an increased processing of Bax 
to the more potent pro-apoptotic 18 kDa form with time (Gao and Dou, 2000; Wood and 
Newcomb, 2000). There was no expression of p21 protein, a potential downstream target of p53 
involved in cell cycle arrest in many cellular model systems, in either untreated or etoposide 
treated hESC by Western blotting or immunofluorescence. This was not due to an inability of the 
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antibody to detect p21 since was readily detected expression of p21 in protein extracts of HEF 
(data not shown). Since CHX is able to inhibit 50% of etoposide-induced apoptosis, it was 
interesting to find out how this relates to the expression of p53 regulated apoptosis modulators. 
As shown in Figure 3.16B preincubation with CHX does not prevent the upregulation of p53, 
suggesting that the majority of its increased expression is due to increased stabilization of p53 
protein and not to de novo synthesis. However, the expression of Bax and PUMA (p53 
downstream targets) and Mcl1 are clearly reduced by this protein synthesis inhibitor, suggesting 
that Bax and PUMA may be important determinants of etoposide-induced apoptosis of hESC. 
In order to determine whether p53 is able to induce upregulation of its gene targets in response to 
other DNA damaging agents hESC were exposure to gamma-irradiation. Upregulation of p53 
expression as well as PUMA was detected as soon as 3h after gamma radiation (Figure 3.16C).  
Because late passage karyotypically abnormal hESC displayed a dramatic reduction in 
etoposide-induced apoptosis as compared to early passage hESC (section 3.4 of this Chapter) 
we assessed the kinetics of p53 upregulation in response to etoposide between both cell lines 
(Figure 3.16D). Under control conditions, levels of p53 are already higher in early passage hESC 
than in late passage cells. Upon exposure to 170 nM of etoposide p53 is clearly upregulated in 
early passage hESC after 4.5 h, but in late passage it is only slightly upregulated at 4.5 and 9h. 
About 75 % of early passage HES-3 cells died at this concentration but late passage show 
resistance to apoptosis. This is not due to a difference in differentiation of late passage cells. In 
fact, late passage cells display higher levels of Oct4 then early passage cells (most likely 
because the population contains a higher proportion of Oct4 positive hESC). Upon exposure of 
late passage hESC to higher etoposide concentrations (1.7 µM) the cells die via apoptosis and 
p53 is upregulated at this concentration. These data shows that there is an association or 
relationship between the response to DNA damage induced apoptosis and p53 levels in hESC 
and it shows that the regulation of this pathway is altered in late passage cells. 
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FIGURE 3.16- Increased expression of p53 and altered expression of p53 downstream 
targets in hESC treated with etoposide and gamma-irradiation.  
(A) HES-2 cells were harvested 1.5, 3, 4.5, 6, 9 and 12 hours after treatment with 170 nM 
etoposide. Protein extracts were resolved on separate polyacrylamide gels and Western blotted 
with antibodies against: p53, PUMA, Bax, cleaved caspase-3, Hdm2, Hdm4, Mcl1 and Oct4. β-
tubulin was used to ensure equal loading. A representative example of 3 independent 
experiments is shown.  
(B) CHX treatment interferes with etoposide-induced upregulation of PUMA and Bax in hESC. 
HES-2 cells were preincubated with or without 1µg/ml CHX for 30 min and treated with 170 nM 
etoposide (Et) for 18 hours. Protein extracts were resolved on separate polyacrylamide gels and 
Western blotted with antibodies against p53, Mcl1, Bax, PUMA and β-tubulin. A representative 
example of 3 independent experiments is shown. 
(C) HES-2 cells were harvested 3, 4.5 and 6h after treatment with gamma-irradiation (1Gy and 10 
Gy). Protein extracts were resolved on separate polyacrilamide gels and Western blotted with 
antibodies against p53, PUMA and β-tubulin 
(D) HES-3 cells early and late passage were treated with 170 or 1700 nM etoposide for the 
indicated timepoints. Protein extracts were resolved on separate polyacrylamide gels and 
Western blotted with antibodies against: p53, Oct4 and β-tubulin. 
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3.10- Discussion 
Because no reports on apoptosis of hESC had been published at the start of this thesis it was 
important to first determine whether hESC display any of the hallmarks of apoptosis. Furthermore 
this is also a prerequisite if one wants to use the established apoptosis assays such as TUNEL 
(as used throughout this study). hESC indeed the display hallmarks of apoptosis (cytochrome c 
release, DNA laddering, caspase activation and chromatin condensation) upon exposure to an 
apoptotic stimulus. In initial experiments, the Annexin V assay was used but because the levels of 
apoptosis in controls were too high, reflecting most likely non-specific damage to the plasma 
membrane during processing of cells rather then translocation of phosphatidylserine to the outer 
layer of the plasma membrane. Therefore, TUNEL was preferentially used to measure apoptosis 
throughout this study. 
Having established that they can die via the intrinsic apoptotic pathway, the effect of different 
apoptotic stimuli on these cells was studied. The data show that hESC are extremely sensitive to 
spontaneous apoptosis, as well as gamma irradiation-, hydrogen peroxide- and etoposide-
induced apoptosis. Indeed, hESC appear to be far more sensitive to etoposide-induced apoptosis 
than other cell lines or primary cell cultures. This high sensitivity of hESC to etoposide induced 
apoptosis is similar to the sensitivity of inner cell mass cells of pre-implantation mouse embryos 
(Exley et al., 1999). Although zygotes were induced to undergo apoptosis
 
after 72 h of incubation 
in 1 µM staurosporine, most of
 
the zygotes did not undergo fragmentation. In contrast, blastocysts, 
from which ESC are derived, can be
 
induced to undergo apoptosis after 6 h of incubation in only
 
10 nM staurosporine. Thus, zygotes appear to be more
 
resistant to the effects of staurosporine 
than blastocysts.  
On the other hand, the extrinsic apoptotic pathway seems not to be operational in hESC since 
TNFα failed to induce apoptosis. This result is similar to a study performed by Sleeper and 
colleagues (Sleeper et al., 2002) who showed that adult neural stem cells did not die upon 
exposure to Fas ligand, despite being very sensitive to intrinsic apoptotic stimuli. Arrays 
performed on H1 cells (Ginis et al., 2004) have shown that hESC expressed several genes 
associated with TNF receptor signaling (TNF-R2, TRAF1, TRAF4 and TRAF6), but Fas and Fas 
ligand were not expressed at detectable levels in both mESC and hESC. Perhaps the extrinsic 
apoptotic pathway is not functional in these cells. To confirm this, Fas ligand mediated apoptosis 
should be also investigated. 
When cultured for long periods of time under serum-free conditions hESC tend to adapt to culture 
conditions. Most likely this adaptation process results from genetic alterations that promote self-
renewal and limit differentiation or apoptosis. Late passage HES-3 cell line with an abnormal 
karyotype showed reduced apoptotic response to etoposide and lower p53 protein levels when 
compared to early passage hESC. The late passage HES-3 cells express the TNF receptor 
superfamily member CD30 on their surface (Tung-Liang Chung, personal communication) and 
CD30 positive cells have been reported to show lower apoptotic response to hydrogen peroxide 
and reduced dependency on (Herszfeld et al., 2006). Furthermore Survivin, an inhibitor of 
apoptosis, is negatively regulated by p53 and is a gene upregulated in CD30 expressing hESC 
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(Ernst Wolvetang, personal communication). This is one of the reasons why the assays 
performed in this study hESC lines were only used up to passage 18 when cultured as per Amit 
et al (2000). It would be very interesting to investigate the apoptotic response of late passage 
hESC with normal karyotypes. Such experiments and regular karyotype analysis (or CGH) of 
hESC overexpressing anti-apoptotic genes such as Mcl1 or Bcl2 during prolonged passage of 
hESCcould provide indications whether changes in the apoptotic threshold of hESC are a cause 
or consequence of the chromosomal abnormalities. 
The sensitivity of hESC (HES-2 and HES-4) to etoposide-induced apoptosis is also dependent on 
their differentiation status. Undifferentiated hESC that express Oct4 are the least resistant to 
etoposide-induced apoptosis as compared to their more differentiated progeny. Given the 
profound effect of the differentiation status of hESC on their rate of apoptosis meaningful data on 
apoptosis in hESC can only be obtained when TUNEL labelled cells are double labelled with at 
least one pluripotency marker, as performed in this study.  
Like mESC, hESC express high levels of p53 protein in the cytoplasm under standard culture and 
serum-free conditions. How ESC can tolerate such high levels of p53 is still unknown. Probably 
post-translational modifications and protein interactions are involved in regulation of p53 
localization in these cells. Parc, a Parkin-like ubiquitin ligase, has been implicated in sequestering 
p53 in the cytoplasm by direct interaction by p53. Together they form a 1 MDa complex in the 
cytoplasm in unstressed cells that serves as a cytoplasmic anchor for p53. Additionally, 
inactivation of this protein even in unstressed cells leads to nuclear localization of endogenous 
p53 and activates p53-dependent apoptosis. On the other hand, Parc overexpression promotes 
cytoplasmic sequestration of ectopic p53 (Nikolaev et al., 2003). Perhaps Parc serves as a bridge 
between p53 and a cytoplasmic structure. In fact, cytoskeletal proteins such as vimentin have 
been shown to contribute to the cytoplasmic sequestration of p53 (Klotzsche et al., 1998). 
Recently, Parc has been shown to form complexes with its related homolog Cullin 7 (Skaar et al., 
2007). Cullin 7 binds to p53’s tetramerization domain. Although its overexpression does not 
sequester p53 in the cytoplasm, it functions to promote cell growth through, in part, antagonizing 
the function of p53 through non-proteolytic ubiquitination (Andrews et al., 2006). Mortalin or Mot2, 
a member of the heat-shock protein Hsp70, is another cytoplasmic protein that has been 
implicated in p53 cytoplasmic sequestration by binding directly to it (Wadhwa et al., 2002). It 
would be very interesting to investigate if these proteins are anchoring p53 to the cytoplasm in 
hESC. Since hESC represent a non-transformed model, it will be also a good opportunity to 
unravel new protein interactions and to obtain more insight into the mechanisms that regulate the 
subcellular localization of p53 in a non-transformed background. 
Members of Bcl2 family are essential for the survival of stem cells. In HSC, growth factors 
including stem cell factor increase transcription of the Mcl1 gene and Mcl1 protein is required to 
increase the survival rate of purified bone marrow progenitors (Opferman et al., 2005). In fact, 
Mcl-1 is the most abundantly and consistently
 
expressed Bcl2 family member in the 
preimplantation embryo (Jurisicova and Acton, 2004) and is the only pro-survival Bcl-2 family 
member
 
whose disruption results in preimplantation embryonic
 
lethality (Rinkenberger et al., 
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2000). The data in this study show that Mcl1 is the main Bcl-2 family member expressed in hESC 
and that Bcl2 protein is not expressed in hESC. 
To unravel the mechanism of apoptosis, the different known regulators mentioned above and 
features of apoptosis were investigated. Initiation of etoposide-induced apoptosis in hESC 
commences around 3 hours after etoposide addition with translocation of the highly-expressed 
cytoplasmic p53 protein to the mitochondria and release of cytochrome c. There is no detectable 
loss of mitochondrial membrane potential, as judged by the maintenance of JC-1 red/green 
fluorescence. Cytochrome c release from mitochondria without loss of mitochondrial membrane 
potential has previously been reported (Finucane et al., 1999; Grubb et al., 2001; Krohn et al., 
1999). Because caspase 3 is activated at three hours after etoposide treatment, apoptosome 
formation and initiation of the apoptotic cascade has most likely already commenced at this stage. 
The dramatic increase in nuclear p53, which occurs at the same time, suggests that there are two 
fractions of cytoplasmic p53 with different functions in apoptosis induction in response to 
etoposide, one that associates with the mitochondria and one that translocates to the nucleus. In 
support of this idea, inhibition of p53 association with mitochondria with PFT-mu prevents only 50 
% of etoposide-induced apoptosis of hESC. Due to failure of cPFT to inhibit p53 transcription 
activity, it is impossible to discriminate one from the other. But since CHX only partially inhibits 
apoptosis this can also indicate that etoposide-induced apoptosis of hESC involves both direct 
mitochondrial transcription independent, and nuclear, transcription dependent functions of p53. 
When p53 associates with the mitochondria upon apoptotic stimuli, it has been reported to 
interact with anti-apoptotic proteins of the Bcl2 family members sequestering anti-apoptotic 
proteins (like Bcl2 and Bcl-xL) and to promote the activation of proapotpotic proteins (such as 
inducing Bax and Bak oligomerization). It is still not completely clear what signals are responsible 
for translocation of p53 to the mitochondria. A study by Dumont and colleagues found that two 
different polymorphisms of the p53 gene gave rise proteins with different subcellular localizations 
(Dumont et al., 2003). At position 72, wild-type p53 can encode either a proline or an arginine and 
these authors found that Arg72 was more effective at inducing apoptosis than Pro72 under stress 
and that this was due to enhanced mitochondrial localization of Arg72 after DNA damage or other 
types of cellular stress. It would be of interest to examine possible differences in post translational 
modifications between nuclear and cytosolic p53 fractions in hESC that may explain the 
simultaneous targeting of p53 to two different subcellular locations. 
The regulation and kinetics of apoptosis in hESC are very similar to those observed for in vivo 
irradiated thymocytes, with a rapid p53 transcription independent first wave of apoptosis followed 
by a second p53 transcription dependent wave (Erster et al., 2004) and a very early upregulation 
of PUMA and Bax coincident with caspase 3 activation. The data suggest that in hESC these two 
waves occur either simultaneously or very soon after one another. In both model systems, 
however, the p53-dependent upregulation of PUMA and Bax appear to be critical determinants. 
In mESC, cytoplasmic p53 protein translocates inefficiently to the nucleus upon nucleotide 
depletion and the cells undergo p53-independent apoptosis in response to DNA damage. This 
may be due to differences between the DNA damage response mechanisms in etoposide-treated 
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cells and cells exposed to nucleotide depletion or to intrinsic differences between mouse and 
human ESC. Nuclear accumulation of p53 in hESC is accompanied by an early upregulation of 
the p53 target gene PUMA, but does not cause an increase in p21. This finding may explain why 
hESC that have suffered etoposide induced DNA damage fail to arrest the cell cycle in G0/G1 and 
preferentially die via apoptosis (as indicated by flow cytometric analysis of DAPI stained hESC 
cultures). In this respect hESC resemble mESC (Xu et al., 2002), which also do not exhibit cell 
cycle arrest or slowdown upon UV-induced DNA damage. In fact, DNA damage response and 
cell-cycle regulation differ markedly between mESC and somatic cells (Hong and Stambrook, 
2004). Spontaneous mutation frequency in mouse somatic cells is approximately 100-fold higher 
than in mESC. mESC also lack a G1 checkpoint and are hypersensitive to ionizing radiation and 
other DNA-damaging agents (Hong and Stambrook, 2004) and these characteristics facilitate 
apoptosis and the removal of cells with a mutational burden from the population.  
In other model systems PUMA, a BH3-only derepressor molecule, counteracts the anti-apoptotic 
function of Mcl1 and induces a pro-apoptotic conformational change in Bax (Kuwana et al., 2005). 
BH3-only Bcl2 family members such as PUMA trigger mitochondrial cytochrome c release without 
loss of mitochondrial membrane potential (Shimizu and Tsujimoto, 2000), as is the case in 
etoposide treated hESC. Alternatively PUMA may be involved in the release of mitochondrially 
associated p53 to further enhance nuclear p53 mediated apoptotic events, as recently 
demonstrated by Chipuk and colleagues (Chipuk et al., 2005). The fact that in hESC p53 
upregulation results in an upregulation of only a subset of p53 target genes, such as PUMA, 
suggests that p53 exhibits target specificity. This may be due to differences in p53 
postranslational modifications, histone modifications or interactions with other transcription factors. 
These data are in contrast to the study by Qin and colleagues (Qin et al., 2006), that was 
published during the course of this study, which indicated that UV- and gamma-radiation induced 
apoptosis of hESC, although p53 dependent, does not lead to accumulation of Bax or Hdm2 and 
does not cause activation of any p53 downstream target genes in luciferase reporter assays. The 
authors postulated that post translational modifications of p53 render the p53 protein 
transcriptionally inactive without interfering with p53’s ability to repress Oct4 and Nanog 
expression. It was consequently concluded that p53 induces apoptosis solely through a 
mitochondrial pathway. However, in that study 30-40 % of the Annexin V positive cells were 
stained with propidium iodide (PI) indicating the occurrence of necrosis, which does not involve 
gene regulation. Indeed, the use of PI staining to detect apoptosis in hESC, as used by Qin and 
colleagues (Qin et al., 2006), should be discouraged since this assay does not discriminate 
between primary and secondary necrosis and apoptosis. In order to determine whether the 
differing results in terms of p53 downstream target activation between our study (using etoposide) 
and the Qin et al study (using UV and gamma radiation) could be due to the different methods to 
induced DNA damage, PUMA modulation was assessed in response to gamma radiation. Similar 
to what we observed for etoposide-induced apoptosis gamma-radiation-induced apoptosis of 
hESC causes increased p53 expression that is accompanied by upregulation of the p53 
downstream target gene PUMA and Hdm2. This leaves the possibility that the differences 
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between the two studies may be due to intrinsic cell line differences (H1 versus HES-2, HES-3 
and HES-4 in the present study), the passage number of the hESC (P42-68 H1 versus less than 
P15 in our study) or the method of propagation (dispase versus collagenase in this study). There 
are probably mechanistic differences between the responses of hESC to the different apoptotic 
stimuli, namely UV irradiation and etoposide treatment (Attardi et al., 2004). For example, UVB 
treatment generally causes activation of p38 and/or wip1 (Takekawa et al., 2000). p38-mediated 
phosphorylation and stabilization of p53 can subsequently cause cytoplasmic sequestration of 
wild-type p53, leading to an absence of p53 target gene modulation (Chouinard et al., 2002) while 
wip1 expression has been shown to suppress both p53-mediated transcription and apoptosis in 
response to UV radiation (Takekawa et al., 2000) 
A working model for etoposide induced apoptosis in hESC is proposed on Figure 3.17. In this 
model, DNA damage leads to stabilization and increased expression of p53 followed by 
translocation of p53 to both the mitochondria, where it possibly interacts with Mcl1, and to the 
nucleus, where it leads to transcriptional upregulation of Bax and PUMA. Bax and PUMA next 
cooperate in triggering cytochrome c release from the mitochondria without loss of membrane 
potential and this subsequently leads to activation of a caspase 3 dependent apoptotic program. 
The presence of two simultaneous pathways to induce p53-mediated apoptosis may be a failsafe 
mechanism reflecting their origin from pluripotent embryonic cells in vivo, where it would be 
important to ensure that genetically abnormal cells do not contribute to the developing tissues 
and the germ line. In order to confirm that p53 is required for apoptosis and to gain more insight 
into the role of p53 in hESC, p53 shRNA transduced cell lines were generated. 
 
 
FIGURE 3.17- A model depicting the role of p53 and p53 downstream targets in the 
regulation of etoposide-induced apoptosis of hESC. 
In response to DNA damage p53 translocates to both the mitochondria, where it possibly 
interacts with Mcl1, as well as to the nucleus where it triggers upregulation of PUMA and 
maintenance of Bax expression. PUMA and Bax subsequently cooperate in facilitating 
cytochrome c release without loss of membrane potential and initiation of the apoptotic cascade. 
See text for details. 
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4.1- p53 is required for etoposide-induced apoptosis 
p53 is considered a critical regulator of genomic integrity due to its ability to trigger apoptosis 
and/or cell cycle arrest in response to genotoxic stress. Because hESC display remarkable 
genomic stability and are highly sensitive to ionising radiation and other DNA-damaging agents, 
the modulation of p53 and other proteins involved in the regulation of apoptosis was examined in 
detail in the last Chapter. In order to determine the requirement of p53 for etoposide-induced 
apoptosis of hESC HES-2 hESC were stably transduced with a lentivirus carrying shRNA 
designed to knockdown p53 mRNA. To control for differences due to the lentiviral transduction 
itself or activation of the RNAi pathway, a cell line stably transduced with GFP (an shRNA 
directed against a gene not expressed in hESC) was used as control. These GFP shRNA 
transduced hESC were found to display a very similar response to etoposide as compared to 
untransduced hESC. 
Using bioinformatic analysis (Invitrogen RNAi Design Services) of the p53 mRNA, two shRNA 
sequences (p53A and p53B) were designed and cloned into the lentiviral construct and stably 
transduced hESC. Western blotting analysis showed that p53A shRNA was most efficient at 
knocking down p53 expression. This construct was next selected for subsequent experiments 
described in this section. 
As shown in Figure 4.1B and 4.1C, p53 shRNA transduced hESC constitutively expressed only 
20% of p53 protein as compared to untransduced HES-2 cells or GFP shRNA transduced HES-2 
cells, and displayed a reduced upregulation of p53 in response to etoposide addition. Importantly, 
these p53 shRNA transduced hESC displayed an 80 % reduction in etoposide-induced apoptosis 
that is consistent with the 80 % reduction in p53 protein expression (Figure 4.1A). These data 
therefore unequivocally demonstrate that etoposide-induced apoptosis of hESC is dependent on 
p53. The reduction of p53 dependent apoptosis in the p53 shRNA transduced hESC is 
accompanied by a constitutive downregulation of Bax expression and an attenuated upregulation 
of PUMA in response to etoposide addition. Therefore, these results strongly suggest that the 
reduction of etoposide-induced apoptosis in p53 knockdown hESC is due to a reduced 
upregulation of PUMA and a constitutively reduced expression of Bax. As shown previously, 
levels of Nanog decreased during the timecourse of exposure to etoposide in control cells, but not 
in p53 shRNA transduced cells (Figure 4.1B). The observation that this no longer occurs in the 
p53 shRNA transduced cells confirms that p53 is indeed required for repression of Nanog 
expression in response to etoposide. (Figure 4.1B). The reduced sensitivity of the p53 shRNA 
transduced hESC to etoposide-induced apoptosis is not due to an increased differentiation since 
levels of Oct4 are similar to levels in control cells (Figure 4.1B). 
 
4.2- p53 is required for spontaneous apoptosis 
Between 10-15 % of hESC (HES-2, HES-3 and HES-4) grown under serum free culture 
conditions (Amit et al., 2004) undergo spontaneous apoptosis over a 18h hour period. As shown 
in Figure 4.1B, HES-2 stably transduced with p53 shRNA and displaying only 20% residual p53 
expression as compared to untransduced or GFP shRNA transduced hESC show a reduction in 
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spontaneous apoptosis from 11.4 ± 5.5% to only 2.6 ± 1.1 % (Figure 4.1A). GFP shRNA 
transduced HES-2 cells display a similar level of spontaneous apoptosis to untransduced HES-2, 
indicating that the reduction in spontaneous apoptosis is not due to the lentiviral transduction per 
se. Although the reason for the relatively high rate of spontaneous apoptosis in hESC serum free 
culture is unknown, these data indicate that spontaneous apoptosis is dependent on p53.  
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FIGURE 4.1- p53 is required for etoposide-induced apoptosis of hESC.  
(A) HES-2 cells were stably transduced with lentivirus carrying shRNA designed to knockdown 
p53 or GFP and grown in serum-free conditions. Untransduced, GFP and p53 shRNA transduced 
hESC were harvested 4.5, 9 and 18 hours after treatment with 170 nM etoposide. Cells were 
subsequently PFA-fixed, labeled with TUNEL, immunostained with the stem cell marker Oct4 and 
analyzed by flow cytometry. Results shown are expressed as percentage means ± S.D. (n=4). (p-
value < 0.05 denoted by *and p-value < 0.01 denoted by ** compared to GFP shRNA transduced 
cell line). 
(B) Downregulation of p53 and p53 downstream targets Bax and PUMA in p53 shRNA 
transduced HES-2 cells. HES-2 cells stably expressing p53 shRNA or GFP shRNA were 
harvested 4.5 and 9 hours after treatment with 170 nM etoposide. Protein extracts were boiled in 
Laemmli buffer, resolved on separate polyacrylamide gels and analyzed by Western blotting with 
p53, PUMA, Bax, Nanog and Oct4 antibodies. β-tubulin was used to ensure equal protein loading.  
(C) Quantification of protein expression using software based densitometric analysis on cross-
reactive bands and the β-tubulin loading controls.  
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4.3- Cell proliferation and cell cycle of p53 shRNA transduced cells 
In many model systems p53 can exert control over cell cycle progression through regulation of 
the expression of cell cycle checkpoint regulators (reviewed by Pietenpol and Stewart, 2002; 
Stewart and Pietenpol, 2001). In order to determine the role of p53 in cell cycle control of hESC 
we measured cell cycle entry via BrdU incorporation in both p53 shRNA and GFP shRNA 
transduced hESC. The CD9 pluripotency marker was use to gate on undifferentiated hESC. This 
is important since cell cycle control of hESC is dramatically altered upon differentiation (Filipczyk 
et al., 2007). No significant differences were found between cell cycle entry of GFP and p53 
shRNA transduced cell lines or distribution cell cycle phases (Figure 4.2). In both cases, a higher 
proportion of cells resides in the S phase of cell cycle as compare to other phases. These data 
therefore indicate that p53 does not play a role in cell cycle entry of hESC or that 80 % reduction 
of p53 is not sufficient to unmask such an effect. 
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FIGURE 4.2- No differences in cell proliferation and distribution of cell cycle phases in p53 
shRNA transduced hESC.  
HES-2 cells were stably transduced with lentivirus carrying shRNA designed to knockdown p53 or 
GFP and grown in serum-free conditions. Both p53 shRNA transduced and GFP shRNA 
transduced (control) hESC immunostained with the stem cell marker CD9 (A), labelled with BrdU 
with In Situ Cell Proliferation Kit, FLUOS (Roche Applied Science) (B) and subsequently analyzed 
by flow cytometry (n=2). (C) Quantification of different phases of cell cycle. 
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4.4- Karyotype of p53 shRNA cells 
The role of p53 in regulation of apoptosis, centrosome duplication and control over G2/M and the 
G1 cell cycle checkpoints can all contribute to the maintenance of genetic stability in other model 
systems. Therefore, the potential role of p53 in the maintenance of genetic stability of hESC was 
investigated. GFP and p53 shRNA transduced cell lines cultured under standard conditions in the 
presence of serum and passaged with mechanical dissociation did not develop karyotypic 
abnormalities up to passage 20 (Figure 4.3) when analysed by G-banding karyotype analysis. 
This analysis was not carried out on hESC cultured in serum-free culture conditions because 
karyotypic abnormalities frequently occur under these conditions and this would make it difficult to 
determine the specific role of p53 in genetic stability of hESC. A more refined analysis, like CHG 
arrays, should be carried out in order to assess the role of p53 in maintenance genetic stability in 
more detail because G-banding karyotype analysis is a low resolution assay that does not identify 
small deletions or mutations. 
p53GFP
A B
 
FIGURE 4.3- Karyotype of p53 shRNA transduced hESC is normal.  
HES-2 cells were stably transduced with lentivirus carrying shRNA designed to knockdown p53 or 
GFP and grown under standard conditions. Cells were processed for G-band karyotyping 
analysis by Cytogenetics Labotory, Monash Medical Centre, Clayton, Victoria, Australia.  
 
 
4.5- p53 controls gene expression under normal hESC culture conditions: Transcriptome 
analysis of GFP and p53 shRNA transduced hESC 
Three biological replicates of hESC (HES-2 and HES-4) transduced with either GFP (control) or 
p53 shRNA were FACS sorted using the cell surface markers CD9 and GCTM2 to obtain a 
population of undifferentiated hESC. RNA was isolated from these fractions and subjected to 
microarray analysis on the 46 k Human Illumina platform. Firstly, the gene expression profile 
results confirmed that p53 mRNA levels in p53 shRNA transduced hESC are reduced (Figure 4.4). 
The data shown in Figure 4.5 demonstrate that biological replicates of transduced cell lines 
display highly similar transcriptome profiles and that a similar set of genes was consistently 
altered between GFP and p53 shRNA transduced cells, independently of the hESC line used.  
Since the data show that p53 shRNA transduced hESC display a reduction in spontaneous 
apoptosis as compared to GFP shRNA transduced hESC this set of differentially expressed 
             
 
 - 107 - 
CHAPTER 4: RNAi to explore role of p53 in hESC 
genes is presumably responsible for this phenotype. There were 148 differentially expressed 
genes in both HES-2 and HES-4 p53 shRNA tranduced cell lines in comparison to their controls 
(94 genes upregulated and 54 downregulated). Consistently differentially expressed genes 
between GFP and p53 shRNA transduced hESC and their functions are shown in Tables A 2.1-A 
2.4 (Appendix II). About 70 % of these genes were found to contain p53 responsive elements in 
their promoters using p53FamTaG database. This database contains p53 family direct target 
genes selected in the human genome and searches for the presence of the p53 responsive 
elements (RE) and the expression profile of these target genes obtained by microarray 
experiments (Sbisa et al., 2007). Some of those genes (like DYRK3, VIM, TRIM22, GALNT13 
and ISG20L1) were previously shown to bind p53 in their promoters (Wei et al., 2006). There are 
genes with known function that have been previously implicated in apoptosis and tumorigenesis, 
among other functions and other genes whose function is unknown. The main ontology groups of 
genes differentially expressed on the network that includes p53 revealed by Ingenuity pathway 
analysis are: 1. Cancer, 2. Cell Cycle, 3. DNA Replication, Recombination and Repair (Figure 
4.6).  
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FIGURE 4.4- Levels of p53 in GFP and p53 shRNA transduced hESC grown under serum-
free conditions measured by gene profile analysis. (H2 = HES-2, H4 = HES-4).   
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A
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FIGURE 4.5– Gene Spring analysis: Genes that are (A) downregulated (54 genes) and (B) 
upregulated (94 genes) in p53 shRNA transduced HES-2 and HES-4 cells in comparison to 
control cell line.  
             
 
 - 109 - 
CHAPTER 4: RNAi to explore role of p53 in hESC 
 
 
FIGURE 4.6- Best scoring network which includes p53 (Ingenuity pathways analysis on genes 
with Bstat > 0 in pairwise analysis). Top Functions: 1. Cancer, 2. Cell Cycle, 3. DNA Replication, 
Recombination, and Repair. 
 
 
4.6- p53 has a small but reproducible effect on spontaneous differentiation 
Even under the best culture conditions a proportion of hESC are known to spontaneously 
differentiate. In order to determine whether p53 plays a role in spontaneous differentiation of 
hESC, Oct4 expression was assessed in spontaneously differentiating p53 shRNA transduced 
hESC and GFP shRNA transduced controls. 
The data show that 80 % reduction in p53 expression has a small but reproducible inhibitory 
effect on spontaneous differentiation of cultured hESC as determined by the slight increase in 
Oct4 expression by flow cytometric analysis in p53 shRNA transduced hESC lines (92.6 % ± 1.52 
% (n=5) as compared to the GFP shRNA transduced controls (82.4 % ± 4.65 % n=5, p<0.01), 
similar to what was observed by Qin et al (Qin et al., 2006) (Figure 4.7).  
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FIGURE 4.7- p53 has a small but reproducible inhibitory effect on spontaneous 
differentiation. HES-2 cells were stably transduced with lentivirus carrying shRNA designed to 
knockdown p53 or GFP and grown in serum-free conditions. Both p53 shRNA transduced and 
GFP shRNA transduced were harvested and subsequently PFA-fixed, immunostained with the 
stem cell marker Oct4 and analyzed by flow cytometry. Results shown are expressed as 
percentage means ± S.D. (n=5). (p-value < 0.01 denoted by ** compared to GFP shRNA 
transduced cell line). 
 
 
4.7- Role of p53 in induced differentiation of hESC with Activin A and BMP4 
To investigate the role of p53 in direct differentiation of hESC, HES-2 cells stably transduced with 
lentivirus carrying shRNA designed to knockdown p53 or GFP were differentiated for 7 days with 
Activin A (20 and 40 ng/ml) or BMP4 (25 and 50 ng/ml) on Matrigel coated culture flasks (Figures 
4.8 and 4.9). The morphology of the colonies was assessed and the levels of p53, Nanog and 
Oct4 were quantified by real time PCR (Q-PCR).  
In terms of morphology, both treatments induced the appearance of differentiated cells, which are 
characterized by increased cell size, higher ratio of cytoplasm nucleus and darker nuclei, forming 
less compacted areas of cells (Figure 4.8). In case of BMP4 treatment, p53 shRNA transduced 
hESC seemed to have a slightly higher proportion of undifferentiated cells, but with Activin A 
treatment the opposite was observed. Real-time PCR analysis gave an unexpected result, 
namely lower levels of ESC marker in p53 shRNA transduced cell lines compared to control even 
in untreated samples (Figure 4.9). This is surprising because p53 was been shown to suppress 
Nanog expression. The concentrations of BMP4 used were more effective in inducing 
differentiation than Activin A. Although both cell lines showed a significant reduction of Nanog and 
Oct4, p53 shRNA transduced cell line expressed higher levels of these ESC markers after BMP4 
treatment (Figure 4.9A), confirming the morphological observations. Levels of p53 decreased with 
BMP4 treatment in GFP shRNA transduced cells.  
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Activin A at 20 ng/ml promoted the maintenance of hESC in undifferentiated state. At 40 ng/ml 
Activin A induced downregulation of Nanog and Oct4 in both cell lines, but p53 shRNA 
transduced cells expressed lower levels of these hESC markers (Figure 4.9B).  
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FIGURE 4.8- Colony morphology of p53 and GFP shRNA transduced hESC upon 
differentiation with Activin A and BMP4. 
HES-2 cells were stably transduced with lentivirus carrying shRNA designed to knockdown p53 or 
GFP. Both p53 shRNA transduced and GFP shRNA transduced hESC were differentiated for 7 
days with (A) BMP4 (25 and 50 ng/ml) and (B) Activin A (Ac, 20 and 40 ng/ml) in Matrigel. Control 
cells were fed with conditioned media (CM). Scale bars = 200 µm. 
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FIGURE 4.9- Differentiation of p53 and GFP shRNA transduced hESC with BMP4 and Activin 
A analysed by Q-PCR analysis.  
HES-2 cells were stably transduced with lentivirus carrying shRNA designed to knockdown p53 or 
GFP. Both p53 shRNA transduced and GFP shRNA transduced hESC were differentiated for 7 
days with (A) BMP4 (25 and 50 ng/ml) and (B) Activin A (Ac, 20 and 40 ng/ml) on Matrigel. 
Control cells were fed with conditioned media (CM). Total RNA was isolated with RNeasy Mini Kit 
(Qiagen) and reversed transcribed using High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). TaqMan
®
 probes (Applied Byosystems) Human p53, Human Oct4 and Human 
Nanog were used to perform Q-PCR. Human GAPDH was used as an endogenous control. 
Samples were run in a 7500 Real-Time PCR System (Applied Biosystems) and data was 
analyzed using 7500 System SDS Software (Applied Biosystems). 
 
 
4.8- Role of p53 hESC in teratoma formation 
As mentioned in Chapter 2, the ability of hESC to form teratomas is the best test of pluripotency 
presently available. This assay was used to evaluate if p53 shRNA transduced hESC showed 
resistance to differentiation or if they have a bias towards a particular cell type. Both GFP and 
p53 shRNA transduced cell lines formed teratomas when implanted beneath the testis capsule of 
SCID mice. GFP shRNA transduced cell line teratomas contained mature adipose tissue, 
immature neural tissue, mature epithelium of uncertain histotype. The remainder of tissue was 
difficult to classify, but an immature stroma (mesenchyme) with a small epithelial component was 
observed. On the other hand, the p53 shRNA transduced cell line teratomas showed immature 
neural tissue, immature loose connective tissue/mesenchyme including some cystic spaces, 
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mature adipose tissue and mature epithelial structures, a very small amount of immature cartilage 
and small amount of squamous epithelium. The main differences between the teratomas 
developed by this two cell lines was that p53 shRNA transduced cell line teratomas were bigger, 
exhibited a higher proportion of immature neural tissue and had cystic spaces. Perhaps these 
cells are more prone undergo differentiation to the neural lineage, or mature more slowly. 
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FIGURE 4.10- Histological analysis of differentiated tissues found in teratomas formed in 
the testis capsule of SCID mice after transplantation of GFP and p53 shRNA transduced 
hESC. Tumours were grown for a period of 6 weeks. Figures show bright field micrographs of 
tissues prepared in sections and stained with H&E.  
(A) and (B) Teratomas formed from GFP shRNA transduced hESC.  
(C) to (G) Teratomas formed from p53 shRNA transduced hESC.  
N- neural tissue, GE- gut like epithelium, E- epithelium, M- mesenchyme tissue; Nr- neural 
rosettes; Mu- muscle; A- adipocytes; Ne- neural epithelium; C-cartilage. 
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4.9- Discussion  
Homologous recombination to generate targeted gene deletions has so far proven to be 
inefficient in hESC. An alternative and more feasible way of investigating the role of a specific 
gene, such as p53, in hESC is to downregulate its expression through RNAi. Using lentiviral-
metiated delivery of shRNA, it was possible to achieve p53 shRNA transduced hESC 
constitutively expressing around 20 % of p53 protein and around 28% of p53 mRNA as compared 
to untransduced or control GFP shRNA transduced hESC. Because suppression of transgenes 
delivered by lentiviral vectors in hESC has been reported, for each assay in which p53 shRNA 
transduced cell lines were used, p53 levels were measured by western blotting or Q-PCR to 
confirm that they were indeed reduced to the levels expected. No evidence of shRNA transgene 
inactivation was ever observed. 
Spontaneous and etoposide-induced apoptosis of hESC is mediated by p53 since reduction of 
p53 expression in HES-2 causes a commensurate reduction in both. These data are in 
agreement with a recent study by Qin et al (Qin et al., 2006), who also showed that spontaneous 
and UV-induced apoptosis of hESC is controlled by p53. Reduction of the pool of p53 by 
lentivirally delivered shRNA leads to a reduced expression of PUMA and Bax, suggesting that 
these proteins may be critical p53 downstream targets for induction of etoposide-induced 
apoptosis in hESC.  
As mentioned in Chapter 1, p53 can be involved in maintaining genetic stability. If p53-mediated 
spontaneous apoptosis is involved in eliminating genetically damaged cells from the ESC 
population, reduction of p53 function should result in an increased frequency of chromosomal 
abnormalities and genetic mutations. However, no significant differences were observed between 
cell cycle of GFP and p53 shRNA transduced cell lines or distribution of cells in cell cycle phases, 
suggesting that any cell cycle checkpoint operation triggered by spontaneous apoptosis is 
unaltered following p53 knockdown. The karyotypes of both cell lines were found to be normal at 
passage 20. Several studies suggest that apoptosis is among the most important p53 functions 
selected against during tumour progression. The defective cell cycle-checkpoints and aneuploidy 
that often coincide with p53 inactivation in human cancers are just byproducts of p53 loss (Jeffers 
et al., 2003) (Duensing and Duensing, 2005) (Schmitt et al., 2002). Furthermore, some cell lines 
can retain a diploid karyotype in the presence of mutated p53 (Lengauer et al., 1998). However, 
p53 inactivation synergizes with oncogenic events or other cellular insults to promote aneuploidy 
and may facilitate chromosomal imbalances through indirect mechanisms. As mentioned before, 
p53 also has been implicated in regulation of centrosome duplication and abnormal amplification 
of centrosomes is the major cause of mitotic defects and chromosome instability in cancer cells 
(Shinmura et al., 2007). A study performed by D'Assoro et al (D'Assoro et al., 2004) showed that 
cells with partial impairment of p53 function can retain normal centrosome numbers similar to 
wild-type cells. However, when exposed to DNA damage, these cells readily developed 
centrosome amplification whereas cells carrying wild-type p53 maintained normal centrosome 
numbers. Perhaps low levels of p53 under physiological conditions are still sufficient to ensure 
that karyotypic abnormalities do not occur in hESC (indeed a low level of p53 may also be 
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sufficient to maintain a normal cell cycle). To test this hypothesis, hESC transduced with shRNA 
to knockdown p53 could be subjected to DNA damage and followed over time to detect if those 
cells develop abnormalities. Other possible explanation for an absence of abnormal karyotypes in 
p53 shRNA transduced hESC are 1) G-banding karyotype analysis is a low resolution assay that 
does not identify small deletions or mutations 2) it takes longer than 20 passages for those 
abnormalities to appear, 3) hESC possess efficient and alternative mechanisms besides p53 
pathway to delete/suppress abnormal cells or display enhanced repair DNA, and 4) p53 has no 
role in maintaining genetic stability in hESC. 
Microarray analysis of untreated GFP and p53 transduced hESC shows that there is a highly 
similar set of up and down regulated mRNAs in both HES-2 and HES-4 p53 shRNA transduced 
hESC in three independent biological replicates. Bioinformatic analysis shows that more than 70 
% of these genes contain p53 responsive elements. Some of p53 regulated genes were 
previously shown to exhibit binding of p53 to consensus p53 binding sites in their promoters by 
CHIP analysis (Wei et al., 2006). These data strongly suggest that the observed gene expression 
changes are not due to viral insertion effects and that even without etoposide treatment, basal 
expression of p53 functions in the control of downstream target genes. These genes should be 
validated by further analysis such as Q-PCR and western blotting. The ontology groups of genes 
differentially expressed on the network that includes p53 revealed by Ingenuity Pathway Analysis 
include carcinogenesis, cell cycle regulation and DNA replication, recombination and repair. This 
may indicate a role of p53 in maintenance of genetic stability in hESC. 
The biological processes of the genes upregulated in p53 shRNA transduced cell lines are cell 
adhesion, transport (amino acid and ion), regulation of pH, G-protein coupled receptor protein 
signalling pathway, lipid metabolic process, proteolysis, cell cycle and development. It is 
noteworthy that some of these upregulated genes may be involved in apoptosis regulation and 
contribute to tumorigenesis. TFF3 (trefoil factor 3) protein decreases apoptosis of colonocytes 
and etoposide-induced apoptosis of AGS human gastric cancer cell line in a p53 dependent 
fashion (Taupin et al., 2000). On the other hand, some of these genes were reported to be 
overexpressed in cancer cell lines. For example, MVP (major vault protein) is overexpressed in 
multidrug-resistant cancer cells (Mossink et al., 2003) and its transcription can be suppressed by 
p53 (Wang and Beck, 1998). Furthermore, MVP has also been claimed to prevent cells from 
undergoing stress response (Yi et al., 2005). Cathepsin K has potent proteolytic activities against 
several extracellular matrix components and its mRNA and protein were found in samples of 
primary breast carcinoma (Castiglioni et al., 1994) and prostate cancer (Brubaker et al., 2003). It 
has been suggested that this protease, like metalloproteases, may contribute to the invasive 
potential of certain cancer cells through the digestion of the extracellular matrix (Funicello et al., 
2007). PTGS1, also known as Cox-1, is highly expressed in a mouse model of epithelial ovarian 
cancer, which lacks p53 but overexpresses c-myc and K-ras or c-myc and Akt (Daikoku et al., 
2006). HSPB8 (heat shock 22kDa protein 8) depending on the cell type and the extent of 
expression can exert both pro- and anti-apoptotic activity (Gober et al., 2003; Gober et al., 
2005)(reviewed by Shemetov et al., 2007). 
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However, there are a few upregulated genes that are known to have a pro-apoptotic role. NRGN 
(neurogranin), also known as RC3, a calcium/calmodulin binding protein can induce induction of 
apoptosis due to cytokine IL-2 deprivation in lymphoid cells (Devireddy and Green, 2003). In this 
model, levels of intracellular Ca
2+ 
levels play a role in T-cell apoptosis. Bin1 (bridging integrator 1) 
is a tumour suppressor that mediates apoptosis by interacting with c-myc (Sakamuro et al., 1996), 
is involved in the negative regulation of progression through cell cycle and can inhibit 
transformation by mutant p53 (Elliott et al., 1999). It has also been reported that Bin1 participates 
in a caspase-independent cell death program (Elliott et al., 2000). These genes can be part of 
simultaneous or alternative mechanisms to suppress the appearance of genetic abnormalities in 
the hESC population. 
The biological processes of the genes downregulated in p53 shRNA transduced cell lines are 
genes include transport, regulation of transcription, nucleic acid metabolic process, cell cycle and 
protein amino acid phosphorylation. Some of the downregulated genes can also contribute to 
tumorigenesis. NME1 (non-metastatic cells 1) which is involved in negative regulation of 
progression through cell cycle, was identified because of its reduced mRNA transcript levels in 
highly metastatic cells (Driouch et al., 1998). CST6 (cystatin E/M) is a secreted inhibitor of 
lysosomal cysteine proteases and its loss of expression is likely associated with the progression 
of a primary tumour to a metastatic phenotype (Ai et al., 2006). TRIM22 (tripartite motif-containing 
22) is a p53 target gene that confers reduced clonogenic growth and differentiation of leukemic U-
937 cells (Obad et al., 2004). This expression of this gene has also been shown to increase in 
response to DNA-damaging treatments in B-lymphoblastoid cell line TK6 (Amundson et al., 2005) 
and in response to cisplatin in TGCTs (Kerley-Hamilton et al., 2005). TMEM43 (transmembrane 
protein 43) is another gene regulated by p53 identified by a genome-wide analysis under hypoxic 
conditions (Hammond et al., 2006). Although the cell cycle inhibitor p21 (CDKN1A) protein was 
not detected (section 3.9 of Chapter 2), levels of this p53 downstream target inhibitor of cell cycle 
were found to be reduced in p53 shRNA transduced cell lines. On the other hand, Bax which was 
found to be downregulated by western blotting analysis did not display differential expression on 
the microarray analysis. In order to validate these results Q-PCR should be performed. 
p53 had a small but reproducible effect in inhibiting spontaneous differentiation. Preliminary 
studies to address the role of p53 in differentiation of hESC revealed a slight resistance of p53 
shRNA transduced cell lines to BMP4-induced differentiation but the opposite was observed in 
relation to Activin A treatment, based on expression of Nanog and Oct4. Because these 
morphogens operate through different pathways, p53 may participate differently in the 
differentiation process induced by them. In GFP shRNA transduced cells p53 levels decreased 
upon differentiation with BMP4. Perhaps more hESC differentiated progeny show regulation of 
p53 similar to somatic cells, where this tumor suppressor gene is kept at low levels. A very 
interesting study performed by Dazard and colleagues (Dazard et al., 2000) explored the 
p53/MDM2 regulatory loop during different transitions of the human epidermal differentiation 
program. They showed that maximum expression of p53 was found in proliferating keratinocytes 
and that a transient induction of MDM2 and a downregulation of p53 characterized the transition 
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from proliferation to differentiation in primary human keratinocytes. These changes correlated 
with an increase in cell size, at the time of irreversible commitment to differentiation. It is 
noteworthy to mention that the differentiation assays performed on p53 and GFP shRNA 
transduced cell line with Activin A and BMP4 are very simple and were just a first approach to 
check if p53 has a role on initial steps of differentiation. Additionally, only technical replicates 
were analyzed. In order to confirm some of the findings, biological replicates should be performed. 
Furthermore, this study only quantified the expression of ESC genes. Because some ESC 
markers also appeared in their progeny or have not been silenced yet during the process of 
differentiation, future studies should use probes to check the expression of known differentiation 
genes. Longer protocols of differentiation into different cell types should also be performed.  
p53 shRNA transduced cells formed teratomas with representative tissues of all three germ 
layers when implanted beneath the testis capsule of SCID mice, therefore they are still pluripotent. 
Teratomas formed with these cells exhibited a higher proportion of immature neural tissue 
compared to control cells, suggesting that these cells are more prone undergo differentiation to 
the neural lineage, or mature more slowly.  
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hESC are derived from the blastocyst of the preimplantation embryo and give rise into cells of all 
lineages of the body. Since they were derived in 1998, significant progress has been made in the 
characterization of the hESC lines. Their differentiation into various cell types has opened the 
possibility to use these cells in cell replacement therapies and as a model for early human 
development. However, the biological characterization of undifferentiated hESC is still poorly 
incomplete. Genetic stability is an aspect that needs also to be addressed in detail in order to 
ensure safe use of these promising cells.  
hESC display unlimited self-renewal, however they do not show obvious signs of transformation if 
cultured under standard conditions. It is not clear how ESC are able to proliferate indefinitely 
without acquiring genetic changes that would lead to oncogenic transformation. This could be 
either due to a very efficient DNA repair or the selective induction of apoptosis in ESC. There is 
little published work on apoptotic signalling pathways in hESC.  
hESC represent a unique cellular model to study regulation of apoptosis, given that they are non-
transformed immortal cells with a normal karyotype, and cannot be directly compared to long-
established cell lines, in which apoptosis pathways are intrinsically altered as part of the 
transformation process, or even to primary cell cultures which display senescence, DNA damage-
induced cell cycle arrest and contact inhibition. Furthermore, it is anticipated that a detailed 
understanding of apoptosis pathways in hESC will be useful for future cell replacement therapies 
using hESC, since it may a allow for the selective elimination of unwanted cell lineages prior or 
subsequent to lineage specific differentiation. Apoptosis can also be used as a quality control 
parameter. For example, if levels of apoptosis are abnormally low, this might be indicative of the 
presence of chromosomal abnormalities, or if levels are too high, this could reflect suboptimal 
culture conditions, like non-suportive MEFs. 
In an effort to better understand apoptosis pathways in hESC, different known regulators of 
apoptosis were investigated. The current study shows that hESC display the classic features of 
apoptosis and, like mESC, are extremely sensitive to both spontaneous and DNA-induced 
apoptosis. Indeed, hESC appear to be far more sensitive to etoposide-induced apoptosis than 
other cell lines or primary cell cultures. Because pluripotent cells can contribute precursors to all 
adult cell lineages, damage to their genomes during embryonic development may cause serious 
developmental malfunctions. Teleologically, it might be better to eliminate pluripotent cells that 
represent a potential oncogenic danger than to attempt to repair them. The high proliferative 
capacity of hESC, or their counterparts in the embryo, can compensate for the loss of some cells 
through apoptosis that would otherwise propagate genetic damage throughout all their 
descendants. At present it remains to be established whether this spontaneous apoptosis, 
although p53-dependendent, is due to suboptimal culture conditions, or whether it is an intrinsic 
feature of hESC that is involved in eliminating cells with acquired DNA damage. However, the 
extrinsic apoptotic pathway seems not to be operational in hESC since TNFα failed to induce 
apoptosis. Other extrinsic pathways, such as Fas ligand mediated apoptosis, should be also 
investigated. 
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When cultured for long periods of time under serum-free conditions, hESC can adapt to culture 
conditions and often gain chromosomal abnormalities resembling the ones observed in hECC. 
This adaptation process result most likely from alterations that lead to better survival. Late 
passage hESC with an abnormal karyotype exhibited reduced apoptotic response to low doses of 
etoposide when compared to early passage diploid cells. This is important to take in account 
especially when studying apoptosis in late passage hESC. Biomarkers of the adapted state, and 
sensitive bioassays for transformation, will be required to monitor cultures for development of 
genetic abnormalities that have phenotypic consequences. 
hESC cultured on MEF feeder cells in the presence of KSR supplemented with 4 ng/ml FGF-2 
(Amit et al., 2004) appear to be a morphologically homogeneous population of undifferentiated 
cells. However, hESC cultured under these conditions are heterogeneous and display various 
degrees of differentiation. This also occurs in hESC under standard conditions (Laslett et al., 
2007) and it is not clear if this heterogeneity is due to intrinsic biological properties of hESC or to 
culture conditions. The sensitivity of hESC to etoposide-induced apoptosis is dependent on their 
differentiation status. Undifferentiated hESC that express Oct4 are the least resistant to 
etoposide-induced apoptosis as compared to their more differentiated progeny. When measuring 
apoptosis or any other biological parameter is important to assess differentiation status of 
populations, because different subpopulations can display different responses. This is particularly 
important when hESC are to be used for cytotoxicity assays (as proposed in many publications). 
In the case of mESC, the relationship between the level of differentiation and the sensitivity of 
mESC to apoptotic stimuli remains unexplored to present knowledge. 
In this study a mixed effect of p53 on differentiation of hESC was observed. Its downregulation 
slightly inhibits spontaneous differentiation and BMP4-induced differentiation, but seems to 
promote differentiation when cells are treated with Activin A. Longer differentiation protocols with 
these morphogens and measurement of differentiation markers of different cell lineages would be 
required to further confirm these preliminary findings. The teratomas formed from p53 shRNA 
transduced cells exhibited a higher proportion of immature neural tissue, suggesting that these 
cells are more prone to undergo differentiation to the neural lineage, or mature more slowly. 
p53 is considered a critical regulator of genomic integrity because of its ability to trigger apoptosis 
and/or cell cycle arrest in response to genotoxic stress. Induction of of apoptosis by p53 can 
occur via both transcription-independent and transcription dependent pathways. The current 
study shows that p53 is required for etoposide-induced apoptosis of hESC and that p53 response 
in these cells involves both mitochondrial and nuclear apoptotic pathways. The presence of two 
simultaneous pathways to induce p53-mediated apoptosis may be a failsafe mechanism of 
pluripotent cells to ensure that abnormal cells do not contribute to the developing tissues and the 
germ line.  
It would be interesting to perform timed gene expression profile analysis to identify known and 
novel genes involved in the apoptotic response of hESC. This is a technical challenge since 
apoptosis progresses very quickly in hESC and RNA in apoptotic cells that have to be sorted by 
flow cytometry (to obtain a population of undifferentiated hESC) can degrade quickly during this 
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process. Such experiments would further represent a good opportunity to study p53 post-
translational modifications involved in the response to different apoptotic stimuli and elucidate the 
differences between mitochondrially and nuclear targeted p53. 
If p53-mediated spontaneous apoptosis is involved in eliminating genetically damaged cells from 
the hESC population, reduction of p53 function should result in an increased frequency of 
chromosomal abnormalities and genetic mutations. This hypothesis is under further investigation. 
G-banding did not reveal an abnormal karyotype of cell lines transduced with p53 shRNA 
mediated knockdown after 20 passages under standard culture conditions. As mentioned above, 
more refined techniques like CGH arrays may identified include other more subtle genetic 
changes in these cells. Also studying the epigenetic status of these cells could elucidate if p53 
plays a role in genetic stability. 
It is puzzling how hESC can tolerate high levels of functional p53 without undergoing cell cycle 
arrest or apoptosis. Gene expression profile analysis of hESC transduced with p53 shRNA and 
GFP shRNA shows that there is a highly similar set of up and down regulated mRNAs in both 
HES-2 and HES-4. Some genes have previously been reported to play a role in apoptosis and 
tumorigenesis, among other functions. Novel p53 regulated genes whose function is unknown 
were also identified. Perhaps future studies should address the validation of some of the genes 
that are differentially expressed, due to reduction of p53 levels and investigate their role in hESC 
biology. The main ontology of genes differentially expressed in the network that includes p53 
relate to carcinogenesis, cell cycle regulation and DNA replication, recombination and repair. This 
may point to a role for p53 in maintenance of genetic stability in hESC. However, the fact that so 
far no chromosomal abnormalities were observed in p53 shRNA transduced cell lines may 
indicate that alternative mechanism may also be operational in hESC. This could involve genes 
like Bin1, responsible for inhibition of transformation. It would be very interesting to downregulate 
both these tumour suppressors to evaluate if they play complementary or alternative roles in 
maintaining genomic stability in hESC by eliminating from the population cells that can become 
transformed. 
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As hESC são derivadas a partir do blastocisto do embrião preimplantatório e dão origem às 
células de todas as lineagem do corpo. Desde a sua descoberta em 1998, progresso tem sido 
feito na caracterização das linhas celulares derivadas. A diferenciação em vários tipos celulares 
abriu a possibilidade de utilizar estas células em terapias de substituição de células e como 
modelo para o devolvimento humano. Contudo, a caracterizção biológica das hESC 
indiferenciadas continua incompleta. A estabilidade genética é também um aspecto que é 
preciso ser estudado em detalhe de modo a assegurar o uso seguro destas células tão 
promissoras. 
hESC possuem um capacidade de auto-renovação ilimitada, contudo elas não exibem sinais de 
transformação óbvios quando cultivadas nas condições padrão. Não é ainda claro como elas são 
capazes de proliferar infinitamente sem adquirirem alterações genéticas que possam levar à 
transformação oncogénica. Isto poder ser devido a uma eficaz reparação no ADN ou a uma 
indução selectiva da apoptose. Existem poucos estudos publicados em vias de sinalização de 
apoptose em hESC.  
hESC representam uma modelo celular único para o estudo de regulação da apoptose, dado que 
são células não transformadas imortais com cariótipo normal e não podem ser comparadas 
directamente com as já há muito estabelecidas linhas celulares, nas quais as vias de sinalização 
de apoptose estão intrinsicamente alteradas como parte do processo de transformação, ou até 
das linhas primárias que exibem senescência e paragem no ciclo celular devido a danos no ADN. 
Por um outro lado, é antecipado que uma melhor compreensão das vias de apoptose das hESC 
irá ser útil em futuras terapias de substituição celular, mas vez que poderá permitir a eliminação 
selectiva de linhagem celulares não desejáveis antes ou depois da diferenciação específica. A 
apoptose pode também ser usada como um parâmetro de controlo de qualidade. Por exemplo, 
se a apoptose for muito baixa poderá ser indicativo da presença de alguma anomalia 
cromossómica ou se for muito elevada poderá ser indicativo de condições de cultura sub-óptimas, 
como MEF não suportivos. 
No sentido de melhor compreender as vias de sinalização de apoptose em hESC, diferentes 
reguladores da apoptose já conhecidos foram investigados. O presente estudo demonstra que as 
hESC exibem características clássicas da apoptose e, como as mESC, são extremamente 
sensíveis à apoptose espontânea e induzida por danos no ADN. De facto, as hESC parecem ser 
mais sensíveis à apoptose induzida por etopósido do que outras linhas celulares ou culturas 
primárias. Devido ao facto das ESC contribuírem para os precurssores de todas a linhagem 
celulares adultas, danos no genoma das ESC pode causar sérias disfuncções no 
desenvolvimento. Teleologicamente, o embrião em desenvolvimento poderá escolher em 
eliminar as células que representam um potencial perigo oncogénico do que tentar repará-las. A 
alta capacidade proliferativa das hESC poderá compensar a perda de algumas que podem pôr 
em risco a população. Presentemente, ainda não se sabe se a apoptose espontânea, embora 
dependente do p53, é devida a condições de cultura sub-óptimas ou a característica intrínsica 
das hESC envolvida na eliminação de danos adquiridos no ADN. Contudo, a via extrínsica de 
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apoptose parece não estar operacional em hESC uma vez que TNFα falhou na indução da 
apoptose. A apoptose mediada por Fas ligante deverá ser também investigada. 
Quando cultivadas por longos períodos de tempo com meios sem soro, as hESC tendem a 
adaptar às condições de cultura e desenvolvem com frequência abnormalidades cromossómicas 
semelhantes às observadas em células embrionárias do carcinoma humanas (hECC). Este 
processo de adaptação resulta muito provavelmente de alterações que levam a melhor uma 
sobrevivência. hESC com muitas passagem e um cariótipo anormal exibem resposta apoptótica 
reduzida a baixas concentrações de etopósido quando comparadas com células passadas 
poucas vezes. Isto é importante ter em conta especialmente qando se estuda a apoptose em 
hESC com elevado número de passagens. Biomarcadores do estado adaptado e bioensaios 
sensíveis à tranformação serão necessárias para monitorizar as culturas relativamente ao 
desenvolvimento de anormalidades genéticas que têm consequências fenotípicas. 
As hESC cultivadas sob camadas de MEF e na presença de KSR suplementado com 4 ng/ml de 
FGF-2 (Amit et al., 2004) aparentam ser uma população morfologicamente homogénea de 
células indiferenciadas. Contudo, hESC cultivadas nestas condições são heterogéneas e exibem 
vários graus de diferenciação. Isto também ocorre hESC cultivadas em condições padrão 
(Laslett et al., 2007) e ainda não é claro se estas diferenças fenotípicas são devidas a 
propriedades biológicas das hESC ou a condições da cultura. A sensibilidade de hESC à 
apoptose induzida pelo etopósido é dependente do estado da sua diferenciação. hESC 
indiferenciadas que expressam Oct4 são menos resistentes à apoptose induzida pelo etopósido 
quando comparadas com a sua progenia mais diferenciada. Quando se mede a apoptose ou 
qualquer outro parâmetro biológico é importante também verificar o estado de diferenciação das 
populações dada porque diferentes subpopulações poderão exibir diferentes respostas. Isto é 
particularmente importante quando as hESC são usado em ensaios citotóxicos (como tem sido 
proposto em muitas publicações). No caso das mESC, a relação entre o estado de diferenciação 
e a sensibilidade a estímulos apoptóticos continua por ser investigada. 
Neste estudo é observado um efeito misto do p53 na differenciação das hESC. A diminuição dos 
seus níveis inibe a diferenciação espontânea e a induzida por BMP4, mas promove a 
diferenciação quando as células são exposta à Activina A. Protocolos de diferenciação mais 
longos com estas morfógenos e medição dos níveis de marcadores de diferenciação de 
diferentes linhagens celulares poderá confirmar estes resultados preliminares. Os teratomas 
formados por estas células exibem uma maior proporção de tecido neural imaturo, o que sugere 
que elas preferencialmente se diferenciam numa linhagem neural ou o seu processo de 
maturação é mais lento. 
O p53 é considerado o regulador crítico da integridade genómica devido à sua capacidade de 
desplotar apoptose e/ou paragem no ciclo celular em resposta a stresse no genoma. A indução 
da apoptose pelo p53 pode ocorre através de vias dependentes ou indepedentes da transcripção. 
O presente estudo mostra que o p53 é requerido na apoptose de hESC induzida por etopósido e 
a resposta do p53 nestas células envolve ambas as vias apoptóticas mitocondrial e nuclear. A 
presença destas duas vias em simultâneo poderá constituir um mecanismo para assegurar que 
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as hESC com mutações não contribuam para os tecidos em desenvolvimento e para a linha 
germinal. 
Seria interessante realizar um estudo do perfil genético para identificar genes com funções 
conhecidas e até no genes involvidos na resposta apoptótica das hESC. A nível técnico isto é um 
desafio porque a apoptose progride muito rapidamene e o RNA pode degradar-se durante o 
processo de isolar as células indiferenciadas. Este modelo representa também uma boa 
oportunidade para estudar as modificações pós-tradução envolvidas nas resposta a diferentes 
estímulos apoptóticas e as enzimas envolvidas. 
Caso a apoptose espontânea mediada pelo p53 esteja envolvida na eliminação de células com 
danos genéticos da população de hESC, a redução da função do p53 deverá resultar um 
aumento da frequência de anormalidades cromossómicas e mutações. Esta hipótese está 
correntemente a ser testada com a passagem destas células e cariotipagem. Este método ainda 
não revelou um cariótipo anormal nas células após 20 passagens sob condições padrão. Como 
anteriormente foi mencionado, técnicas mais refinadas poderão identificar alterações genéticas 
mais subtis. Também o estudo do estado epigenético poderá elucidar se o p53 tem um papel na 
estabilidade genética. 
É intrigante como as ESC podem tolerar elevados níveis de expressão de p53 functional sem 
que ocorra paragem no ciclo celular ou apoptose. Análise dos perfis de expressão genética 
células infectadas com shRNA para o p53 e GFP revela que um conjunto muito similar de 
mRNAs sofre aumento ou diminuição em ambas HES-2 and HES-4. Alguns desses genes já 
form implicados na apoptose e na tumorigénesis, entre outras funções. Outros têm função 
desconhecida. Estudos futuros deverão validar estes resultados de genes expressos 
diferentemente devido a uma redução nos níveis de p53 e investigar o papel na biologia das 
hESC. As funções principais dos genes diferentemente expressos que contêm o p53 estão 
envolvidos em carcinogénesis, regulação do ciclo celular e replicação, recombinação e 
reparação do ADN. Isto poderá evidenciar o papel do p53 na manutenção da estabilidade das 
hESC. O facto de não terem sido detectadas anormalidades cromossómicas nas hESC que 
expressam shRNA para diminuir os níveis de p53 poderá sugerir que mecanismos alternativos 
são operacionais em hESC, envolvendo genes como o Bin1, responsáveis pela inibição da 
transformação. Seria muito interessante também diminiuir os níveis de expressão desses 
supressores de tumor para avaliar que eles desempenham mecanismos complementares ou 
alternativos na manutenção da estabilidade genómica das hESC através da eliminação de 
populações de células que poderam tornar-se transformadas. 
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Formulas for commonly used reagents 
10% SDS 
Dissolve 100 g of SDS (Sigma-Aldrich) [Cat No: L4390] in 900 ml ddH2O, heating a 65 °C water 
bath to assist dissolution. Adjust the pH to 7.2 by adding a few drops of concentrated HCl (Lab-
Scan) [Cat No: A8601]. Make up to 1 liter with ddH2O and store at RT. 
 
10% Tween 20  
Dissolve 10 g of Tween 20 (Sigma-Aldrich) [Cat No: 1379] in 90 ml ddH2O. Store at RT. 
 
5 M NaOH 
Dissolve 200g of NaOH pellets (AnalaR) [Cat No: 10252.4x] in 800 ml of ddH2O, taking care with 
generated heat. Make up to 1 liter in ddH2O and store at RT. 
 
1.5 M Tris-HCl pH 8.8 
Dissolve 90.75 g of Tris base (Merk) [Cat No: 108382] in 350 ml of ddH2O. Adjust to pH with HCl 
(Lab-Scan) [Cat No: A8601] and make up to 400 ml with ddH2O. 
 
0.5 M Tris-HCl pH 6.8 
Dissolve 15 g of Tris base (Merk) [Cat No: 108382] in 350 ml of ddH2O. Adjust to pH with HCl 
(Lab-Scan) [Cat No: A8601] and make up to 250 ml with ddH2O. 
 
0.5 M EDTA pH 8.0 
Add 186.1 g of disodium ethylenediaminetetra-acetate.2H2O (EDTA salt) (AppliChem GmbH) 
[Cat No: A1104] to 800 ml of ddH2O and stir vigorously on a magnetic stirrer. Adjust to pH 8.0 
with NaOH (~20 g of NaOH pellets) (AnalaR) [Cat No: 10252.4x], bringing the EDTA salt into 
solution. Autoclave and store at RT. 
 
50x TAE  
484 g  Tris-base (Merk) [Cat No: 108382] 
114.2 g Glacial acetic acid (Lab-Scan) [Cat No: A8401] 
200 ml 0.5 M EDTA (AppliChem GmbH) [Cat No: A1104] 
 
Combine all reagents and bring to final volume of 2 liters with ddH2O. For 1x TAE working 
solution, dilute 200 ml of 50x TAE stock to 10 liters of ddH2O and store at RT. 
 
DNA electrophoresis loading dye  
For 10x DNA gel-loading dye, the following mix is made up in ddH2O and stored at -20 °C: 
0.25% (w/v) Orange G (Sigma-Aldrich) [Cat No: O7252] 
15% (v/v) Ficoll ® 400 (Sigma-Aldrich) [Cat No: F4375] 
 
5 M NaOH 
Dissolve 200g of NaOH pellets (AnalaR) [Cat No: 10252.4x] in 800 ml of ddH2O, taking care with 
generated heat. Make up to 1 liter in ddH2O and store at RT. 
 
1.5 M Tris-HCl pH 8.8 
Dissolve 90.75 g of Tris base (Merk) [Cat No: 108382] in 350 ml of ddH2O. Adjust to pH with HCl 
(Lab-Scan) [Cat No: A8601] and make up to 400 ml with ddH2O. 
 
0.5 M Tris-HCl pH 6.8 
Dissolve 15 g of Tris base (Merk) [Cat No: 108382] in 350 ml of ddH2O. Adjust to pH with HCl 
(Lab-Scan) [Cat No: A8601] and make up to 250 ml with ddH2O. 
 
0.5 M EDTA pH 8.0 
Add 186.1 g of disodium ethylenediaminetetra-acetate.2H2O (EDTA salt) (AppliChem) [Cat No: 
A1104] to 800 ml of ddH2O and stir vigorously on a magnetic stirrer. Adjust to pH 8.0 with NaOH 
(~20 g of NaOH pellets) (AnalaR) [Cat No: 10252.4x], bringing the EDTA salt into solution. 
Autoclave and store at RT. 
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4% Paraformaldehyde (PFA) 
Add 2 g of PFA (Merk) [Cat No:294474L] to 45 ml of PBS and heat approximately at 50 °C. Add 
20-40 µl of 5 M NaOH and stir to dissolve. Adjust to pH to 7.4 with HCl (Lab-Scan) [Cat No: 
A8601] and make up to 50 ml with PBS. 
 
10% Ammonium persulfate (APS) 
Make fresh just before use. Weigh 0.1g of APS (Sigma-Aldrich) [Cat No: A3678] into a 
polypropylene 1.7 ml microtubes (Axygen, Union City CA, USA) [Cat No: MCT175-C]. Add 1ml of 
ddH2O and discard after use.  
 
Running buffer (2x) 
12.2 g of Tris base (Merk) [Cat No: 108382] 
57.65g of Glycine (Merk) [Cat No: 104201] 
20 ml of 10% SDS 
 
Dissolve 12.2 g of Tris base and 57.65g of Glycine in 800 ml of ddH2O. Add 20 ml of 10% SDS 
and make up to 2 liters with ddH2O. Store at RT. 
 
3x Laemmli Loading Buffer (Reducing) (50ml) 
9.375 ml 1M Tris pH 6.8 
3.0 g SDS (Sigma-Aldrich) [Cat No: L4390]  
15 ml Glycerol (Sigma-Aldrich) [Cat No: G2025] 
15 mg Bromophenol blue (Sigma-Aldrich) [Cat No: B6131] (add 1ml of a 15mg/ml solution of 
bromophenol blue in ddH2O) 
 
Dissolve 3g SDS in 10 ml ddH2O. Add 9.375ml 1M Tris to 26.5ml with ddH2O. Add 1ml of 
bromophenol blue solution. Combine with 15 ml glycerol and mix well. Total volume should be 
42.5 ml. Prepare 850 µl aliquots. Before use, add 150 µl of β-Mercaptoethanol (Sigma-Aldrich) 
[Cat No: M7154] and dilute to 1x. 
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TABLE A 2.1- List of genes upregulated in p53 shRNA transduced hESC (Ingenuity Pathways Analysis)   
           
Common 
name 
Fold 
Change 
B-
stat Genbank Biological process/role 
p53 
RE 
 30.40 9.68 AI810049   
HTR7 8.25 9.25 NM_000872 G-protein coupled receptor protein signaling pathway  
PLCD1 2.84 5.75 NM_006225 Lipid metabolic process, Intracellular signaling cascade 6 
APOBEC3B 1.87 5.39 NM_004900 Growth or cell cycle control  2 
ATP6V1B1 2.99 5.34 NM_001692 Ion transport, regulation of pH, ATP synthesis coupled proton transport 5 
SLC7A14 3.82 4.49 NM_020949 Transport, amino acid transport 4 
CXXC4 3.16 4.47 NM_025212 Negative regulation of Wnt receptor signaling pathway 3 
VASH1 1.93 4.45 NM_014909 Cell cycle arrest, anti-angiogenesis  5 
SDSL 2.25 4.33 NM_138432 Amino acid metabolic process 3 
TFF3 1.99 4.15 NM_003226 Defense response, digestion, resistance to apoptosis  2 
CAPN11 1.83 3.39 NM_007058 Proteolysis 5 
PCDH11Y 2.48 3.05 NM_032971 Cell adhesion  
C1QL4 2.68 2.87 NM_001008223 Phosphate transport  
PCDH11X 3.38 2.72 NM_032967 Cell adhesion  
KIAA1509 1.72 2.58 BX640973   
C11orf11 2.27 2.50 NM_006133 Lipid catabolic process 3 
NRGN 2.73 2.37 NM_006176 Signal transduction, nervous system development, apoptosis  
LHFP 1.76 2.24 NM_005780  3 
VSIG2 2.95 2.10 NM_014312   
OLFML3 1.65 1.97 NM_020190   
TFPI 1.83 1.94 NM_006287 Blood coagulation 3 
EDNRB 2.01 1.91 NM_003991 Migration; regulation of pH, G-protein signaling, differentiation  
ZNF467 1.97 1.84 NM_207336 Regulation of transcription, DNA-dependent 1 
ASB9 1.74 1.83 NM_024087 Intracellular signaling cascade 10 
FOLR1 2.20 1.81 NM_016724 Receptor-mediated endocytosis, folic acid metabolic process, proliferation, cell viability 5 
LIX1L 1.80 1.68 NM_153713  2 
BIN1 1.83 1.64 NM_139348 Negative regulation of progression through cell cycle, development, cell differentiation  
GLDN 1.65 1.57 NM_181789 Phosphate transport, nervous system development, cell differentiation 4 
TFPI 2.02 1.56 NM_001032281 Blood coagulation  
DYRK3 1.55 1.48 NM_003582 Protein amino acid phosphorylation, erythrocyte differentiation 1 
FBXL2 1.52 1.35 NM_012157 Protein modification process, proteolysis, ubiquitin cycle 3 
MFNG 1.72 1.31 NM_002405 Pattern specification process 7 
SLC25A34 2.20 1.30 NM_207348 Transport 5 
LOC401074 1.78 1.28 XM_942831   
C2orf11 2.36 1.27 NM_144629  6 
HGC6.3 2.03 1.25 AB016902   
CYTL1 1.80 1.25 NM_018659 Signal transduction 2 
EPDR1 1.51 1.24 NM_017549 Cell-matrix adhesion 3 
HLA-DPA1 1.91 1.23 NM_033554 Immune response, antigen processing and presentation  
DLGAP2 2.08 1.22 NM_004745 Cell-cell signaling, nerve-nerve synaptic transmission  
PTGS1 1.92 1.21 NM_080591 Lipid metabolic process, blood pressure regulation, proliferation, apoptosis 7 
VIM 1.62 1.17 NM_003380 Cell motility 2 
PRICKLE1 1.90 1.11 NM_153026  5 
KCNK12 1.80 1.07 NM_022055 Ion transport, potassium ion transport  
OSAP 1.51 1.04 NM_032623   
PHF7 1.51 1.00 NM_016483  3 
SYNE2 1.71 0.99 NM_015180  4 
CAMP 2.90 0.90 NM_004345 Defense response to bacterium  
HTR7 2.28 0.89 NM_019859 G-protein coupled receptor protein signaling pathway, circadian rhythm, circulation 2 
FAM46C 2.18 0.89 NM_017709  1 
EDNRB 2.11 0.86 NM_003991   
UTS2 1.77 0.84 NM_021995 Muscle contraction, synaptic transmission, blood pressure regulation, proliferation 1 
RAB3GAP1 1.54 0.78 AI872635   
KEL 1.91 0.77 NM_000420 Protein amino acid N-linked glycosylation, proteolysis, vasoconstriction 7 
PMP22 1.76 0.70 NM_153322 
Synaptic transmission, peripheral nervous system development, mechanosensory behavior, 
 negative regulation of cell proliferation 7 
PDE6G 1.83 0.69 NM_002602 
Activation of MAPK, visual perception, EGF receptor signaling pathway and G-protein coupled  
receptor protein signaling pathway 2 
LGALS3BP 1.53 0.68 NM_005567 Cellular defense response; cell adhesion; signal transduction 3 
SELENBP1 1.47 0.68 NM_003944 Protein transport 2 
IL11RA 1.48 0.63 NM_004512  4 
MLLT4 1.74 0.62 NM_005936 Cell adhesion, signal transduction, cell-cell signaling  
SERPINA5 1.78 0.56 NM_000624 Spermatogenesis, fusion of sperm to egg plasma membrane 2 
SHMT1 1.69 0.56 NM_004169 Glycine and L-serine metabolic processes, one-carbon compound metabolic process 8 
LOC647534 1.49 0.51 XM_942883   
LOC143381 2.56 0.50 BX648964   
CLDN19 1.83 0.48 NM_148960 Visual perception, calcium-independent cell-cell adhesion, response to stimulus 4 
WFIKKN1 1.86 0.46 NM_053284  2 
FAM43B 1.68 0.45 NM_207334   
STARD8 1.45 0.44 NM_014725 Signal transduction 3 
RAB36 2.17 0.44 NM_004914 Small GTPase mediated signal transduction, protein transport 5 
ACTN3 1.74 0.41 NM_001104 Muscle contraction, regulation of apoptosis, focal adhesion formation  
GEFT 1.66 0.41 NM_182947 Regulation of Rho protein signal transduction  1 
MVP 1.52 0.41 NM_005115 Response to drug (overexpressed in multidrug-resistant cancer cells) 5 
KIAA1086 1.67 0.41 XM_940014   
ANKRD19 1.91 0.40 NM_001010925 5 
MB 1.65 0.39 NM_005368 Response to hypoxia, oxygen transport, enucleate erythrocyte differentiation 5 
HSPB8 1.95 0.37 NM_014365 Protein folding, apoptosis and growth 9 
 1.51 0.36 CA407939   
TXNDC13 1.77 0.36 NM_021156 Electron transport, cell redox homeostasis 2 
LOC645550 2.06 0.34 XM_928570   
ATP1A2 1.62 0.34 NM_000702 
Potassium and sodium ion transport; regulation of striated muscle contraction, sperm motility,  
cellular hydrogen ion homeostasis 7 
LOC641860 2.09 0.34 XM_935765   
TUBAL3 1.61 0.23 NM_024803 Microtubule-based movement, protein polymerization  
PCBD1 1.59 0.21 NM_001001939 Tetrahydrobiopterin biosynthetic process; protein homotetramerization and hetero-oligomerization  
IL12RB2 2.02 0.18 NM_001559 Cell surface receptor linked signal transduction, positive regulation of cell proliferation  
CD79B 1.96 0.18 NM_000626 
Immune response, cell surface receptor linked signal transduction, proliferation, apoptosis, survival,  
adhesion, development, cell cycle progression 
CBX4 1.45 0.15 NM_003655 
Chromatin modification, assembly or disassembly; regulation of transcription, DNA-dependent,  
ubiquitin cycle; anti-apoptosis 3 
ARHGEF6 1.50 0.13 NM_004840 Apoptosis, JNK cascade, regulation of Rho protein signal transduction 5 
TMEM88 1.90 0.11 NM_203411  5 
CPXM 1.45 0.11 NM_019609 Proteolysis, cell adhesion 3 
FZD2 1.44 0.06 NM_001466 
Establishment of tissue polarity, Wnt receptor and G-protein coupled receptor protein signaling pathways,  
cell-cell signaling, development 2 
IL11RA 1.94 0.06 NM_147162 Proliferation, response, hematopoiesis, differentiation, formation, accumulation 4 
SC5DL 1.44 0.04 NM_006918 Lipid metabolic process, sterol biosynthetic process 2 
LOC440928 2.07 0.04 XM_942885   
CTSK 1.67 0.00 NM_000396 Proteolysis   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE A 2.2- List of functions of upregulated genes in p53 shRNA transduced hESC (Ingenuity Pathways Analysis) 
Function Molecules 
Cell Signaling 
PDE6G,CAPN11,CD79B,EDNRB,MFNG,CLDN19,UTS2,PTGS1,HSPB8,MLLT4,IL12RB2,HLA-
DPA1,NRGN,PLCD1,CYTL1,CAMP,SERPINA5,LGALS3BP,ARHGEF6,HTR7,TFPI,FZD2,CXXC4,ACTN3 
Cardiovascular System 
Development and Function PLCD1,VASH1,MB,EDNRB,UTS2,ATP1A2,PTGS1,VIM,KEL,TFPI 
Cellular Movement VASH1,TFF3,CAMP,EDNRB,SERPINA5,ARHGEF6,UTS2,MLLT4,VIM,TFPI,BIN1 
Cardiovascular Disease MB,EDNRB,SERPINA5,PTGS1,ATP1A2,UTS2,TFPI,BIN1 
Cancer TFF3,EDNRB,CD79B,PTGS1,HSPB8,OLFML3,VIM,FOLR1,PLCD1,VASH1,LGALS3BP,ATP1A2,TFPI,ATP6V1B1,ACTN3 
Molecular Transport MB,EDNRB,CD79B,PTGS1,UTS2,VIM,NRGN,FOLR1,PLCD1,CAMP,HTR7,ATP1A2,FZD2,MVP,IL11RA 
Vitamin and Mineral Metabolism PLCD1,CAMP,EDNRB,CD79B,HTR7,UTS2,FZD2,NRGN,FOLR1 
Tissue Morphology MB,EDNRB,ATP1A2,UTS2,PTGS1,MLLT4,VIM,GEFT,ACTN3 
Immunological Disease CAMP,PTGS1,ATP1A2,HSPB8,VIM,IL12RB2,SELENBP1 
Inflammatory Disease CAMP,CD79B,ATP1A2,PTGS1,HSPB8,VIM,IL12RB2,IL11RA 
Cell Death TFF3,EDNRB,CD79B,PTGS1,HSPB8,IL12RB2,BIN1,NRGN,PMP22,CAMP,LGALS3BP,ATP1A2,MVP 
Cellular Growth and Proliferation TFF3,EDNRB,UTS2,PTGS1,HSPB8,VIM,IL12RB2,BIN1,FOLR1,PLCD1,PMP22,SHMT1,TFPI,MVP 
Protein Degradation CTSK,SERPINA5,FBXL2,CPXM1 
Carbohydrate Metabolism EDNRB,MFNG,TFPI,MVP,IL11RA 
Hematological Disease CAMP,MB,PTGS1,TFPI,FOLR1,SELENBP1,IL11RA 
Dermatological Diseases and 
Conditions PLCD1,PMP22,CAMP,CD79B,PTGS1,ATP1A2,HSPB8,NRGN,IL11RA,FOLR1 
Neurological Disease PMP22,EDNRB,HTR7,ARHGEF6,ATP1A2,HSPB8,VIM,IL12RB2 
Skeletal and Muscular Disorders CTSK,CD79B,PTGS1,HSPB8,VIM,BIN1,IL11RA 
Cell-To-Cell Signaling and 
Interaction PMP22,TFF3,CAMP,LGALS3BP,HTR7,UTS2,MLLT4,VIM,TFPI,NRGN 
Nervous System Development and 
Function PMP22,EDNRB,HTR7,UTS2,VIM,GEFT,BIN1,NRGN 
Metabolic Disease ATP1A2,HTR7,PTGS1,ATP6V1B1 
Organismal Injury and 
Abnormalities ATP1A2,HTR7,PTGS1,UTS2,VIM,IL11RA 
Respiratory Disease MB,EDNRB,PTGS1,SELENBP1 
Connective Tissue Disorders CD79B,PTGS1,HSPB8,VIM,IL11RA 
Cellular Development PMP22,CD79B,EDNRB,PTGS1,IL12RB2,GEFT,FZD2,BIN1,DYRK3,IL11RA 
Organismal Development PLCD1,MB,PTGS1 
Organ Development PLCD1,MB,EDNRB,IL11RA 
Cell Morphology PMP22,TFF3,CAMP,EDNRB,SERPINA5,HTR7,MLLT4,IL12RB2,ATP6V1B1 
Drug Metabolism PTGS1,VIM,TFPI,MVP,IL11RA,FOLR1 
Lipid Metabolism PLCD1,PTGS1,VIM,SC5DL 
Small Molecule Biochemistry EDNRB,MFNG,UTS2,PTGS1,VIM,MLLT4,SC5DL,FOLR1,PLCD1,CAMP,HTR7,ATP1A2,SHMT1,TFPI,MVP,IL11RA 
Skeletal and Muscular System CTSK,MB,ATP1A2,UTS2,GEFT,ACTN3,IL11RA 
Development and Function 
Immune Response CAMP,CD79B,CLDN19,PTGS1,ARHGEF6,UTS2,MLLT4,IL12RB2,ACTN3 
Cell Cycle VIM 
Cellular Compromise VIM,BIN1 
Cellular Function and Maintenance CD79B,VIM,BIN1,FOLR1 
Connective Tissue Development 
and Function HTR7,GEFT,FZD2 
DNA Replication, Recombination, 
and Repair TFF3,CAMP,ATP1A2,VIM,BIN1,FOLR1 
Developmental Disorder CTSK,ARHGEF6 
Digestive System Development and 
Function TFF3,EDNRB,PTGS1,FOLR1 
Embryonic Development PMP22,EDNRB,PTGS1,MLLT4,FZD2,CXXC4,NRGN,IL11RA 
Gene Expression CAMP,ZNF467 
Genetic Disorder PMP22,CTSK,ARHGEF6,HSPB8 
Hair and Skin Development and 
Function PLCD1,MB,EDNRB 
Hematological System 
Development and Function CAMP,CD79B,SERPINA5,PTGS1,ARHGEF6,UTS2,IL12RB2,TFPI,DYRK3,IL11RA 
Hepatic System Development and 
Function PTGS1 
Nucleic Acid Metabolism CAMP,HTR7,UTS2,ATP1A2,SHMT1,MLLT4,FOLR1 
Organ Morphology EDNRB,SERPINA5,PTGS1,FOLR1,IL11RA 
Renal and Urological Disease EDNRB,PTGS1,ATP6V1B1 
Reproductive System Disease TFF3,EDNRB,SERPINA5,PTGS1,ATP6V1B1,FOLR1 
Respiratory System Development 
and Function ATP1A2,PTGS1,IL11RA 
Amino Acid Metabolism EDNRB,SHMT1,SDSL,FOLR1 
Tissue Development TFF3,CTSK,LGALS3BP,PTGS1,MLLT4,GEFT,TFPI,FZD2,IL11RA 
Organismal Functions TFF3,PTGS1 
Auditory Disease CAMP 
Behavior CLDN19 
Cellular Assembly and Organization PMP22,CTSK,CAMP,VIM,GEFT,BIN1 
Gastrointestinal Disease TFF3,ATP1A2,PTGS1 
Immune and Lymphatic System 
Development and Function IL12RB2 
Infectious Disease CAMP,PTGS1,FOLR1 
Renal and Urological System 
Development and Function PMP22,TFF3,CAMP,EDNRB,ATP6V1B1 
Reproductive System Development 
and Function PLCD1,SERPINA5,ATP1A2,PTGS1,MLLT4 
Tumor Morphology TFF3 
Protein Synthesis CTSK,SERPINA5,FBXL2,CPXM1,FOLR1 
Ophthalmic Disease PTGS1 
Nutritional Disease IL11RA 
Psychological Disorders IL11RA 
Energy Production CAMP,ATP1A2,SHMT1 
Protein Trafficking EDNRB,FOLR1 
Post-Translational Modification CD79B,EDNRB,FBXL2,KEL 
Organismal Survival PLCD1,PTGS1,IL11RA,FOLR1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE A 2.3- List of genes downregulated in p53 shRNA transduced hESC (Ingenuity Pathways Analysis)  
       
Common 
name  
Fold 
Change B-stat Genbank Biological process/role 
 p53 
RE 
TP53 7.72 5.961 NM_000546 
Nucleotide-excision repair, regulation of transcription, protein complex assembly, response to DNA damage stimulus,  
apoptosis, cell cycle, development, cell aging 
DPEP3 9.26 5.020 NM_022357 Proteolysis 4 
MCFD2 2.03 4.837 NM_139279 ER to Golgi vesicle-mediated transport; protein transport and pluripotency, survival of rat neural stem cells 3 
TRIM22 2.16 4.501 NM_006074 Regulation of transcription, DNA-dependent, immune response, response to virus  3 
LOC651997 2.02 4.280 XM_941292   
KCNAB1 2.94 4.036 NM_172159 Ion transport; potassium ion transport 4 
 1.81 3.012 AW445083   
DDX6 3.08 2.751 NM_004397 May contribute to the cell proliferation and carcinogenesis. 5 
ADFP 1.70 2.145 NM_001122  3 
LOC647784 2.25 2.131 XM_943395   
ZNF676 1.67 2.043 NM_001001411 Regulation of transcription, DNA-dependent  
NTRK3 1.67 1.897 NM_002530 
Protein amino acid phosphorylation, transmembrane receptor protein tyrosine kinase signaling pathway, 
multicellular organismal development, cell differentiation 3 
AP1M2 1.76 1.695 NM_005498 Protein complex assembly, protein targeting, vesicle targeting 4 
CST6 2.07 1.681 NM_001323 Epidermis development; anatomical structure morphogenesis 2 
C20orf23 2.26 1.628 NM_024704 Microtubule-based movement, cell communication 7 
DDX19B 1.79 1.361 NM_001014451 mRNA export from nucleus 8 
TMEM99 1.60 1.286 NM_145274  3 
NALP7 1.75 1.268 NM_139176  3 
RCN3 1.75 1.242 NM_020650  3 
HBA1 1.83 1,239 NM_000558 Hemolysis, erythropoiesis, cell viability, apoptosis, formation, cell death 7 
AK2 1.49 1.208 NM_001625 Nucleic acid metabolic process and may play a role in apoptosis. 1 
SNAI3 1.56 1.154 NM_178310   
NME1 1.61 1.060 NM_198175 
Negative regulation of cell proliferation and progression through cell cycle, nucleotide metabolic process,  
regulation of apoptosis, negative regulation 
CDKN1A 2.47 1.013 NM_078467 
Response to DNA damage stimulus, cell cycle arrest, regulation of cyclin-dependent protein kinase activity,  
apoptosis, non-apoptotic programmed cell death 7 
GALNT13 2.16 1.010 NM_052917 Protein amino acid O-linked glycosylation 1 
ANKRD41 1.55 0.950 NM_152363  5 
TCERG1L 1.69 0.909 NM_174937  3 
 1.69 0.907 BU621341   
ANXA2 1.63 0.898 NM_001002857 Skeletal development and phospholipase inhibitor activity 4 
 1.73 0.897 CN292254   
LOC651029 1.73 0.879 XM_944471   
SAPS1 1.73 0.794 NM_014931 Regulation of phosphoprotein phosphatase activity 9 
ATP2A1 1.76 0.583 CB850608 Cation and proton transport; regulation of striated muscle contraction  
 1.48 0.581 XM_373970   
ISG20L1 1.38 0.515 NM_022767  2 
LOC653203 1.52 0.491 XM_927850   
FAM48B1 1.67 0.483 XM_093087   
MPZL1 1.48 0.407 NM_003953 Transmembrane receptor protein tyrosine kinase signaling pathway, cell-cell signaling 8 
XKRY 1.39 0.394 NM_004677   
HIST1H2BH 2.56 0.351 NM_003524 Nucleosome assembly, chromosome organization and biogenesis  
NOXO1 1.64 0.329 NM_144603 Superoxide metabolic process, cell communication 1 
 1.76 0.328 BG217697   
 1.88 0.273 CA391986   
TMEM43 1.38 0.209 NM_024334  4 
 1.66 0.188 DA236664   
NALP7 1.64 0.182 NM_206828 Defense response  
MARVELD3 1.44 0.175 NM_001017967  2 
CCL2 1.75 0.171 NM_002982 
Protein phosphorylation, cellular calcium ion homeostasis; anti-apoptosis; chemotaxis; cell adhesion; G-protein signaling,  
JAK-STAT cascade, cell-cell signaling, morphogenesis 4 
CST6 3.60 0.164 NM_001323  2 
OR4F21 1.56 0.110 NM_001005504   
BRP44L 1.42 0.070 NM_016098  5 
C1orf24 1.53 0.020 NM_052966   
TEK 1.77 0.013 NM_000459 
Protein phosphorylation, cell-matrix adhesion, transmembrane receptor protein tyrosine kinase signaling pathway;  
cell-cell signaling and adhesion, regulation cell migration and angiogenesis 3 
LOC196264 1.47 0.008 NM_198275   3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE A 2.4- List of functions of downregulated genes in p53 shRNA transduced hESC (Ingenuity Pathways Analysis) 
Function Molecules 
Cellular Movement TP53,NME1,CCL2,CDKN1A,ANXA2,CST6,TEK 
Cellular Growth and Proliferation TP53,NME1,CCL2,NTRK3,ADFP,CDKN1A,ANXA2,TRIM22,AK2,CST6,TEK 
Cancer TP53,NME1,CCL2,NTRK3,CDKN1A,ANXA2,TRIM22,CST6,TEK 
Cell Cycle TP53,NTRK3,CDKN1A 
Cell-To-Cell Signaling and Interaction TP53,NME1,CCL2,CDKN1A,ANXA2 
DNA Replication, Recombination, and Repair TP53,NME1,CDKN1A 
Nucleic Acid Metabolism TP53,NME1,AK2,DDX19B 
Renal and Urological Disease TP53,CCL2,CDKN1A 
Small Molecule Biochemistry TP53,NME1,CDKN1A 
Hematological Disease TP53,NME1,CCL2,NTRK3,CDKN1A,HBA1,MCFD2,ANXA2 
Tumor Morphology TP53,NME1,CCL2,CDKN1A,TEK 
Hepatic System Development and Function TP53,CDKN1A 
Neurological Disease TP53,CCL2,NTRK3,CDKN1A 
Cellular Function and Maintenance TP53,NME1,CDKN1A 
Cell Death TP53,NTRK3,CDKN1A,MCFD2 
Cellular Development TP53,NME1,CCL2,NTRK3,CDKN1A,ANXA2,TEK 
Gastrointestinal Disease TP53,CDKN1A 
Hematological System Development and Function TP53,CCL2,CDKN1A,ANXA2,TEK 
Immune and Lymphatic System Development and Function TP53,CCL2,CDKN1A,ANXA2 
Skeletal and Muscular Disorders TP53,CCL2,CDKN1A 
Cell Signaling TP53,MPZL1,CCL2,NTRK3,CDKN1A,TEK 
Respiratory Disease TP53,CDKN1A 
Endocrine System Disorders TP53,CDKN1A,ANXA2 
Cellular Assembly and Organization TP53,CDKN1A 
Hair and Skin Development and Function TP53,CDKN1A 
Tissue Morphology TP53,CDKN1A 
Immune Response TP53,CCL2,CDKN1A,TRIM22 
Connective Tissue Disorders TP53,CCL2,NTRK3,CDKN1A 
Inflammatory Disease TP53,CCL2,CDKN1A 
Organismal Survival TP53,CCL2,NTRK3,CDKN1A,TEK 
Cardiovascular System Development and Function TP53,CCL2,ANXA2,TEK 
Immunological Disease TP53,NME1,CCL2,CDKN1A 
Skeletal and Muscular System Development and Function TP53,CCL2,CDKN1A 
Cell Morphology TP53,CCL2,NTRK3,CDKN1A,ANXA2,TEK 
Reproductive System Disease TP53,NME1,CDKN1A,ANXA2,CST6,TEK 
Cellular Compromise TP53,CDKN1A 
Connective Tissue Development and Function TP53,CCL2,NTRK3,CDKN1A 
Organismal Development TP53,CCL2,ANXA2,TEK 
Dermatological Diseases and Conditions TP53,NME1,CDKN1A 
Lipid Metabolism TP53,CDKN1A 
Tissue Development TP53,CCL2,CDKN1A,TEK 
Organ Morphology TP53,CDKN1A 
Gene Expression TP53,CDKN1A 
Free Radical Scavenging TP53,CDKN1A 
Hepatic System Disease TP53,CDKN1A 
Molecular Transport TP53,CDKN1A 
Renal and Urological System Development and Function TP53,CDKN1A 
Digestive System Development and Function TP53 
Nervous System Development and Function CDKN1A 
RNA Post-Transcriptional Modification TP53 
Reproductive System Development and Function TP53 
 
 
